Sentence,Tags
BRCA1 is secreted and exhibits properties of a granin .,"(('BRCA1', 'O'), ('is', 'O'), ('secreted', 'O'), ('and', 'O'), ('exhibits', 'O'), ('properties', 'O'), ('of', 'O'), ('a', 'O'), ('granin', 'O'), ('.', 'O'))"
"However , the function of the BRCA1 protein has remained elusive .","(('However', 'O'), (',', 'O'), ('the', 'O'), ('function', 'O'), ('of', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('protein', 'O'), ('has', 'O'), ('remained', 'O'), ('elusive', 'O'), ('.', 'O'))"
We now show that BRCA1 encodes a 190 - kD protein with sequence homology and biochemical analogy to the granin protein family .,"(('We', 'O'), ('now', 'O'), ('show', 'O'), ('that', 'O'), ('BRCA1', 'O'), ('encodes', 'O'), ('a', 'O'), ('190', 'O'), ('-', 'O'), ('kD', 'O'), ('protein', 'O'), ('with', 'O'), ('sequence', 'O'), ('homology', 'O'), ('and', 'O'), ('biochemical', 'O'), ('analogy', 'O'), ('to', 'O'), ('the', 'O'), ('granin', 'O'), ('protein', 'O'), ('family', 'O'), ('.', 'O'))"
"Interestingly , BRCA2 also includes a motif similar to the granin consensus at the C terminus of the protein .","(('Interestingly', 'O'), (',', 'O'), ('BRCA2', 'O'), ('also', 'O'), ('includes', 'O'), ('a', 'O'), ('motif', 'O'), ('similar', 'O'), ('to', 'O'), ('the', 'O'), ('granin', 'O'), ('consensus', 'O'), ('at', 'O'), ('the', 'O'), ('C', 'O'), ('terminus', 'O'), ('of', 'O'), ('the', 'O'), ('protein', 'O'), ('.', 'O'))"
"Both BRCA1 and the granins localize to secretory vesicles , are secreted by a regulated pathway , are post - translationally glycosylated and are responsive to hormones .","(('Both', 'O'), ('BRCA1', 'O'), ('and', 'O'), ('the', 'O'), ('granins', 'O'), ('localize', 'O'), ('to', 'O'), ('secretory', 'O'), ('vesicles', 'O'), (',', 'O'), ('are', 'O'), ('secreted', 'O'), ('by', 'O'), ('a', 'O'), ('regulated', 'O'), ('pathway', 'O'), (',', 'O'), ('are', 'O'), ('post', 'O'), ('-', 'O'), ('translationally', 'O'), ('glycosylated', 'O'), ('and', 'O'), ('are', 'O'), ('responsive', 'O'), ('to', 'O'), ('hormones', 'O'), ('.', 'O'))"
"As a regulated secretory protein , BRCA1 appears to function by a mechanism not previously described for tumour suppressor gene products . .","(('As', 'O'), ('a', 'O'), ('regulated', 'O'), ('secretory', 'O'), ('protein', 'O'), (',', 'O'), ('BRCA1', 'O'), ('appears', 'O'), ('to', 'O'), ('function', 'O'), ('by', 'O'), ('a', 'O'), ('mechanism', 'O'), ('not', 'O'), ('previously', 'O'), ('described', 'O'), ('for', 'O'), ('tumour', 'B'), ('suppressor', 'O'), ('gene', 'O'), ('products', 'O'), ('.', 'O'), ('.', 'O'))"
"Women who carry a mutation in the BRCA1 gene ( on chromosome 17q21 ) , have an 80 % risk of breast cancer and a 40 % risk of ovarian cancer by the age of 70 ( ref . 1 ) .","(('Women', 'O'), ('who', 'O'), ('carry', 'O'), ('a', 'O'), ('mutation', 'O'), ('in', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('gene', 'O'), ('(', 'O'), ('on', 'O'), ('chromosome', 'O'), ('17q21', 'O'), (')', 'O'), (',', 'O'), ('have', 'O'), ('an', 'O'), ('80', 'O'), ('%', 'O'), ('risk', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('and', 'O'), ('a', 'O'), ('40', 'O'), ('%', 'O'), ('risk', 'O'), ('of', 'O'), ('ovarian', 'B'), ('cancer', 'I'), ('by', 'O'), ('the', 'O'), ('age', 'O'), ('of', 'O'), ('70', 'O'), ('(', 'O'), ('ref', 'O'), ('.', 'O'), ('1', 'O'), (')', 'O'), ('.', 'O'))"
The variable penetrance of BRCA1 suggests that other genetic and non - genetic factors play a role in tumourigenesis in these individuals .,"(('The', 'O'), ('variable', 'O'), ('penetrance', 'O'), ('of', 'O'), ('BRCA1', 'O'), ('suggests', 'O'), ('that', 'O'), ('other', 'O'), ('genetic', 'O'), ('and', 'O'), ('non', 'O'), ('-', 'O'), ('genetic', 'O'), ('factors', 'O'), ('play', 'O'), ('a', 'O'), ('role', 'O'), ('in', 'O'), ('tumourigenesis', 'B'), ('in', 'O'), ('these', 'O'), ('individuals', 'O'), ('.', 'O'))"
"The HRAS1 variable number of tandem repeats ( VNTR ) polymorphism , located 1 kilobase ( kb ) downstream of the HRAS1 proto - oncogene ( chromosome 11p15 . 5 ) is one possible genetic modifier of cancer penetrance .","(('The', 'O'), ('HRAS1', 'O'), ('variable', 'O'), ('number', 'O'), ('of', 'O'), ('tandem', 'O'), ('repeats', 'O'), ('(', 'O'), ('VNTR', 'O'), (')', 'O'), ('polymorphism', 'O'), (',', 'O'), ('located', 'O'), ('1', 'O'), ('kilobase', 'O'), ('(', 'O'), ('kb', 'O'), (')', 'O'), ('downstream', 'O'), ('of', 'O'), ('the', 'O'), ('HRAS1', 'O'), ('proto', 'O'), ('-', 'O'), ('oncogene', 'O'), ('(', 'O'), ('chromosome', 'O'), ('11p15', 'O'), ('.', 'O'), ('5', 'O'), (')', 'O'), ('is', 'O'), ('one', 'O'), ('possible', 'O'), ('genetic', 'O'), ('modifier', 'O'), ('of', 'O'), ('cancer', 'B'), ('penetrance', 'O'), ('.', 'O'))"
"Individuals who have rare alleles of the VNTR have an increased risk of certain types of cancers , including breast cancer ( 2 - 4 ) .","(('Individuals', 'O'), ('who', 'O'), ('have', 'O'), ('rare', 'O'), ('alleles', 'O'), ('of', 'O'), ('the', 'O'), ('VNTR', 'O'), ('have', 'O'), ('an', 'O'), ('increased', 'O'), ('risk', 'O'), ('of', 'O'), ('certain', 'O'), ('types', 'O'), ('of', 'O'), ('cancers', 'B'), (',', 'O'), ('including', 'O'), ('breast', 'B'), ('cancer', 'I'), ('(', 'O'), ('2', 'O'), ('-', 'O'), ('4', 'O'), (')', 'O'), ('.', 'O'))"
The risk for ovarian cancer was 2 .,"(('The', 'O'), ('risk', 'O'), ('for', 'O'), ('ovarian', 'B'), ('cancer', 'I'), ('was', 'O'), ('2', 'O'), ('.', 'O'))"
"11 times greater for BRCA1 carriers harbouring one or two rare HRAS1 alleles , compared to carriers with only common alleles ( P = 0 . 015 ) .","(('11', 'O'), ('times', 'O'), ('greater', 'O'), ('for', 'O'), ('BRCA1', 'O'), ('carriers', 'O'), ('harbouring', 'O'), ('one', 'O'), ('or', 'O'), ('two', 'O'), ('rare', 'O'), ('HRAS1', 'O'), ('alleles', 'O'), (',', 'O'), ('compared', 'O'), ('to', 'O'), ('carriers', 'O'), ('with', 'O'), ('only', 'O'), ('common', 'O'), ('alleles', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('015', 'O'), (')', 'O'), ('.', 'O'))"
Susceptibility to breast cancer did not appear to be affected by the presence of rare HRAS1 alleles .,"(('Susceptibility', 'O'), ('to', 'O'), ('breast', 'B'), ('cancer', 'I'), ('did', 'O'), ('not', 'O'), ('appear', 'O'), ('to', 'O'), ('be', 'O'), ('affected', 'O'), ('by', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('rare', 'O'), ('HRAS1', 'O'), ('alleles', 'O'), ('.', 'O'))"
3 .,"(('3', 'O'), ('.', 'O'))"
"Characterisation of the expression of this gene in patient tissues has thus far generated conflicting data on alterations in the steady state levels of DMPK mRNA , and on the final DMPK protein levels in the presence of the expansion .","(('Characterisation', 'O'), ('of', 'O'), ('the', 'O'), ('expression', 'O'), ('of', 'O'), ('this', 'O'), ('gene', 'O'), ('in', 'O'), ('patient', 'O'), ('tissues', 'O'), ('has', 'O'), ('thus', 'O'), ('far', 'O'), ('generated', 'O'), ('conflicting', 'O'), ('data', 'O'), ('on', 'O'), ('alterations', 'O'), ('in', 'O'), ('the', 'O'), ('steady', 'O'), ('state', 'O'), ('levels', 'O'), ('of', 'O'), ('DMPK', 'O'), ('mRNA', 'O'), (',', 'O'), ('and', 'O'), ('on', 'O'), ('the', 'O'), ('final', 'O'), ('DMPK', 'O'), ('protein', 'O'), ('levels', 'O'), ('in', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('the', 'O'), ('expansion', 'O'), ('.', 'O'))"
We have searched for genes associated with a CpG island at the 3 end of DMPK .,"(('We', 'O'), ('have', 'O'), ('searched', 'O'), ('for', 'O'), ('genes', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('CpG', 'O'), ('island', 'O'), ('at', 'O'), ('the', 'O'), ('3', 'O'), ('end', 'O'), ('of', 'O'), ('DMPK', 'O'), ('.', 'O'))"
Sequencing of this region shows that the island extends over 3 .,"(('Sequencing', 'O'), ('of', 'O'), ('this', 'O'), ('region', 'O'), ('shows', 'O'), ('that', 'O'), ('the', 'O'), ('island', 'O'), ('extends', 'O'), ('over', 'O'), ('3', 'O'), ('.', 'O'))"
5 kb and is interrupted by the ( CTG ) n repeat .,"(('5', 'O'), ('kb', 'O'), ('and', 'O'), ('is', 'O'), ('interrupted', 'O'), ('by', 'O'), ('the', 'O'), ('(', 'O'), ('CTG', 'O'), (')', 'O'), ('n', 'O'), ('repeat', 'O'), ('.', 'O'))"
Comparison of genomic sequences downstream ( centromeric ) of the repeat in human and mouse identified regions of significant homology .,"(('Comparison', 'O'), ('of', 'O'), ('genomic', 'O'), ('sequences', 'O'), ('downstream', 'O'), ('(', 'O'), ('centromeric', 'O'), (')', 'O'), ('of', 'O'), ('the', 'O'), ('repeat', 'O'), ('in', 'O'), ('human', 'O'), ('and', 'O'), ('mouse', 'O'), ('identified', 'O'), ('regions', 'O'), ('of', 'O'), ('significant', 'O'), ('homology', 'O'), ('.', 'O'))"
These correspond to exons of a gene predicted to encode a homeodomain protein .,"(('These', 'O'), ('correspond', 'O'), ('to', 'O'), ('exons', 'O'), ('of', 'O'), ('a', 'O'), ('gene', 'O'), ('predicted', 'O'), ('to', 'O'), ('encode', 'O'), ('a', 'O'), ('homeodomain', 'O'), ('protein', 'O'), ('.', 'O'))"
"For improvement over previous studies , a new set of primers has been designed , which allow for amplification of the coding and splicing sequences only .","(('For', 'O'), ('improvement', 'O'), ('over', 'O'), ('previous', 'O'), ('studies', 'O'), (',', 'O'), ('a', 'O'), ('new', 'O'), ('set', 'O'), ('of', 'O'), ('primers', 'O'), ('has', 'O'), ('been', 'O'), ('designed', 'O'), (',', 'O'), ('which', 'O'), ('allow', 'O'), ('for', 'O'), ('amplification', 'O'), ('of', 'O'), ('the', 'O'), ('coding', 'O'), ('and', 'O'), ('splicing', 'O'), ('sequences', 'O'), ('only', 'O'), ('.', 'O'))"
"The positioning of the polymerase chain reaction ( PCR ) primers was such that the resulting PCR products were of different sizes , which enabled us to analyze two different exons simultaneously and still distinguish between the banding profiles for both ( biplex analysis ) .","(('The', 'O'), ('positioning', 'O'), ('of', 'O'), ('the', 'O'), ('polymerase', 'O'), ('chain', 'O'), ('reaction', 'O'), ('(', 'O'), ('PCR', 'O'), (')', 'O'), ('primers', 'O'), ('was', 'O'), ('such', 'O'), ('that', 'O'), ('the', 'O'), ('resulting', 'O'), ('PCR', 'O'), ('products', 'O'), ('were', 'O'), ('of', 'O'), ('different', 'O'), ('sizes', 'O'), (',', 'O'), ('which', 'O'), ('enabled', 'O'), ('us', 'O'), ('to', 'O'), ('analyze', 'O'), ('two', 'O'), ('different', 'O'), ('exons', 'O'), ('simultaneously', 'O'), ('and', 'O'), ('still', 'O'), ('distinguish', 'O'), ('between', 'O'), ('the', 'O'), ('banding', 'O'), ('profiles', 'O'), ('for', 'O'), ('both', 'O'), ('(', 'O'), ('biplex', 'O'), ('analysis', 'O'), (')', 'O'), ('.', 'O'))"
"By using this approach , we were able to identify mutation in 22 new patients , but the overall efficiency of the procedure when we used a single - pass regimen was only 48 % .","(('By', 'O'), ('using', 'O'), ('this', 'O'), ('approach', 'O'), (',', 'O'), ('we', 'O'), ('were', 'O'), ('able', 'O'), ('to', 'O'), ('identify', 'O'), ('mutation', 'O'), ('in', 'O'), ('22', 'O'), ('new', 'O'), ('patients', 'O'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('overall', 'O'), ('efficiency', 'O'), ('of', 'O'), ('the', 'O'), ('procedure', 'O'), ('when', 'O'), ('we', 'O'), ('used', 'O'), ('a', 'O'), ('single', 'O'), ('-', 'O'), ('pass', 'O'), ('regimen', 'O'), ('was', 'O'), ('only', 'O'), ('48', 'O'), ('%', 'O'), ('.', 'O'))"
The mutations were small insertions and deletions and point mutations in roughly equal proportions . .,"(('The', 'O'), ('mutations', 'O'), ('were', 'O'), ('small', 'O'), ('insertions', 'O'), ('and', 'O'), ('deletions', 'O'), ('and', 'O'), ('point', 'O'), ('mutations', 'O'), ('in', 'O'), ('roughly', 'O'), ('equal', 'O'), ('proportions', 'O'), ('.', 'O'), ('.', 'O'))"
Allele - specific amino acid substitutions ( Ser189 - - > Phe ; Gly444 - - > Arg ) cause impaired C2 secretion .,"(('Allele', 'O'), ('-', 'O'), ('specific', 'O'), ('amino', 'O'), ('acid', 'O'), ('substitutions', 'O'), ('(', 'O'), ('Ser189', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('Phe', 'O'), (';', 'O'), ('Gly444', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('Arg', 'O'), (')', 'O'), ('cause', 'O'), ('impaired', 'O'), ('C2', 'O'), ('secretion', 'O'), ('.', 'O'))"
"One is in exon 5 ( nucleotide C566 - - > T ; Ser189 - - > Phe ) of the C2Q0 gene linked to the MHC haplotype A11 , B35 , DRw1 , BFS , C4A0B1 .","(('One', 'O'), ('is', 'O'), ('in', 'O'), ('exon', 'O'), ('5', 'O'), ('(', 'O'), ('nucleotide', 'O'), ('C566', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('T', 'O'), (';', 'O'), ('Ser189', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('Phe', 'O'), (')', 'O'), ('of', 'O'), ('the', 'O'), ('C2Q0', 'O'), ('gene', 'O'), ('linked', 'O'), ('to', 'O'), ('the', 'O'), ('MHC', 'O'), ('haplotype', 'O'), ('A11', 'O'), (',', 'O'), ('B35', 'O'), (',', 'O'), ('DRw1', 'O'), (',', 'O'), ('BFS', 'O'), (',', 'O'), ('C4A0B1', 'O'), ('.', 'O'))"
"The other is in exon 11 ( G1930 - - > A ; Gly444 - - > Arg ) of the C2Q0 gene linked to the MHC haplotype A2 , B5 , DRw4 , BFS , C4A3B1 .","(('The', 'O'), ('other', 'O'), ('is', 'O'), ('in', 'O'), ('exon', 'O'), ('11', 'O'), ('(', 'O'), ('G1930', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('A', 'O'), (';', 'O'), ('Gly444', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('Arg', 'O'), (')', 'O'), ('of', 'O'), ('the', 'O'), ('C2Q0', 'O'), ('gene', 'O'), ('linked', 'O'), ('to', 'O'), ('the', 'O'), ('MHC', 'O'), ('haplotype', 'O'), ('A2', 'O'), (',', 'O'), ('B5', 'O'), (',', 'O'), ('DRw4', 'O'), (',', 'O'), ('BFS', 'O'), (',', 'O'), ('C4A3B1', 'O'), ('.', 'O'))"
Each mutant C2 gene product is retained early in the secretory pathway .,"(('Each', 'O'), ('mutant', 'O'), ('C2', 'O'), ('gene', 'O'), ('product', 'O'), ('is', 'O'), ('retained', 'O'), ('early', 'O'), ('in', 'O'), ('the', 'O'), ('secretory', 'O'), ('pathway', 'O'), ('.', 'O'))"
These mutants provide models for elucidating the C2 secretory pathway . .,"(('These', 'O'), ('mutants', 'O'), ('provide', 'O'), ('models', 'O'), ('for', 'O'), ('elucidating', 'O'), ('the', 'O'), ('C2', 'O'), ('secretory', 'O'), ('pathway', 'O'), ('.', 'O'), ('.', 'O'))"
"In one family , both alleles were normal in the parents and one sister ; thus , the mutation originated de novo in the proposita .","(('In', 'O'), ('one', 'O'), ('family', 'O'), (',', 'O'), ('both', 'O'), ('alleles', 'O'), ('were', 'O'), ('normal', 'O'), ('in', 'O'), ('the', 'O'), ('parents', 'O'), ('and', 'O'), ('one', 'O'), ('sister', 'O'), (';', 'O'), ('thus', 'O'), (',', 'O'), ('the', 'O'), ('mutation', 'O'), ('originated', 'O'), ('de', 'O'), ('novo', 'O'), ('in', 'O'), ('the', 'O'), ('proposita', 'O'), ('.', 'O'))"
"The second patient also had asymptomatic parents who , however , were not available for study .","(('The', 'O'), ('second', 'O'), ('patient', 'O'), ('also', 'O'), ('had', 'O'), ('asymptomatic', 'O'), ('parents', 'O'), ('who', 'O'), (',', 'O'), ('however', 'O'), (',', 'O'), ('were', 'O'), ('not', 'O'), ('available', 'O'), ('for', 'O'), ('study', 'O'), ('.', 'O'))"
"The structural consequences of the identified mutation , resulting in the CyS2010 - > Arg substitution , were evaluated by expression of the vWF carboxyl - terminal domain containing residues 1366 - 2050 .","(('The', 'O'), ('structural', 'O'), ('consequences', 'O'), ('of', 'O'), ('the', 'O'), ('identified', 'O'), ('mutation', 'O'), (',', 'O'), ('resulting', 'O'), ('in', 'O'), ('the', 'O'), ('CyS2010', 'O'), ('-', 'O'), ('>', 'O'), ('Arg', 'O'), ('substitution', 'O'), (',', 'O'), ('were', 'O'), ('evaluated', 'O'), ('by', 'O'), ('expression', 'O'), ('of', 'O'), ('the', 'O'), ('vWF', 'O'), ('carboxyl', 'O'), ('-', 'O'), ('terminal', 'O'), ('domain', 'O'), ('containing', 'O'), ('residues', 'O'), ('1366', 'O'), ('-', 'O'), ('2050', 'O'), ('.', 'O'))"
"Insect cells infected with recombinant baculovirus expressing normal vWF sequence secreted a disulfide linked dimeric molecule with an apparent molecular mass of 150 kDa before reduction , yielding a single band of 80 kDa after disulfide bond reduction .","(('Insect', 'O'), ('cells', 'O'), ('infected', 'O'), ('with', 'O'), ('recombinant', 'O'), ('baculovirus', 'O'), ('expressing', 'O'), ('normal', 'O'), ('vWF', 'O'), ('sequence', 'O'), ('secreted', 'O'), ('a', 'O'), ('disulfide', 'O'), ('linked', 'O'), ('dimeric', 'O'), ('molecule', 'O'), ('with', 'O'), ('an', 'O'), ('apparent', 'O'), ('molecular', 'O'), ('mass', 'O'), ('of', 'O'), ('150', 'O'), ('kDa', 'O'), ('before', 'O'), ('reduction', 'O'), (',', 'O'), ('yielding', 'O'), ('a', 'O'), ('single', 'O'), ('band', 'O'), ('of', 'O'), ('80', 'O'), ('kDa', 'O'), ('after', 'O'), ('disulfide', 'O'), ('bond', 'O'), ('reduction', 'O'), ('.', 'O'))"
"In contrast , cells expressing the mutant fragment secreted a monomeric molecule of apparent molecular mass of 80 kDa , which remained unchanged after reduction .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('cells', 'O'), ('expressing', 'O'), ('the', 'O'), ('mutant', 'O'), ('fragment', 'O'), ('secreted', 'O'), ('a', 'O'), ('monomeric', 'O'), ('molecule', 'O'), ('of', 'O'), ('apparent', 'O'), ('molecular', 'O'), ('mass', 'O'), ('of', 'O'), ('80', 'O'), ('kDa', 'O'), (',', 'O'), ('which', 'O'), ('remained', 'O'), ('unchanged', 'O'), ('after', 'O'), ('reduction', 'O'), ('.', 'O'))"
"The Rho family of GTPases control diverse biological processes , including cell morphology and mitogenesis .","(('The', 'O'), ('Rho', 'O'), ('family', 'O'), ('of', 'O'), ('GTPases', 'O'), ('control', 'O'), ('diverse', 'O'), ('biological', 'O'), ('processes', 'O'), (',', 'O'), ('including', 'O'), ('cell', 'O'), ('morphology', 'O'), ('and', 'O'), ('mitogenesis', 'O'), ('.', 'O'))"
This interaction is dependent on the presence of the G protein - binding domain .,"(('This', 'O'), ('interaction', 'O'), ('is', 'O'), ('dependent', 'O'), ('on', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('the', 'O'), ('G', 'O'), ('protein', 'O'), ('-', 'O'), ('binding', 'O'), ('domain', 'O'), ('.', 'O'))"
Cellular expression of epitope - tagged WASP produces clusters of WASP that are highly enriched in polymerized actin .,"(('Cellular', 'O'), ('expression', 'O'), ('of', 'O'), ('epitope', 'O'), ('-', 'O'), ('tagged', 'O'), ('WASP', 'O'), ('produces', 'O'), ('clusters', 'O'), ('of', 'O'), ('WASP', 'O'), ('that', 'O'), ('are', 'O'), ('highly', 'O'), ('enriched', 'O'), ('in', 'O'), ('polymerized', 'O'), ('actin', 'O'), ('.', 'O'))"
"This clustering is not observed with a C - terminally deleted WASP and is inhibited by coexpression with dominant negative CDC42Hs - N17 , but not with dominant negative forms of Rac or Rho .","(('This', 'O'), ('clustering', 'O'), ('is', 'O'), ('not', 'O'), ('observed', 'O'), ('with', 'O'), ('a', 'O'), ('C', 'O'), ('-', 'O'), ('terminally', 'O'), ('deleted', 'O'), ('WASP', 'O'), ('and', 'O'), ('is', 'O'), ('inhibited', 'O'), ('by', 'O'), ('coexpression', 'O'), ('with', 'O'), ('dominant', 'O'), ('negative', 'O'), ('CDC42Hs', 'O'), ('-', 'O'), ('N17', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('with', 'O'), ('dominant', 'O'), ('negative', 'O'), ('forms', 'O'), ('of', 'O'), ('Rac', 'O'), ('or', 'O'), ('Rho', 'O'), ('.', 'O'))"
The WASP sequence contains two novel domains that are homologous to other proteins involved in action organization . .,"(('The', 'O'), ('WASP', 'O'), ('sequence', 'O'), ('contains', 'O'), ('two', 'O'), ('novel', 'O'), ('domains', 'O'), ('that', 'O'), ('are', 'O'), ('homologous', 'O'), ('to', 'O'), ('other', 'O'), ('proteins', 'O'), ('involved', 'O'), ('in', 'O'), ('action', 'O'), ('organization', 'O'), ('.', 'O'), ('.', 'O'))"
"In 5 of 14 patients ( 35 % ) , elevated plasma concentrations of very long chain fatty acids were detected .","(('In', 'O'), ('5', 'O'), ('of', 'O'), ('14', 'O'), ('patients', 'O'), ('(', 'O'), ('35', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('elevated', 'O'), ('plasma', 'O'), ('concentrations', 'O'), ('of', 'O'), ('very', 'O'), ('long', 'O'), ('chain', 'O'), ('fatty', 'O'), ('acids', 'O'), ('were', 'O'), ('detected', 'O'), ('.', 'O'))"
None of these patients had adrenocortical antibodies .,"(('None', 'O'), ('of', 'O'), ('these', 'O'), ('patients', 'O'), ('had', 'O'), ('adrenocortical', 'O'), ('antibodies', 'O'), ('.', 'O'))"
Tumor suppression and apoptosis of human prostate carcinoma mediated by a genetic locus within human chromosome 10pter - q11 .,"(('Tumor', 'B'), ('suppression', 'O'), ('and', 'O'), ('apoptosis', 'O'), ('of', 'O'), ('human', 'O'), ('prostate', 'B'), ('carcinoma', 'I'), ('mediated', 'O'), ('by', 'O'), ('a', 'O'), ('genetic', 'O'), ('locus', 'O'), ('within', 'O'), ('human', 'O'), ('chromosome', 'O'), ('10pter', 'O'), ('-', 'O'), ('q11', 'O'), ('.', 'O'))"
"Yet , despite a large international effort , little is known about the molecular mechanisms that underlie this devastating disease .","(('Yet', 'O'), (',', 'O'), ('despite', 'O'), ('a', 'O'), ('large', 'O'), ('international', 'O'), ('effort', 'O'), (',', 'O'), ('little', 'O'), ('is', 'O'), ('known', 'O'), ('about', 'O'), ('the', 'O'), ('molecular', 'O'), ('mechanisms', 'O'), ('that', 'O'), ('underlie', 'O'), ('this', 'O'), ('devastating', 'O'), ('disease', 'O'), ('.', 'O'))"
"Prostate secretory epithelial cells and androgen - dependent prostate carcinomas undergo apoptosis in response to androgen deprivation and , furthermore , most prostate carcinomas become androgen independent and refractory to further therapeutic manipulations during disease progression .","(('Prostate', 'O'), ('secretory', 'O'), ('epithelial', 'O'), ('cells', 'O'), ('and', 'O'), ('androgen', 'O'), ('-', 'O'), ('dependent', 'O'), ('prostate', 'B'), ('carcinomas', 'I'), ('undergo', 'O'), ('apoptosis', 'O'), ('in', 'O'), ('response', 'O'), ('to', 'O'), ('androgen', 'O'), ('deprivation', 'O'), ('and', 'O'), (',', 'O'), ('furthermore', 'O'), (',', 'O'), ('most', 'O'), ('prostate', 'B'), ('carcinomas', 'I'), ('become', 'O'), ('androgen', 'O'), ('independent', 'O'), ('and', 'O'), ('refractory', 'O'), ('to', 'O'), ('further', 'O'), ('therapeutic', 'O'), ('manipulations', 'O'), ('during', 'O'), ('disease', 'O'), ('progression', 'O'), ('.', 'O'))"
Definition of the genetic events that trigger apoptosis in the prostate could provide important insights into critical pathways in normal development as well as elucidate the perturbations of those key pathways in neoplastic transformation .,"(('Definition', 'O'), ('of', 'O'), ('the', 'O'), ('genetic', 'O'), ('events', 'O'), ('that', 'O'), ('trigger', 'O'), ('apoptosis', 'O'), ('in', 'O'), ('the', 'O'), ('prostate', 'O'), ('could', 'O'), ('provide', 'O'), ('important', 'O'), ('insights', 'O'), ('into', 'O'), ('critical', 'O'), ('pathways', 'O'), ('in', 'O'), ('normal', 'O'), ('development', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('elucidate', 'O'), ('the', 'O'), ('perturbations', 'O'), ('of', 'O'), ('those', 'O'), ('key', 'O'), ('pathways', 'O'), ('in', 'O'), ('neoplastic', 'B'), ('transformation', 'O'), ('.', 'O'))"
We report the functional definition of a novel genetic locus within human chromosome 10pter - q11 that mediates both in vivo tumor suppression and in vitro apoptosis of prostatic adenocarcinoma cells .,"(('We', 'O'), ('report', 'O'), ('the', 'O'), ('functional', 'O'), ('definition', 'O'), ('of', 'O'), ('a', 'O'), ('novel', 'O'), ('genetic', 'O'), ('locus', 'O'), ('within', 'O'), ('human', 'O'), ('chromosome', 'O'), ('10pter', 'O'), ('-', 'O'), ('q11', 'O'), ('that', 'O'), ('mediates', 'O'), ('both', 'O'), ('in', 'O'), ('vivo', 'O'), ('tumor', 'B'), ('suppression', 'O'), ('and', 'O'), ('in', 'O'), ('vitro', 'O'), ('apoptosis', 'O'), ('of', 'O'), ('prostatic', 'B'), ('adenocarcinoma', 'I'), ('cells', 'O'), ('.', 'O'))"
A defined fragment of human chromosome 10 was transferred via microcell fusion into a prostate adenocarcinoma cell line .,"(('A', 'O'), ('defined', 'O'), ('fragment', 'O'), ('of', 'O'), ('human', 'O'), ('chromosome', 'O'), ('10', 'O'), ('was', 'O'), ('transferred', 'O'), ('via', 'O'), ('microcell', 'O'), ('fusion', 'O'), ('into', 'O'), ('a', 'O'), ('prostate', 'B'), ('adenocarcinoma', 'I'), ('cell', 'O'), ('line', 'O'), ('.', 'O'))"
Microcell hybrids containing only the region 10pter - q11 were suppressed for tumorigenicity following injection of microcell hybrids into nude mice .,"(('Microcell', 'O'), ('hybrids', 'O'), ('containing', 'O'), ('only', 'O'), ('the', 'O'), ('region', 'O'), ('10pter', 'O'), ('-', 'O'), ('q11', 'O'), ('were', 'O'), ('suppressed', 'O'), ('for', 'O'), ('tumorigenicity', 'B'), ('following', 'O'), ('injection', 'O'), ('of', 'O'), ('microcell', 'O'), ('hybrids', 'O'), ('into', 'O'), ('nude', 'O'), ('mice', 'O'), ('.', 'O'))"
"Furthermore , the complemented hybrids undergo programmed cell death in vitro via a mechanism that does not require nuclear localization of p53 .","(('Furthermore', 'O'), (',', 'O'), ('the', 'O'), ('complemented', 'O'), ('hybrids', 'O'), ('undergo', 'O'), ('programmed', 'O'), ('cell', 'O'), ('death', 'I'), ('in', 'O'), ('vitro', 'O'), ('via', 'O'), ('a', 'O'), ('mechanism', 'O'), ('that', 'O'), ('does', 'O'), ('not', 'O'), ('require', 'O'), ('nuclear', 'O'), ('localization', 'O'), ('of', 'O'), ('p53', 'O'), ('.', 'O'))"
"These data functionally define a novel genetic locus , designated PAC1 , for prostate adenocarcinoma 1 , involved in tumor suppression of human prostate carcinoma and furthermore strongly suggest that the cell death pathway can be functionally restored in prostatic adenocarcinoma . .","(('These', 'O'), ('data', 'O'), ('functionally', 'O'), ('define', 'O'), ('a', 'O'), ('novel', 'O'), ('genetic', 'O'), ('locus', 'O'), (',', 'O'), ('designated', 'O'), ('PAC1', 'O'), (',', 'O'), ('for', 'O'), ('prostate', 'B'), ('adenocarcinoma', 'I'), ('1', 'O'), (',', 'O'), ('involved', 'O'), ('in', 'O'), ('tumor', 'B'), ('suppression', 'O'), ('of', 'O'), ('human', 'O'), ('prostate', 'B'), ('carcinoma', 'I'), ('and', 'O'), ('furthermore', 'O'), ('strongly', 'O'), ('suggest', 'O'), ('that', 'O'), ('the', 'O'), ('cell', 'O'), ('death', 'O'), ('pathway', 'O'), ('can', 'O'), ('be', 'O'), ('functionally', 'O'), ('restored', 'O'), ('in', 'O'), ('prostatic', 'B'), ('adenocarcinoma', 'I'), ('.', 'O'), ('.', 'O'))"
Low incidence of BRCA2 mutations in breast carcinoma and other cancers .,"(('Low', 'O'), ('incidence', 'O'), ('of', 'O'), ('BRCA2', 'O'), ('mutations', 'O'), ('in', 'O'), ('breast', 'B'), ('carcinoma', 'I'), ('and', 'O'), ('other', 'O'), ('cancers', 'B'), ('.', 'O'))"
Inherited mutant alleles of familial tumour suppressor genes predispose individuals to particular types of cancer .,"(('Inherited', 'O'), ('mutant', 'O'), ('alleles', 'O'), ('of', 'O'), ('familial', 'O'), ('tumour', 'B'), ('suppressor', 'O'), ('genes', 'O'), ('predispose', 'O'), ('individuals', 'O'), ('to', 'O'), ('particular', 'O'), ('types', 'O'), ('of', 'O'), ('cancer', 'B'), ('.', 'O'))"
This finding suggests that other genes may be the principal targets for somatic mutation in breast carcinoma .,"(('This', 'O'), ('finding', 'O'), ('suggests', 'O'), ('that', 'O'), ('other', 'O'), ('genes', 'O'), ('may', 'O'), ('be', 'O'), ('the', 'O'), ('principal', 'O'), ('targets', 'O'), ('for', 'O'), ('somatic', 'O'), ('mutation', 'O'), ('in', 'O'), ('breast', 'B'), ('carcinoma', 'I'), ('.', 'O'))"
"Like BRCA1 , BRCA2 behaves as a dominantly inherited tumour suppressor gene .","(('Like', 'O'), ('BRCA1', 'O'), (',', 'O'), ('BRCA2', 'O'), ('behaves', 'O'), ('as', 'O'), ('a', 'O'), ('dominantly', 'O'), ('inherited', 'O'), ('tumour', 'B'), ('suppressor', 'O'), ('gene', 'O'), ('.', 'O'))"
"The BRCA2 coding sequence is huge , composed of 26 exons that span 10 , 443 bp .","(('The', 'O'), ('BRCA2', 'O'), ('coding', 'O'), ('sequence', 'O'), ('is', 'O'), ('huge', 'O'), (',', 'O'), ('composed', 'O'), ('of', 'O'), ('26', 'O'), ('exons', 'O'), ('that', 'O'), ('span', 'O'), ('10', 'O'), (',', 'O'), ('443', 'O'), ('bp', 'O'), ('.', 'O'))"
"Surprisingly , mutations in BRCA2 are infrequent in cancers including breast carcinoma .","(('Surprisingly', 'O'), (',', 'O'), ('mutations', 'O'), ('in', 'O'), ('BRCA2', 'O'), ('are', 'O'), ('infrequent', 'O'), ('in', 'O'), ('cancers', 'B'), ('including', 'O'), ('breast', 'B'), ('carcinoma', 'I'), ('.', 'O'))"
"Nine different germ - line mutations in the BRCA1 breast and ovarian cancer susceptibility gene were identified in 15 of 47 kindreds from southern Sweden , by use of SSCP and heteroduplex analysis of all exons and flanking intron region and by a protein - truncation test for exon 11 , followed by direct sequencing .","(('Nine', 'O'), ('different', 'O'), ('germ', 'O'), ('-', 'O'), ('line', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('breast', 'B'), ('and', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('susceptibility', 'O'), ('gene', 'O'), ('were', 'O'), ('identified', 'O'), ('in', 'O'), ('15', 'O'), ('of', 'O'), ('47', 'O'), ('kindreds', 'O'), ('from', 'O'), ('southern', 'O'), ('Sweden', 'O'), (',', 'O'), ('by', 'O'), ('use', 'O'), ('of', 'O'), ('SSCP', 'O'), ('and', 'O'), ('heteroduplex', 'O'), ('analysis', 'O'), ('of', 'O'), ('all', 'O'), ('exons', 'O'), ('and', 'O'), ('flanking', 'O'), ('intron', 'O'), ('region', 'O'), ('and', 'O'), ('by', 'O'), ('a', 'O'), ('protein', 'O'), ('-', 'O'), ('truncation', 'O'), ('test', 'O'), ('for', 'O'), ('exon', 'O'), ('11', 'O'), (',', 'O'), ('followed', 'O'), ('by', 'O'), ('direct', 'O'), ('sequencing', 'O'), ('.', 'O'))"
"All but one of the mutations are predicted to give rise to premature translation termination and include seven frameshift insertions or deletions , a nonsense mutation , and a splice acceptor site mutation .","(('All', 'O'), ('but', 'O'), ('one', 'O'), ('of', 'O'), ('the', 'O'), ('mutations', 'O'), ('are', 'O'), ('predicted', 'O'), ('to', 'O'), ('give', 'O'), ('rise', 'O'), ('to', 'O'), ('premature', 'O'), ('translation', 'O'), ('termination', 'O'), ('and', 'O'), ('include', 'O'), ('seven', 'O'), ('frameshift', 'O'), ('insertions', 'O'), ('or', 'O'), ('deletions', 'O'), (',', 'O'), ('a', 'O'), ('nonsense', 'O'), ('mutation', 'O'), (',', 'O'), ('and', 'O'), ('a', 'O'), ('splice', 'O'), ('acceptor', 'O'), ('site', 'O'), ('mutation', 'O'), ('.', 'O'))"
The remaining mutation is a missense mutation ( Cys61Gly ) in the zinc - binding motif .,"(('The', 'O'), ('remaining', 'O'), ('mutation', 'O'), ('is', 'O'), ('a', 'O'), ('missense', 'O'), ('mutation', 'O'), ('(', 'O'), ('Cys61Gly', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('zinc', 'O'), ('-', 'O'), ('binding', 'O'), ('motif', 'O'), ('.', 'O'))"
"Four novel Swedish founding mutations were identified the nucleotide 2595 deletion A was found in five families , the C 1806 T nonsense mutation in three families , the 3166 insertion TGAGA in three families , and the nucleotide 1201 deletion 11 in two families .","(('Four', 'O'), ('novel', 'O'), ('Swedish', 'O'), ('founding', 'O'), ('mutations', 'O'), ('were', 'O'), ('identified', 'O'), ('the', 'O'), ('nucleotide', 'O'), ('2595', 'O'), ('deletion', 'O'), ('A', 'O'), ('was', 'O'), ('found', 'O'), ('in', 'O'), ('five', 'O'), ('families', 'O'), (',', 'O'), ('the', 'O'), ('C', 'O'), ('1806', 'O'), ('T', 'O'), ('nonsense', 'O'), ('mutation', 'O'), ('in', 'O'), ('three', 'O'), ('families', 'O'), (',', 'O'), ('the', 'O'), ('3166', 'O'), ('insertion', 'O'), ('TGAGA', 'O'), ('in', 'O'), ('three', 'O'), ('families', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('nucleotide', 'O'), ('1201', 'O'), ('deletion', 'O'), ('11', 'O'), ('in', 'O'), ('two', 'O'), ('families', 'O'), ('.', 'O'))"
Analysis of the intragenic polymorphism D17S855 supports common origins of the mutations .,"(('Analysis', 'O'), ('of', 'O'), ('the', 'O'), ('intragenic', 'O'), ('polymorphism', 'O'), ('D17S855', 'O'), ('supports', 'O'), ('common', 'O'), ('origins', 'O'), ('of', 'O'), ('the', 'O'), ('mutations', 'O'), ('.', 'O'))"
"Eleven of the 15 kindreds manifesting BRCA1 mutations were breast - ovarian cancer families , several of them with a predominant ovarian cancer phenotype .","(('Eleven', 'O'), ('of', 'O'), ('the', 'O'), ('15', 'O'), ('kindreds', 'O'), ('manifesting', 'O'), ('BRCA1', 'O'), ('mutations', 'O'), ('were', 'O'), ('breast', 'B'), ('-', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('families', 'O'), (',', 'O'), ('several', 'O'), ('of', 'O'), ('them', 'O'), ('with', 'O'), ('a', 'O'), ('predominant', 'O'), ('ovarian', 'B'), ('cancer', 'I'), ('phenotype', 'O'), ('.', 'O'))"
The set of 32 families in which no BRCA1 alterations were detected included 1 breast - ovarian cancer kindred manifesting clear linkage to the BRCA1 region and loss of the wild - type chromosome in associated tumors .,"(('The', 'O'), ('set', 'O'), ('of', 'O'), ('32', 'O'), ('families', 'O'), ('in', 'O'), ('which', 'O'), ('no', 'O'), ('BRCA1', 'O'), ('alterations', 'O'), ('were', 'O'), ('detected', 'O'), ('included', 'O'), ('1', 'O'), ('breast', 'B'), ('-', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('kindred', 'O'), ('manifesting', 'O'), ('clear', 'O'), ('linkage', 'O'), ('to', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('region', 'O'), ('and', 'O'), ('loss', 'O'), ('of', 'O'), ('the', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('chromosome', 'O'), ('in', 'O'), ('associated', 'O'), ('tumors', 'B'), ('.', 'O'))"
"In all , 12 of 16 kindreds manifesting BRCA1 mutation or linkage contained ovarian cancer , as compared with only 6 of the remaining 31 families ( P < . 001 ) .","(('In', 'O'), ('all', 'O'), (',', 'O'), ('12', 'O'), ('of', 'O'), ('16', 'O'), ('kindreds', 'O'), ('manifesting', 'O'), ('BRCA1', 'O'), ('mutation', 'O'), ('or', 'O'), ('linkage', 'O'), ('contained', 'O'), ('ovarian', 'B'), ('cancer', 'I'), (',', 'O'), ('as', 'O'), ('compared', 'O'), ('with', 'O'), ('only', 'O'), ('6', 'O'), ('of', 'O'), ('the', 'O'), ('remaining', 'O'), ('31', 'O'), ('families', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('.', 'O'))"
Rapid detection of regionally clustered germ - line BRCA1 mutations by multiplex heteroduplex analysis .,"(('Rapid', 'O'), ('detection', 'O'), ('of', 'O'), ('regionally', 'O'), ('clustered', 'O'), ('germ', 'O'), ('-', 'O'), ('line', 'O'), ('BRCA1', 'O'), ('mutations', 'O'), ('by', 'O'), ('multiplex', 'O'), ('heteroduplex', 'O'), ('analysis', 'O'), ('.', 'O'))"
Germ - line mutations of the BRCA1 gene are responsible for a substantial proportion of families with multiple cases of early - onset breast and / or ovarian cancer .,"(('Germ', 'O'), ('-', 'O'), ('line', 'O'), ('mutations', 'O'), ('of', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('gene', 'O'), ('are', 'O'), ('responsible', 'O'), ('for', 'O'), ('a', 'O'), ('substantial', 'O'), ('proportion', 'O'), ('of', 'O'), ('families', 'O'), ('with', 'O'), ('multiple', 'O'), ('cases', 'O'), ('of', 'O'), ('early', 'O'), ('-', 'O'), ('onset', 'O'), ('breast', 'B'), ('and', 'I'), ('/', 'I'), ('or', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('.', 'O'))"
"Since the isolation of BRCA1 last year , > 65 distinct mutations scattered throughout the coding region have been detected , making analysis of the gene time consuming and technically challenging .","(('Since', 'O'), ('the', 'O'), ('isolation', 'O'), ('of', 'O'), ('BRCA1', 'O'), ('last', 'O'), ('year', 'O'), (',', 'O'), ('>', 'O'), ('65', 'O'), ('distinct', 'O'), ('mutations', 'O'), ('scattered', 'O'), ('throughout', 'O'), ('the', 'O'), ('coding', 'O'), ('region', 'O'), ('have', 'O'), ('been', 'O'), ('detected', 'O'), (',', 'O'), ('making', 'O'), ('analysis', 'O'), ('of', 'O'), ('the', 'O'), ('gene', 'O'), ('time', 'O'), ('consuming', 'O'), ('and', 'O'), ('technically', 'O'), ('challenging', 'O'), ('.', 'O'))"
We have developed a multiplex heteroduplex analysis that is designed to analyze one - quarter of the coding sequence in a single - step screening procedure and that will detect approximately 50 % of all BRCA1 mutations so far reported in breast / ovarian cancer families .,"(('We', 'O'), ('have', 'O'), ('developed', 'O'), ('a', 'O'), ('multiplex', 'O'), ('heteroduplex', 'O'), ('analysis', 'O'), ('that', 'O'), ('is', 'O'), ('designed', 'O'), ('to', 'O'), ('analyze', 'O'), ('one', 'O'), ('-', 'O'), ('quarter', 'O'), ('of', 'O'), ('the', 'O'), ('coding', 'O'), ('sequence', 'O'), ('in', 'O'), ('a', 'O'), ('single', 'O'), ('-', 'O'), ('step', 'O'), ('screening', 'O'), ('procedure', 'O'), ('and', 'O'), ('that', 'O'), ('will', 'O'), ('detect', 'O'), ('approximately', 'O'), ('50', 'O'), ('%', 'O'), ('of', 'O'), ('all', 'O'), ('BRCA1', 'O'), ('mutations', 'O'), ('so', 'O'), ('far', 'O'), ('reported', 'O'), ('in', 'O'), ('breast', 'B'), ('/', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('families', 'O'), ('.', 'O'))"
We have used this technique to analyze BRCA1 in 162 families with a history of breast and / or ovarian cancer and identified 12 distinct mutations in 35 families . .,"(('We', 'O'), ('have', 'O'), ('used', 'O'), ('this', 'O'), ('technique', 'O'), ('to', 'O'), ('analyze', 'O'), ('BRCA1', 'O'), ('in', 'O'), ('162', 'O'), ('families', 'O'), ('with', 'O'), ('a', 'O'), ('history', 'O'), ('of', 'O'), ('breast', 'B'), ('and', 'I'), ('/', 'I'), ('or', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('and', 'O'), ('identified', 'O'), ('12', 'O'), ('distinct', 'O'), ('mutations', 'O'), ('in', 'O'), ('35', 'O'), ('families', 'O'), ('.', 'O'), ('.', 'O'))"
"Codon 344 is a key residue within the tetramerisation domain , and the amino acid substitution of a proline for a leucine is predicted to have profound implications for tetramerisation and potentially DNA binding .","(('Codon', 'O'), ('344', 'O'), ('is', 'O'), ('a', 'O'), ('key', 'O'), ('residue', 'O'), ('within', 'O'), ('the', 'O'), ('tetramerisation', 'O'), ('domain', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('amino', 'O'), ('acid', 'O'), ('substitution', 'O'), ('of', 'O'), ('a', 'O'), ('proline', 'O'), ('for', 'O'), ('a', 'O'), ('leucine', 'O'), ('is', 'O'), ('predicted', 'O'), ('to', 'O'), ('have', 'O'), ('profound', 'O'), ('implications', 'O'), ('for', 'O'), ('tetramerisation', 'O'), ('and', 'O'), ('potentially', 'O'), ('DNA', 'O'), ('binding', 'O'), ('.', 'O'))"
"A cell line has been established from the tumour of the proband and cytogenetic and molecular studies carried out , providing an extensive analysis in this family . .","(('A', 'O'), ('cell', 'O'), ('line', 'O'), ('has', 'O'), ('been', 'O'), ('established', 'O'), ('from', 'O'), ('the', 'O'), ('tumour', 'B'), ('of', 'O'), ('the', 'O'), ('proband', 'O'), ('and', 'O'), ('cytogenetic', 'O'), ('and', 'O'), ('molecular', 'O'), ('studies', 'O'), ('carried', 'O'), ('out', 'O'), (',', 'O'), ('providing', 'O'), ('an', 'O'), ('extensive', 'O'), ('analysis', 'O'), ('in', 'O'), ('this', 'O'), ('family', 'O'), ('.', 'O'), ('.', 'O'))"
Previous investigations by Southern blot hybridization and PCR fragment - length analysis had revealed mutations in 48 patients .,"(('Previous', 'O'), ('investigations', 'O'), ('by', 'O'), ('Southern', 'O'), ('blot', 'O'), ('hybridization', 'O'), ('and', 'O'), ('PCR', 'O'), ('fragment', 'O'), ('-', 'O'), ('length', 'O'), ('analysis', 'O'), ('had', 'O'), ('revealed', 'O'), ('mutations', 'O'), ('in', 'O'), ('48', 'O'), ('patients', 'O'), ('.', 'O'))"
Here we report on the analysis of the remaining 71 patients .,"(('Here', 'O'), ('we', 'O'), ('report', 'O'), ('on', 'O'), ('the', 'O'), ('analysis', 'O'), ('of', 'O'), ('the', 'O'), ('remaining', 'O'), ('71', 'O'), ('patients', 'O'), ('.', 'O'))"
"By applying heteroduplex analysis , nonisotopic SSCP , and direct sequencing , we detected germ - line mutations resulting in premature termination codons or disruption of splice signals in 51 ( 72 % ) of the 71 patients .","(('By', 'O'), ('applying', 'O'), ('heteroduplex', 'O'), ('analysis', 'O'), (',', 'O'), ('nonisotopic', 'O'), ('SSCP', 'O'), (',', 'O'), ('and', 'O'), ('direct', 'O'), ('sequencing', 'O'), (',', 'O'), ('we', 'O'), ('detected', 'O'), ('germ', 'O'), ('-', 'O'), ('line', 'O'), ('mutations', 'O'), ('resulting', 'O'), ('in', 'O'), ('premature', 'O'), ('termination', 'O'), ('codons', 'O'), ('or', 'O'), ('disruption', 'O'), ('of', 'O'), ('splice', 'O'), ('signals', 'O'), ('in', 'O'), ('51', 'O'), ('(', 'O'), ('72', 'O'), ('%', 'O'), (')', 'O'), ('of', 'O'), ('the', 'O'), ('71', 'O'), ('patients', 'O'), ('.', 'O'))"
Four patients also showed rare sequence variants .,"(('Four', 'O'), ('patients', 'O'), ('also', 'O'), ('showed', 'O'), ('rare', 'O'), ('sequence', 'O'), ('variants', 'O'), ('.', 'O'))"
No region of the RB1 gene was preferentially involved in single base substitutions .,"(('No', 'O'), ('region', 'O'), ('of', 'O'), ('the', 'O'), ('RB1', 'O'), ('gene', 'O'), ('was', 'O'), ('preferentially', 'O'), ('involved', 'O'), ('in', 'O'), ('single', 'O'), ('base', 'O'), ('substitutions', 'O'), ('.', 'O'))"
Recurrent transitions were observed at most of the 14 codons within the RB1 .,"(('Recurrent', 'O'), ('transitions', 'O'), ('were', 'O'), ('observed', 'O'), ('at', 'O'), ('most', 'O'), ('of', 'O'), ('the', 'O'), ('14', 'O'), ('codons', 'O'), ('within', 'O'), ('the', 'O'), ('RB1', 'O'), ('.', 'O'))"
"No mutation was observed in exons 25 - 27 , although this region contains two CGA codons .","(('No', 'O'), ('mutation', 'O'), ('was', 'O'), ('observed', 'O'), ('in', 'O'), ('exons', 'O'), ('25', 'O'), ('-', 'O'), ('27', 'O'), (',', 'O'), ('although', 'O'), ('this', 'O'), ('region', 'O'), ('contains', 'O'), ('two', 'O'), ('CGA', 'O'), ('codons', 'O'), ('.', 'O'))"
This suggests that mutations within the 3 - terminal region of the RB1 gene may not be oncogenic .,"(('This', 'O'), ('suggests', 'O'), ('that', 'O'), ('mutations', 'O'), ('within', 'O'), ('the', 'O'), ('3', 'O'), ('-', 'O'), ('terminal', 'O'), ('region', 'O'), ('of', 'O'), ('the', 'O'), ('RB1', 'O'), ('gene', 'O'), ('may', 'O'), ('not', 'O'), ('be', 'O'), ('oncogenic', 'O'), ('.', 'O'))"
"When these data were combined with the results of our previous investigations , mutations were identified in a total of 99 ( 83 % ) of 119 patients .","(('When', 'O'), ('these', 'O'), ('data', 'O'), ('were', 'O'), ('combined', 'O'), ('with', 'O'), ('the', 'O'), ('results', 'O'), ('of', 'O'), ('our', 'O'), ('previous', 'O'), ('investigations', 'O'), (',', 'O'), ('mutations', 'O'), ('were', 'O'), ('identified', 'O'), ('in', 'O'), ('a', 'O'), ('total', 'O'), ('of', 'O'), ('99', 'O'), ('(', 'O'), ('83', 'O'), ('%', 'O'), (')', 'O'), ('of', 'O'), ('119', 'O'), ('patients', 'O'), ('.', 'O'))"
"The spectrum comprises 15 % large deletions , 26 % small length alterations , and 42 % base substitutions .","(('The', 'O'), ('spectrum', 'O'), ('comprises', 'O'), ('15', 'O'), ('%', 'O'), ('large', 'O'), ('deletions', 'O'), (',', 'O'), ('26', 'O'), ('%', 'O'), ('small', 'O'), ('length', 'O'), ('alterations', 'O'), (',', 'O'), ('and', 'O'), ('42', 'O'), ('%', 'O'), ('base', 'O'), ('substitutions', 'O'), ('.', 'O'))"
"Most large analyses that defined the limits of the normal and pathological size ranges employed PCR assays , which included the CAG repeats and a CCG repeat tract that was thought to be invariant .","(('Most', 'O'), ('large', 'O'), ('analyses', 'O'), ('that', 'O'), ('defined', 'O'), ('the', 'O'), ('limits', 'O'), ('of', 'O'), ('the', 'O'), ('normal', 'O'), ('and', 'O'), ('pathological', 'O'), ('size', 'O'), ('ranges', 'O'), ('employed', 'O'), ('PCR', 'O'), ('assays', 'O'), (',', 'O'), ('which', 'O'), ('included', 'O'), ('the', 'O'), ('CAG', 'O'), ('repeats', 'O'), ('and', 'O'), ('a', 'O'), ('CCG', 'O'), ('repeat', 'O'), ('tract', 'O'), ('that', 'O'), ('was', 'O'), ('thought', 'O'), ('to', 'O'), ('be', 'O'), ('invariant', 'O'), ('.', 'O'))"
Many of these experiments found an overlap between the normal and disease size ranges .,"(('Many', 'O'), ('of', 'O'), ('these', 'O'), ('experiments', 'O'), ('found', 'O'), ('an', 'O'), ('overlap', 'O'), ('between', 'O'), ('the', 'O'), ('normal', 'O'), ('and', 'O'), ('disease', 'O'), ('size', 'O'), ('ranges', 'O'), ('.', 'O'))"
Subsequent findings that the CCG repeats vary by 8 trinucleotide lengths suggested that the limits of the normal and disease size ranges should be reevaluated with assays that exclude the CCG polymorphism .,"(('Subsequent', 'O'), ('findings', 'O'), ('that', 'O'), ('the', 'O'), ('CCG', 'O'), ('repeats', 'O'), ('vary', 'O'), ('by', 'O'), ('8', 'O'), ('trinucleotide', 'O'), ('lengths', 'O'), ('suggested', 'O'), ('that', 'O'), ('the', 'O'), ('limits', 'O'), ('of', 'O'), ('the', 'O'), ('normal', 'O'), ('and', 'O'), ('disease', 'O'), ('size', 'O'), ('ranges', 'O'), ('should', 'O'), ('be', 'O'), ('reevaluated', 'O'), ('with', 'O'), ('assays', 'O'), ('that', 'O'), ('exclude', 'O'), ('the', 'O'), ('CCG', 'O'), ('polymorphism', 'O'), ('.', 'O'))"
"Since patients with between 30 and 40 repeats are rare , a consortium was assembled to collect such individuals .","(('Since', 'O'), ('patients', 'O'), ('with', 'O'), ('between', 'O'), ('30', 'O'), ('and', 'O'), ('40', 'O'), ('repeats', 'O'), ('are', 'O'), ('rare', 'O'), (',', 'O'), ('a', 'O'), ('consortium', 'O'), ('was', 'O'), ('assembled', 'O'), ('to', 'O'), ('collect', 'O'), ('such', 'O'), ('individuals', 'O'), ('.', 'O'))"
All 178 samples were reanalyzed in Cambridge by using assays specific for the CAG repeats .,"(('All', 'O'), ('178', 'O'), ('samples', 'O'), ('were', 'O'), ('reanalyzed', 'O'), ('in', 'O'), ('Cambridge', 'O'), ('by', 'O'), ('using', 'O'), ('assays', 'O'), ('specific', 'O'), ('for', 'O'), ('the', 'O'), ('CAG', 'O'), ('repeats', 'O'), ('.', 'O'))"
We have optimized methods for reliable sizing of CAG repeats and show cases that demonstrate the dangers of using PCR assays that include both the CAG and CCG polymorphisms .,"(('We', 'O'), ('have', 'O'), ('optimized', 'O'), ('methods', 'O'), ('for', 'O'), ('reliable', 'O'), ('sizing', 'O'), ('of', 'O'), ('CAG', 'O'), ('repeats', 'O'), ('and', 'O'), ('show', 'O'), ('cases', 'O'), ('that', 'O'), ('demonstrate', 'O'), ('the', 'O'), ('dangers', 'O'), ('of', 'O'), ('using', 'O'), ('PCR', 'O'), ('assays', 'O'), ('that', 'O'), ('include', 'O'), ('both', 'O'), ('the', 'O'), ('CAG', 'O'), ('and', 'O'), ('CCG', 'O'), ('polymorphisms', 'O'), ('.', 'O'))"
"Mutations in ASPA that lead to loss of enzymatic activity have been identified , and E285A and Y231X are the two predominant mutations that account for 97 % of the mutant chromosomes in Ashkenazi Jewish patients .","(('Mutations', 'O'), ('in', 'O'), ('ASPA', 'O'), ('that', 'O'), ('lead', 'O'), ('to', 'O'), ('loss', 'O'), ('of', 'O'), ('enzymatic', 'O'), ('activity', 'O'), ('have', 'O'), ('been', 'O'), ('identified', 'O'), (',', 'O'), ('and', 'O'), ('E285A', 'O'), ('and', 'O'), ('Y231X', 'O'), ('are', 'O'), ('the', 'O'), ('two', 'O'), ('predominant', 'O'), ('mutations', 'O'), ('that', 'O'), ('account', 'O'), ('for', 'O'), ('97', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('mutant', 'O'), ('chromosomes', 'O'), ('in', 'O'), ('Ashkenazi', 'O'), ('Jewish', 'O'), ('patients', 'O'), ('.', 'O'))"
Eight novel and three previously characterized mutations accounted for 80 % ( 40 / 50 ) of mutant chromosomes .,"(('Eight', 'O'), ('novel', 'O'), ('and', 'O'), ('three', 'O'), ('previously', 'O'), ('characterized', 'O'), ('mutations', 'O'), ('accounted', 'O'), ('for', 'O'), ('80', 'O'), ('%', 'O'), ('(', 'O'), ('40', 'O'), ('/', 'O'), ('50', 'O'), (')', 'O'), ('of', 'O'), ('mutant', 'O'), ('chromosomes', 'O'), ('.', 'O'))"
"The A305E missense mutation accounted for 48 % ( 24 / 50 ) of mutant chromosomes in patients of western European descent , while the two predominant Jewish mutations each accounted for a single mutant chromosome .","(('The', 'O'), ('A305E', 'O'), ('missense', 'O'), ('mutation', 'O'), ('accounted', 'O'), ('for', 'O'), ('48', 'O'), ('%', 'O'), ('(', 'O'), ('24', 'O'), ('/', 'O'), ('50', 'O'), (')', 'O'), ('of', 'O'), ('mutant', 'O'), ('chromosomes', 'O'), ('in', 'O'), ('patients', 'O'), ('of', 'O'), ('western', 'O'), ('European', 'O'), ('descent', 'O'), (',', 'O'), ('while', 'O'), ('the', 'O'), ('two', 'O'), ('predominant', 'O'), ('Jewish', 'O'), ('mutations', 'O'), ('each', 'O'), ('accounted', 'O'), ('for', 'O'), ('a', 'O'), ('single', 'O'), ('mutant', 'O'), ('chromosome', 'O'), ('.', 'O'))"
"The eight novel mutations identified included 1 - and 4 - bp deletions ( 32 deltaT and 876 deltaAGAA , respectively ) and I16T , G27R , D114E , G123E , C152Y , and R168C missense mutations .","(('The', 'O'), ('eight', 'O'), ('novel', 'O'), ('mutations', 'O'), ('identified', 'O'), ('included', 'O'), ('1', 'O'), ('-', 'O'), ('and', 'O'), ('4', 'O'), ('-', 'O'), ('bp', 'O'), ('deletions', 'O'), ('(', 'O'), ('32', 'O'), ('deltaT', 'O'), ('and', 'O'), ('876', 'O'), ('deltaAGAA', 'O'), (',', 'O'), ('respectively', 'O'), (')', 'O'), ('and', 'O'), ('I16T', 'O'), (',', 'O'), ('G27R', 'O'), (',', 'O'), ('D114E', 'O'), (',', 'O'), ('G123E', 'O'), (',', 'O'), ('C152Y', 'O'), (',', 'O'), ('and', 'O'), ('R168C', 'O'), ('missense', 'O'), ('mutations', 'O'), ('.', 'O'))"
The heterozygosity for 876 deltaAGAA mutation was identified in three independent patients from England .,"(('The', 'O'), ('heterozygosity', 'O'), ('for', 'O'), ('876', 'O'), ('deltaAGAA', 'O'), ('mutation', 'O'), ('was', 'O'), ('identified', 'O'), ('in', 'O'), ('three', 'O'), ('independent', 'O'), ('patients', 'O'), ('from', 'O'), ('England', 'O'), ('.', 'O'))"
"Six single - base changes leading to missense mutations were identified in patients from Turkey ( D114E , R168C ) , The Netherlands ( I16T ) , Germany ( G27R ) , Ireland ( C152Y ) , and Canada ( G123E ) .","(('Six', 'O'), ('single', 'O'), ('-', 'O'), ('base', 'O'), ('changes', 'O'), ('leading', 'O'), ('to', 'O'), ('missense', 'O'), ('mutations', 'O'), ('were', 'O'), ('identified', 'O'), ('in', 'O'), ('patients', 'O'), ('from', 'O'), ('Turkey', 'O'), ('(', 'O'), ('D114E', 'O'), (',', 'O'), ('R168C', 'O'), (')', 'O'), (',', 'O'), ('The', 'O'), ('Netherlands', 'O'), ('(', 'O'), ('I16T', 'O'), (')', 'O'), (',', 'O'), ('Germany', 'O'), ('(', 'O'), ('G27R', 'O'), (')', 'O'), (',', 'O'), ('Ireland', 'O'), ('(', 'O'), ('C152Y', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('Canada', 'O'), ('(', 'O'), ('G123E', 'O'), (')', 'O'), ('.', 'O'))"
A PCR - based protocol is described that was used to introduce mutations in wild - type cDNA .,"(('A', 'O'), ('PCR', 'O'), ('-', 'O'), ('based', 'O'), ('protocol', 'O'), ('is', 'O'), ('described', 'O'), ('that', 'O'), ('was', 'O'), ('used', 'O'), ('to', 'O'), ('introduce', 'O'), ('mutations', 'O'), ('in', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('cDNA', 'O'), ('.', 'O'))"
The entire coding sequence of the Atm transcript was cloned and found to contain an open reading frame encoding a protein of 3066 amino acids with 84 % overall identity and 91 % similarity to the human ATM protein .,"(('The', 'O'), ('entire', 'O'), ('coding', 'O'), ('sequence', 'O'), ('of', 'O'), ('the', 'O'), ('Atm', 'O'), ('transcript', 'O'), ('was', 'O'), ('cloned', 'O'), ('and', 'O'), ('found', 'O'), ('to', 'O'), ('contain', 'O'), ('an', 'O'), ('open', 'O'), ('reading', 'O'), ('frame', 'O'), ('encoding', 'O'), ('a', 'O'), ('protein', 'O'), ('of', 'O'), ('3066', 'O'), ('amino', 'O'), ('acids', 'O'), ('with', 'O'), ('84', 'O'), ('%', 'O'), ('overall', 'O'), ('identity', 'O'), ('and', 'O'), ('91', 'O'), ('%', 'O'), ('similarity', 'O'), ('to', 'O'), ('the', 'O'), ('human', 'O'), ('ATM', 'O'), ('protein', 'O'), ('.', 'O'))"
Variable levels of expression of Atm were observed in different tissues .,"(('Variable', 'O'), ('levels', 'O'), ('of', 'O'), ('expression', 'O'), ('of', 'O'), ('Atm', 'O'), ('were', 'O'), ('observed', 'O'), ('in', 'O'), ('different', 'O'), ('tissues', 'O'), ('.', 'O'))"
"Fluorescence in situ hybridization and linkage analysis located the Atm gene on mouse chromosome 9 , band 9C , in a region homologous to the ATM region on human chromosome 11q22 - q23 . .","(('Fluorescence', 'O'), ('in', 'O'), ('situ', 'O'), ('hybridization', 'O'), ('and', 'O'), ('linkage', 'O'), ('analysis', 'O'), ('located', 'O'), ('the', 'O'), ('Atm', 'O'), ('gene', 'O'), ('on', 'O'), ('mouse', 'O'), ('chromosome', 'O'), ('9', 'O'), (',', 'O'), ('band', 'O'), ('9C', 'O'), (',', 'O'), ('in', 'O'), ('a', 'O'), ('region', 'O'), ('homologous', 'O'), ('to', 'O'), ('the', 'O'), ('ATM', 'O'), ('region', 'O'), ('on', 'O'), ('human', 'O'), ('chromosome', 'O'), ('11q22', 'O'), ('-', 'O'), ('q23', 'O'), ('.', 'O'), ('.', 'O'))"
A distinct feature of the mouse gene is an expanded polymorphic GGA trinucleotide repeat that codes for polyglycine and varies from 15 to 17 triplets in different Mus musculus strains .,"(('A', 'O'), ('distinct', 'O'), ('feature', 'O'), ('of', 'O'), ('the', 'O'), ('mouse', 'O'), ('gene', 'O'), ('is', 'O'), ('an', 'O'), ('expanded', 'O'), ('polymorphic', 'O'), ('GGA', 'O'), ('trinucleotide', 'O'), ('repeat', 'O'), ('that', 'O'), ('codes', 'O'), ('for', 'O'), ('polyglycine', 'O'), ('and', 'O'), ('varies', 'O'), ('from', 'O'), ('15', 'O'), ('to', 'O'), ('17', 'O'), ('triplets', 'O'), ('in', 'O'), ('different', 'O'), ('Mus', 'O'), ('musculus', 'O'), ('strains', 'O'), ('.', 'O'))"
The genomic structure of the mouse WASP gene is expressed as an approximately 2 .,"(('The', 'O'), ('genomic', 'O'), ('structure', 'O'), ('of', 'O'), ('the', 'O'), ('mouse', 'O'), ('WASP', 'O'), ('gene', 'O'), ('is', 'O'), ('expressed', 'O'), ('as', 'O'), ('an', 'O'), ('approximately', 'O'), ('2', 'O'), ('.', 'O'))"
4 - kb mRNA in thymus and spleen .,"(('4', 'O'), ('-', 'O'), ('kb', 'O'), ('mRNA', 'O'), ('in', 'O'), ('thymus', 'O'), ('and', 'O'), ('spleen', 'O'), ('.', 'O'))"
Chromosomal mapping in an interspecific M .,"(('Chromosomal', 'O'), ('mapping', 'O'), ('in', 'O'), ('an', 'O'), ('interspecific', 'O'), ('M', 'O'), ('.', 'O'))"
"Musculus / M . spretus backcross placed the Wasp locus near the centromere of the mouse X chromosome , inseparable from Gata1 , Tcfe3 , and scurfy ( sf ) .","(('Musculus', 'O'), ('/', 'O'), ('M', 'O'), ('.', 'O'), ('spretus', 'O'), ('backcross', 'O'), ('placed', 'O'), ('the', 'O'), ('Wasp', 'O'), ('locus', 'O'), ('near', 'O'), ('the', 'O'), ('centromere', 'O'), ('of', 'O'), ('the', 'O'), ('mouse', 'O'), ('X', 'O'), ('chromosome', 'O'), (',', 'O'), ('inseparable', 'O'), ('from', 'O'), ('Gata1', 'O'), (',', 'O'), ('Tcfe3', 'O'), (',', 'O'), ('and', 'O'), ('scurfy', 'O'), ('(', 'O'), ('sf', 'O'), (')', 'O'), ('.', 'O'))"
"Northern analysis of sf tissue samples indicated the presence of WASP mRNA in liver and skin , presumably as a consequence of lymphocytic infiltration , but non abnormalities in the amount or size of mRNA present .","(('Northern', 'O'), ('analysis', 'O'), ('of', 'O'), ('sf', 'O'), ('tissue', 'O'), ('samples', 'O'), ('indicated', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('WASP', 'O'), ('mRNA', 'O'), ('in', 'O'), ('liver', 'O'), ('and', 'O'), ('skin', 'O'), (',', 'O'), ('presumably', 'O'), ('as', 'O'), ('a', 'O'), ('consequence', 'O'), ('of', 'O'), ('lymphocytic', 'O'), ('infiltration', 'O'), (',', 'O'), ('but', 'O'), ('non', 'O'), ('abnormalities', 'O'), ('in', 'O'), ('the', 'O'), ('amount', 'O'), ('or', 'O'), ('size', 'O'), ('of', 'O'), ('mRNA', 'O'), ('present', 'O'), ('.', 'O'))"
OBJECTIVE .,"(('OBJECTIVE', 'O'), ('.', 'O'))"
METHODS .,"(('METHODS', 'O'), ('.', 'O'))"
"Using a specific radioimmunoassay , we determined colchicine concentrations in the serum and breast milk of 4 patients at various time points , following oral administration of the drug .","(('Using', 'O'), ('a', 'O'), ('specific', 'O'), ('radioimmunoassay', 'O'), (',', 'O'), ('we', 'O'), ('determined', 'O'), ('colchicine', 'O'), ('concentrations', 'O'), ('in', 'O'), ('the', 'O'), ('serum', 'O'), ('and', 'O'), ('breast', 'O'), ('milk', 'O'), ('of', 'O'), ('4', 'O'), ('patients', 'O'), ('at', 'O'), ('various', 'O'), ('time', 'O'), ('points', 'O'), (',', 'O'), ('following', 'O'), ('oral', 'O'), ('administration', 'O'), ('of', 'O'), ('the', 'O'), ('drug', 'O'), ('.', 'O'))"
RESULTS .,"(('RESULTS', 'O'), ('.', 'O'))"
Colchicine was found to be excreted in breast milk .,"(('Colchicine', 'O'), ('was', 'O'), ('found', 'O'), ('to', 'O'), ('be', 'O'), ('excreted', 'O'), ('in', 'O'), ('breast', 'O'), ('milk', 'O'), ('.', 'O'))"
Its levels ranged between 1 .,"(('Its', 'O'), ('levels', 'O'), ('ranged', 'O'), ('between', 'O'), ('1', 'O'), ('.', 'O'))"
9 and 8 .,"(('9', 'O'), ('and', 'O'), ('8', 'O'), ('.', 'O'))"
"6 ng / ml , which were similar to those found in the serum ( parallel concentration time curves ) .","(('6', 'O'), ('ng', 'O'), ('/', 'O'), ('ml', 'O'), (',', 'O'), ('which', 'O'), ('were', 'O'), ('similar', 'O'), ('to', 'O'), ('those', 'O'), ('found', 'O'), ('in', 'O'), ('the', 'O'), ('serum', 'O'), ('(', 'O'), ('parallel', 'O'), ('concentration', 'O'), ('time', 'O'), ('curves', 'O'), (')', 'O'), ('.', 'O'))"
"However , there appeared to be a considerable variation in colchicine milk concentration among the different patients , which might be related to individual breast milk composition and , possibly , to other nutritional or metabolic factors .","(('However', 'O'), (',', 'O'), ('there', 'O'), ('appeared', 'O'), ('to', 'O'), ('be', 'O'), ('a', 'O'), ('considerable', 'O'), ('variation', 'O'), ('in', 'O'), ('colchicine', 'O'), ('milk', 'O'), ('concentration', 'O'), ('among', 'O'), ('the', 'O'), ('different', 'O'), ('patients', 'O'), (',', 'O'), ('which', 'O'), ('might', 'O'), ('be', 'O'), ('related', 'O'), ('to', 'O'), ('individual', 'O'), ('breast', 'O'), ('milk', 'O'), ('composition', 'O'), ('and', 'O'), (',', 'O'), ('possibly', 'O'), (',', 'O'), ('to', 'O'), ('other', 'O'), ('nutritional', 'O'), ('or', 'O'), ('metabolic', 'O'), ('factors', 'O'), ('.', 'O'))"
CONCLUSION .,"(('CONCLUSION', 'O'), ('.', 'O'))"
The extensive peripheral tissue binding and relatively low concentration of colchicine in breast milk suggests that the amount ingested by the infant is small .,"(('The', 'O'), ('extensive', 'O'), ('peripheral', 'O'), ('tissue', 'O'), ('binding', 'O'), ('and', 'O'), ('relatively', 'O'), ('low', 'O'), ('concentration', 'O'), ('of', 'O'), ('colchicine', 'O'), ('in', 'O'), ('breast', 'O'), ('milk', 'O'), ('suggests', 'O'), ('that', 'O'), ('the', 'O'), ('amount', 'O'), ('ingested', 'O'), ('by', 'O'), ('the', 'O'), ('infant', 'O'), ('is', 'O'), ('small', 'O'), ('.', 'O'))"
"The effect of altered expression levels of DMPK , which is ubiquitously expressed in all muscle cell lineages during development , was examined by disrupting the endogenous Dmpk gene and overexpressing a normal human DMPK transgene in mice .","(('The', 'O'), ('effect', 'O'), ('of', 'O'), ('altered', 'O'), ('expression', 'O'), ('levels', 'O'), ('of', 'O'), ('DMPK', 'O'), (',', 'O'), ('which', 'O'), ('is', 'O'), ('ubiquitously', 'O'), ('expressed', 'O'), ('in', 'O'), ('all', 'O'), ('muscle', 'O'), ('cell', 'O'), ('lineages', 'O'), ('during', 'O'), ('development', 'O'), (',', 'O'), ('was', 'O'), ('examined', 'O'), ('by', 'O'), ('disrupting', 'O'), ('the', 'O'), ('endogenous', 'O'), ('Dmpk', 'O'), ('gene', 'O'), ('and', 'O'), ('overexpressing', 'O'), ('a', 'O'), ('normal', 'O'), ('human', 'O'), ('DMPK', 'O'), ('transgene', 'O'), ('in', 'O'), ('mice', 'O'), ('.', 'O'))"
These results strengthen the contention that simple loss - or gain - of - expression of DMPK is not the only crucial requirement for development of the disease . .,"(('These', 'O'), ('results', 'O'), ('strengthen', 'O'), ('the', 'O'), ('contention', 'O'), ('that', 'O'), ('simple', 'O'), ('loss', 'O'), ('-', 'O'), ('or', 'O'), ('gain', 'O'), ('-', 'O'), ('of', 'O'), ('-', 'O'), ('expression', 'O'), ('of', 'O'), ('DMPK', 'O'), ('is', 'O'), ('not', 'O'), ('the', 'O'), ('only', 'O'), ('crucial', 'O'), ('requirement', 'O'), ('for', 'O'), ('development', 'O'), ('of', 'O'), ('the', 'O'), ('disease', 'O'), ('.', 'O'), ('.', 'O'))"
Adult Dmpk - / - mice show ultrastructural changes in muscle and a 50 % decrease in force generation compared to young mice .,"(('Adult', 'O'), ('Dmpk', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), ('mice', 'O'), ('show', 'O'), ('ultrastructural', 'O'), ('changes', 'O'), ('in', 'O'), ('muscle', 'O'), ('and', 'O'), ('a', 'O'), ('50', 'O'), ('%', 'O'), ('decrease', 'O'), ('in', 'O'), ('force', 'O'), ('generation', 'O'), ('compared', 'O'), ('to', 'O'), ('young', 'O'), ('mice', 'O'), ('.', 'O'))"
The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse .,"(('The', 'O'), ('tumor', 'O'), ('suppressor', 'O'), ('gene', 'O'), ('Brca1', 'O'), ('is', 'O'), ('required', 'O'), ('for', 'O'), ('embryonic', 'O'), ('cellular', 'O'), ('proliferation', 'O'), ('in', 'O'), ('the', 'O'), ('mouse', 'O'), ('.', 'O'))"
Mutations of the BRCA1 gone in humans are associated with predisposition to breast and ovarian cancers .,"(('Mutations', 'O'), ('of', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('gone', 'O'), ('in', 'O'), ('humans', 'O'), ('are', 'O'), ('associated', 'O'), ('with', 'O'), ('predisposition', 'O'), ('to', 'O'), ('breast', 'B'), ('and', 'I'), ('ovarian', 'I'), ('cancers', 'I'), ('.', 'O'))"
We show here that Brca1 + / - mice are normal and fertile and lack tumors by age eleven months .,"(('We', 'O'), ('show', 'O'), ('here', 'O'), ('that', 'O'), ('Brca1', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('mice', 'O'), ('are', 'O'), ('normal', 'O'), ('and', 'O'), ('fertile', 'O'), ('and', 'O'), ('lack', 'O'), ('tumors', 'B'), ('by', 'O'), ('age', 'O'), ('eleven', 'O'), ('months', 'O'), ('.', 'O'))"
Homozygous Brca1 ( 5 - 6 ) mutant mice die before day 7 .,"(('Homozygous', 'O'), ('Brca1', 'O'), ('(', 'O'), ('5', 'O'), ('-', 'O'), ('6', 'O'), (')', 'O'), ('mutant', 'O'), ('mice', 'O'), ('die', 'O'), ('before', 'O'), ('day', 'O'), ('7', 'O'), ('.', 'O'))"
5 of embryogenesis .,"(('5', 'O'), ('of', 'O'), ('embryogenesis', 'O'), ('.', 'O'))"
"Mutant embryos are poorly developed , with no evidence of mesoderm formation .","(('Mutant', 'O'), ('embryos', 'O'), ('are', 'O'), ('poorly', 'O'), ('developed', 'O'), (',', 'O'), ('with', 'O'), ('no', 'O'), ('evidence', 'O'), ('of', 'O'), ('mesoderm', 'O'), ('formation', 'O'), ('.', 'O'))"
"The extraembryonic region is abnormal , but aggregation with wild - type tetraploid embryos does not rescue the lethality .","(('The', 'O'), ('extraembryonic', 'O'), ('region', 'O'), ('is', 'O'), ('abnormal', 'O'), (',', 'O'), ('but', 'O'), ('aggregation', 'O'), ('with', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('tetraploid', 'O'), ('embryos', 'O'), ('does', 'O'), ('not', 'O'), ('rescue', 'O'), ('the', 'O'), ('lethality', 'O'), ('.', 'O'))"
"In vivo , mutant embryos do not exhibit increased apoptosis but show reduced cell proliferation accompanied by decreased expression of cyclin E and mdm - 2 , a regulator of p53 activity .","(('In', 'O'), ('vivo', 'O'), (',', 'O'), ('mutant', 'O'), ('embryos', 'O'), ('do', 'O'), ('not', 'O'), ('exhibit', 'O'), ('increased', 'O'), ('apoptosis', 'O'), ('but', 'O'), ('show', 'O'), ('reduced', 'O'), ('cell', 'O'), ('proliferation', 'O'), ('accompanied', 'O'), ('by', 'O'), ('decreased', 'O'), ('expression', 'O'), ('of', 'O'), ('cyclin', 'O'), ('E', 'O'), ('and', 'O'), ('mdm', 'O'), ('-', 'O'), ('2', 'O'), (',', 'O'), ('a', 'O'), ('regulator', 'O'), ('of', 'O'), ('p53', 'O'), ('activity', 'O'), ('.', 'O'))"
The expression of cyclin - dependent kinase inhibitor p21 is dramatically increased in the mutant embryos .,"(('The', 'O'), ('expression', 'O'), ('of', 'O'), ('cyclin', 'O'), ('-', 'O'), ('dependent', 'O'), ('kinase', 'O'), ('inhibitor', 'O'), ('p21', 'O'), ('is', 'O'), ('dramatically', 'O'), ('increased', 'O'), ('in', 'O'), ('the', 'O'), ('mutant', 'O'), ('embryos', 'O'), ('.', 'O'))"
Buttressing these in vivo observations is the fact that mutant blastocyst growth is grossly impaired in vitro .,"(('Buttressing', 'O'), ('these', 'O'), ('in', 'O'), ('vivo', 'O'), ('observations', 'O'), ('is', 'O'), ('the', 'O'), ('fact', 'O'), ('that', 'O'), ('mutant', 'O'), ('blastocyst', 'O'), ('growth', 'O'), ('is', 'O'), ('grossly', 'O'), ('impaired', 'O'), ('in', 'O'), ('vitro', 'O'), ('.', 'O'))"
"Thus , the death of Brca1 ( 5 - 6 ) mutant embryos prior to gastrulation may be due to a failure of the proliferative burst required for the development of the different germ layers .","(('Thus', 'O'), (',', 'O'), ('the', 'O'), ('death', 'O'), ('of', 'O'), ('Brca1', 'O'), ('(', 'O'), ('5', 'O'), ('-', 'O'), ('6', 'O'), (')', 'O'), ('mutant', 'O'), ('embryos', 'O'), ('prior', 'O'), ('to', 'O'), ('gastrulation', 'O'), ('may', 'O'), ('be', 'O'), ('due', 'O'), ('to', 'O'), ('a', 'O'), ('failure', 'O'), ('of', 'O'), ('the', 'O'), ('proliferative', 'O'), ('burst', 'O'), ('required', 'O'), ('for', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('the', 'O'), ('different', 'O'), ('germ', 'O'), ('layers', 'O'), ('.', 'O'))"
Increased coronary heart disease in Japanese - American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels .,"(('Increased', 'O'), ('coronary', 'B'), ('heart', 'I'), ('disease', 'I'), ('in', 'O'), ('Japanese', 'O'), ('-', 'O'), ('American', 'O'), ('men', 'O'), ('with', 'O'), ('mutation', 'O'), ('in', 'O'), ('the', 'O'), ('cholesteryl', 'O'), ('ester', 'O'), ('transfer', 'O'), ('protein', 'O'), ('gene', 'O'), ('despite', 'O'), ('increased', 'O'), ('HDL', 'O'), ('levels', 'O'), ('.', 'O'))"
The cholesteryl ester transfer protein ( CETP ) mediates the transfer of cholesteryl esters from HDL to other lipoproteins and is a key participant in the reverse transport of cholesterol from the periphery to the liver .,"(('The', 'O'), ('cholesteryl', 'O'), ('ester', 'O'), ('transfer', 'O'), ('protein', 'O'), ('(', 'O'), ('CETP', 'O'), (')', 'O'), ('mediates', 'O'), ('the', 'O'), ('transfer', 'O'), ('of', 'O'), ('cholesteryl', 'O'), ('esters', 'O'), ('from', 'O'), ('HDL', 'O'), ('to', 'O'), ('other', 'O'), ('lipoproteins', 'O'), ('and', 'O'), ('is', 'O'), ('a', 'O'), ('key', 'O'), ('participant', 'O'), ('in', 'O'), ('the', 'O'), ('reverse', 'O'), ('transport', 'O'), ('of', 'O'), ('cholesterol', 'O'), ('from', 'O'), ('the', 'O'), ('periphery', 'O'), ('to', 'O'), ('the', 'O'), ('liver', 'O'), ('.', 'O'))"
"A high prevalence of two different CETP gene mutations ( D442G , 5 . 1 % ; intron 14G A , 0 . 5 % ) , was found in 3 , 469 men of Japanese ancestry in the Honolulu Heart Program and mutations were associated with decreased CETP ( - 35 % ) and increased HDL chol levels ( + 10 % for D442G ) .","(('A', 'O'), ('high', 'O'), ('prevalence', 'O'), ('of', 'O'), ('two', 'O'), ('different', 'O'), ('CETP', 'O'), ('gene', 'O'), ('mutations', 'O'), ('(', 'O'), ('D442G', 'O'), (',', 'O'), ('5', 'O'), ('.', 'O'), ('1', 'O'), ('%', 'O'), (';', 'O'), ('intron', 'O'), ('14G', 'O'), ('A', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('was', 'O'), ('found', 'O'), ('in', 'O'), ('3', 'O'), (',', 'O'), ('469', 'O'), ('men', 'O'), ('of', 'O'), ('Japanese', 'O'), ('ancestry', 'O'), ('in', 'O'), ('the', 'O'), ('Honolulu', 'O'), ('Heart', 'O'), ('Program', 'O'), ('and', 'O'), ('mutations', 'O'), ('were', 'O'), ('associated', 'O'), ('with', 'O'), ('decreased', 'O'), ('CETP', 'O'), ('(', 'O'), ('-', 'O'), ('35', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('increased', 'O'), ('HDL', 'O'), ('chol', 'O'), ('levels', 'O'), ('(', 'O'), ('+', 'O'), ('10', 'O'), ('%', 'O'), ('for', 'O'), ('D442G', 'O'), (')', 'O'), ('.', 'O'))"
"55 ( P = . 02 ) ; after additional adjustment for HDL levels , the RR was 1 .","(('55', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('.', 'O'), ('02', 'O'), (')', 'O'), (';', 'O'), ('after', 'O'), ('additional', 'O'), ('adjustment', 'O'), ('for', 'O'), ('HDL', 'O'), ('levels', 'O'), (',', 'O'), ('the', 'O'), ('RR', 'O'), ('was', 'O'), ('1', 'O'), ('.', 'O'))"
68 ( P = . 008 ) .,"(('68', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('.', 'O'), ('008', 'O'), (')', 'O'), ('.', 'O'))"
Similar RR values were obtained for the D442G mutation alone .,"(('Similar', 'O'), ('RR', 'O'), ('values', 'O'), ('were', 'O'), ('obtained', 'O'), ('for', 'O'), ('the', 'O'), ('D442G', 'O'), ('mutation', 'O'), ('alone', 'O'), ('.', 'O'))"
"The findings suggest that both HDL concentration and the dynamics of cholesterol transport through HDL ( i . e . , reverse cholesterol transport ) determine the anti - atherogenicity of the HDL fraction .","(('The', 'O'), ('findings', 'O'), ('suggest', 'O'), ('that', 'O'), ('both', 'O'), ('HDL', 'O'), ('concentration', 'O'), ('and', 'O'), ('the', 'O'), ('dynamics', 'O'), ('of', 'O'), ('cholesterol', 'O'), ('transport', 'O'), ('through', 'O'), ('HDL', 'O'), ('(', 'O'), ('i', 'O'), ('.', 'O'), ('e', 'O'), ('.', 'O'), (',', 'O'), ('reverse', 'O'), ('cholesterol', 'O'), ('transport', 'O'), (')', 'O'), ('determine', 'O'), ('the', 'O'), ('anti', 'O'), ('-', 'O'), ('atherogenicity', 'B'), ('of', 'O'), ('the', 'O'), ('HDL', 'O'), ('fraction', 'O'), ('.', 'O'))"
Mapping the homolog of the human Rb1 gene to chromosome 14 of higher primates .,"(('Mapping', 'O'), ('the', 'O'), ('homolog', 'O'), ('of', 'O'), ('the', 'O'), ('human', 'O'), ('Rb1', 'O'), ('gene', 'O'), ('to', 'O'), ('chromosome', 'O'), ('14', 'O'), ('of', 'O'), ('higher', 'O'), ('primates', 'O'), ('.', 'O'))"
2 2 .,"(('2', 'O'), ('2', 'O'), ('.', 'O'))"
A unique sequence human Rb1 cosmid DNA probe has been used to localize this region on apes Chr 14 by the FISH technique .,"(('A', 'O'), ('unique', 'O'), ('sequence', 'O'), ('human', 'O'), ('Rb1', 'O'), ('cosmid', 'O'), ('DNA', 'O'), ('probe', 'O'), ('has', 'O'), ('been', 'O'), ('used', 'O'), ('to', 'O'), ('localize', 'O'), ('this', 'O'), ('region', 'O'), ('on', 'O'), ('apes', 'O'), ('Chr', 'O'), ('14', 'O'), ('by', 'O'), ('the', 'O'), ('FISH', 'O'), ('technique', 'O'), ('.', 'O'))"
The conservation of the Rb1 gene in higher primates at the corresponding equivalent chromosome locus ( 14q14 ) of the human may serve as a phylogenetic marker to further trace the evolutionary pathway of human descent .,"(('The', 'O'), ('conservation', 'O'), ('of', 'O'), ('the', 'O'), ('Rb1', 'O'), ('gene', 'O'), ('in', 'O'), ('higher', 'O'), ('primates', 'O'), ('at', 'O'), ('the', 'O'), ('corresponding', 'O'), ('equivalent', 'O'), ('chromosome', 'O'), ('locus', 'O'), ('(', 'O'), ('14q14', 'O'), (')', 'O'), ('of', 'O'), ('the', 'O'), ('human', 'O'), ('may', 'O'), ('serve', 'O'), ('as', 'O'), ('a', 'O'), ('phylogenetic', 'O'), ('marker', 'O'), ('to', 'O'), ('further', 'O'), ('trace', 'O'), ('the', 'O'), ('evolutionary', 'O'), ('pathway', 'O'), ('of', 'O'), ('human', 'O'), ('descent', 'O'), ('.', 'O'))"
"Mutation analysis in 19 families of German , Swiss and Turkish descent by single - strand conformation polymorphism and sequencing resulted in the detection of seven novel and 10 known mutations .","(('Mutation', 'O'), ('analysis', 'O'), ('in', 'O'), ('19', 'O'), ('families', 'O'), ('of', 'O'), ('German', 'O'), (',', 'O'), ('Swiss', 'O'), ('and', 'O'), ('Turkish', 'O'), ('descent', 'O'), ('by', 'O'), ('single', 'O'), ('-', 'O'), ('strand', 'O'), ('conformation', 'O'), ('polymorphism', 'O'), ('and', 'O'), ('sequencing', 'O'), ('resulted', 'O'), ('in', 'O'), ('the', 'O'), ('detection', 'O'), ('of', 'O'), ('seven', 'O'), ('novel', 'O'), ('and', 'O'), ('10', 'O'), ('known', 'O'), ('mutations', 'O'), ('.', 'O'))"
A striking clustering of missense mutations in the first four exons contrasted with a random distribution of nonsense mutations .,"(('A', 'O'), ('striking', 'O'), ('clustering', 'O'), ('of', 'O'), ('missense', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('first', 'O'), ('four', 'O'), ('exons', 'O'), ('contrasted', 'O'), ('with', 'O'), ('a', 'O'), ('random', 'O'), ('distribution', 'O'), ('of', 'O'), ('nonsense', 'O'), ('mutations', 'O'), ('.', 'O'))"
More than 85 % of all known missense mutations were localized in the amino - terminal stretch of the WASP gene product ; this region contained a mutational hot spot at codon 86 .,"(('More', 'O'), ('than', 'O'), ('85', 'O'), ('%', 'O'), ('of', 'O'), ('all', 'O'), ('known', 'O'), ('missense', 'O'), ('mutations', 'O'), ('were', 'O'), ('localized', 'O'), ('in', 'O'), ('the', 'O'), ('amino', 'O'), ('-', 'O'), ('terminal', 'O'), ('stretch', 'O'), ('of', 'O'), ('the', 'O'), ('WASP', 'O'), ('gene', 'O'), ('product', 'O'), (';', 'O'), ('this', 'O'), ('region', 'O'), ('contained', 'O'), ('a', 'O'), ('mutational', 'O'), ('hot', 'O'), ('spot', 'O'), ('at', 'O'), ('codon', 'O'), ('86', 'O'), ('.', 'O'))"
A substitution at codon 86 resulted in an extremely variable expression of the disease in a large Swiss family .,"(('A', 'O'), ('substitution', 'O'), ('at', 'O'), ('codon', 'O'), ('86', 'O'), ('resulted', 'O'), ('in', 'O'), ('an', 'O'), ('extremely', 'O'), ('variable', 'O'), ('expression', 'O'), ('of', 'O'), ('the', 'O'), ('disease', 'O'), ('in', 'O'), ('a', 'O'), ('large', 'O'), ('Swiss', 'O'), ('family', 'O'), ('.', 'O'))"
"An extended homology search revealed a distant relationship of this stretch to the vasodilator - stimulated phosphoprotein ( VASP ) , which is involved in the maintenance of cyto - architecture by interacting with actin - like filaments . .","(('An', 'O'), ('extended', 'O'), ('homology', 'O'), ('search', 'O'), ('revealed', 'O'), ('a', 'O'), ('distant', 'O'), ('relationship', 'O'), ('of', 'O'), ('this', 'O'), ('stretch', 'O'), ('to', 'O'), ('the', 'O'), ('vasodilator', 'O'), ('-', 'O'), ('stimulated', 'O'), ('phosphoprotein', 'O'), ('(', 'O'), ('VASP', 'O'), (')', 'O'), (',', 'O'), ('which', 'O'), ('is', 'O'), ('involved', 'O'), ('in', 'O'), ('the', 'O'), ('maintenance', 'O'), ('of', 'O'), ('cyto', 'O'), ('-', 'O'), ('architecture', 'O'), ('by', 'O'), ('interacting', 'O'), ('with', 'O'), ('actin', 'O'), ('-', 'O'), ('like', 'O'), ('filaments', 'O'), ('.', 'O'), ('.', 'O'))"
Influence of PAX6 gene dosage on development : overexpression causes severe eye abnormalities .,"(('Influence', 'O'), ('of', 'O'), ('PAX6', 'O'), ('gene', 'O'), ('dosage', 'O'), ('on', 'O'), ('development', 'O'), (':', 'O'), ('overexpression', 'O'), ('causes', 'O'), ('severe', 'O'), ('eye', 'B'), ('abnormalities', 'I'), ('.', 'O'))"
"To investigate the role of gene dosage in more detail , we have generated yeast artificial chromosome transgenic mice carrying the human PAX6 locus .","(('To', 'O'), ('investigate', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('gene', 'O'), ('dosage', 'O'), ('in', 'O'), ('more', 'O'), ('detail', 'O'), (',', 'O'), ('we', 'O'), ('have', 'O'), ('generated', 'O'), ('yeast', 'O'), ('artificial', 'O'), ('chromosome', 'O'), ('transgenic', 'O'), ('mice', 'O'), ('carrying', 'O'), ('the', 'O'), ('human', 'O'), ('PAX6', 'O'), ('locus', 'O'), ('.', 'O'))"
"When crossed onto the Small eye background , the transgene rescues the mutant phenotype .","(('When', 'O'), ('crossed', 'O'), ('onto', 'O'), ('the', 'O'), ('Small', 'O'), ('eye', 'O'), ('background', 'O'), (',', 'O'), ('the', 'O'), ('transgene', 'O'), ('rescues', 'O'), ('the', 'O'), ('mutant', 'O'), ('phenotype', 'O'), ('.', 'O'))"
"Thus , at least five different eye phenotypes are associated with changes in PAX6 expression .","(('Thus', 'O'), (',', 'O'), ('at', 'O'), ('least', 'O'), ('five', 'O'), ('different', 'O'), ('eye', 'O'), ('phenotypes', 'O'), ('are', 'O'), ('associated', 'O'), ('with', 'O'), ('changes', 'O'), ('in', 'O'), ('PAX6', 'O'), ('expression', 'O'), ('.', 'O'))"
Heterodimer formation and activity in the human enzyme galactose - 1 - phosphate uridylyltransferase .,"(('Heterodimer', 'O'), ('formation', 'O'), ('and', 'O'), ('activity', 'O'), ('in', 'O'), ('the', 'O'), ('human', 'O'), ('enzyme', 'O'), ('galactose', 'O'), ('-', 'O'), ('1', 'O'), ('-', 'O'), ('phosphate', 'O'), ('uridylyltransferase', 'O'), ('.', 'O'))"
One of the fundamental questions concerning expression and function of dimeric enzymes involves the impact of naturally occurring mutations on subunit assembly and heterodimer activity .,"(('One', 'O'), ('of', 'O'), ('the', 'O'), ('fundamental', 'O'), ('questions', 'O'), ('concerning', 'O'), ('expression', 'O'), ('and', 'O'), ('function', 'O'), ('of', 'O'), ('dimeric', 'O'), ('enzymes', 'O'), ('involves', 'O'), ('the', 'O'), ('impact', 'O'), ('of', 'O'), ('naturally', 'O'), ('occurring', 'O'), ('mutations', 'O'), ('on', 'O'), ('subunit', 'O'), ('assembly', 'O'), ('and', 'O'), ('heterodimer', 'O'), ('activity', 'O'), ('.', 'O'))"
"Furthermore , the broad range of phenotypic severity observed in these patients raises the possibility that allelic combination , not just allelic constitution , may play some role in determining outcome .","(('Furthermore', 'O'), (',', 'O'), ('the', 'O'), ('broad', 'O'), ('range', 'O'), ('of', 'O'), ('phenotypic', 'O'), ('severity', 'O'), ('observed', 'O'), ('in', 'O'), ('these', 'O'), ('patients', 'O'), ('raises', 'O'), ('the', 'O'), ('possibility', 'O'), ('that', 'O'), ('allelic', 'O'), ('combination', 'O'), (',', 'O'), ('not', 'O'), ('just', 'O'), ('allelic', 'O'), ('constitution', 'O'), (',', 'O'), ('may', 'O'), ('play', 'O'), ('some', 'O'), ('role', 'O'), ('in', 'O'), ('determining', 'O'), ('outcome', 'O'), ('.', 'O'))"
"In the work described herein , we have selected two distinct naturally occurring null mutations of GALT , Q188R and R333W , and asked the questions ( i ) what are the impacts of these mutations on subunit assembly , and ( ii ) if heterodimers do form , are they active ?","(('In', 'O'), ('the', 'O'), ('work', 'O'), ('described', 'O'), ('herein', 'O'), (',', 'O'), ('we', 'O'), ('have', 'O'), ('selected', 'O'), ('two', 'O'), ('distinct', 'O'), ('naturally', 'O'), ('occurring', 'O'), ('null', 'O'), ('mutations', 'O'), ('of', 'O'), ('GALT', 'O'), (',', 'O'), ('Q188R', 'O'), ('and', 'O'), ('R333W', 'O'), (',', 'O'), ('and', 'O'), ('asked', 'O'), ('the', 'O'), ('questions', 'O'), ('(', 'O'), ('i', 'O'), (')', 'O'), ('what', 'O'), ('are', 'O'), ('the', 'O'), ('impacts', 'O'), ('of', 'O'), ('these', 'O'), ('mutations', 'O'), ('on', 'O'), ('subunit', 'O'), ('assembly', 'O'), (',', 'O'), ('and', 'O'), ('(', 'O'), ('ii', 'O'), (')', 'O'), ('if', 'O'), ('heterodimers', 'O'), ('do', 'O'), ('form', 'O'), (',', 'O'), ('are', 'O'), ('they', 'O'), ('active', 'O'), ('?', 'O'))"
"To answer these questions , we have established a yeast system for the coexpression of epitope - tagged alleles of human GALT and investigated both the extent of specific GALT subunit interactions and the activity of defined heterodimer pools .","(('To', 'O'), ('answer', 'O'), ('these', 'O'), ('questions', 'O'), (',', 'O'), ('we', 'O'), ('have', 'O'), ('established', 'O'), ('a', 'O'), ('yeast', 'O'), ('system', 'O'), ('for', 'O'), ('the', 'O'), ('coexpression', 'O'), ('of', 'O'), ('epitope', 'O'), ('-', 'O'), ('tagged', 'O'), ('alleles', 'O'), ('of', 'O'), ('human', 'O'), ('GALT', 'O'), ('and', 'O'), ('investigated', 'O'), ('both', 'O'), ('the', 'O'), ('extent', 'O'), ('of', 'O'), ('specific', 'O'), ('GALT', 'O'), ('subunit', 'O'), ('interactions', 'O'), ('and', 'O'), ('the', 'O'), ('activity', 'O'), ('of', 'O'), ('defined', 'O'), ('heterodimer', 'O'), ('pools', 'O'), ('.', 'O'))"
We have found that both homodimers and heterodimers do form involving each of the mutant subunits tested and that both heterodimer pools retain substantial enzymatic activity .,"(('We', 'O'), ('have', 'O'), ('found', 'O'), ('that', 'O'), ('both', 'O'), ('homodimers', 'O'), ('and', 'O'), ('heterodimers', 'O'), ('do', 'O'), ('form', 'O'), ('involving', 'O'), ('each', 'O'), ('of', 'O'), ('the', 'O'), ('mutant', 'O'), ('subunits', 'O'), ('tested', 'O'), ('and', 'O'), ('that', 'O'), ('both', 'O'), ('heterodimer', 'O'), ('pools', 'O'), ('retain', 'O'), ('substantial', 'O'), ('enzymatic', 'O'), ('activity', 'O'), ('.', 'O'))"
"Cleavage of huntingtin by apopain , a proapoptotic cysteine protease , is modulated by the polyglutamine tract .","(('Cleavage', 'O'), ('of', 'O'), ('huntingtin', 'O'), ('by', 'O'), ('apopain', 'O'), (',', 'O'), ('a', 'O'), ('proapoptotic', 'O'), ('cysteine', 'O'), ('protease', 'O'), (',', 'O'), ('is', 'O'), ('modulated', 'O'), ('by', 'O'), ('the', 'O'), ('polyglutamine', 'O'), ('tract', 'O'), ('.', 'O'))"
"Apopain , a human counterpart of the nematode cysteine protease death - gene product , CED - 3 , has a key role in proteolytic events leading to apoptosis .","(('Apopain', 'O'), (',', 'O'), ('a', 'O'), ('human', 'O'), ('counterpart', 'O'), ('of', 'O'), ('the', 'O'), ('nematode', 'O'), ('cysteine', 'O'), ('protease', 'O'), ('death', 'O'), ('-', 'O'), ('gene', 'O'), ('product', 'O'), (',', 'O'), ('CED', 'O'), ('-', 'O'), ('3', 'O'), (',', 'O'), ('has', 'O'), ('a', 'O'), ('key', 'O'), ('role', 'O'), ('in', 'O'), ('proteolytic', 'O'), ('events', 'O'), ('leading', 'O'), ('to', 'O'), ('apoptosis', 'O'), ('.', 'O'))"
"The rate of cleavage increases with the length of the huntingtin polyglutamine tract , providing an explanation for the gain - of - function associated with CAG expansion .","(('The', 'O'), ('rate', 'O'), ('of', 'O'), ('cleavage', 'O'), ('increases', 'O'), ('with', 'O'), ('the', 'O'), ('length', 'O'), ('of', 'O'), ('the', 'O'), ('huntingtin', 'O'), ('polyglutamine', 'O'), ('tract', 'O'), (',', 'O'), ('providing', 'O'), ('an', 'O'), ('explanation', 'O'), ('for', 'O'), ('the', 'O'), ('gain', 'O'), ('-', 'O'), ('of', 'O'), ('-', 'O'), ('function', 'O'), ('associated', 'O'), ('with', 'O'), ('CAG', 'O'), ('expansion', 'O'), ('.', 'O'))"
The 5 ' end of the BRCA1 gene lies within a duplicated region of human chromosome 17q21 .,"(('The', 'O'), ('5', 'O'), (""'"", 'O'), ('end', 'O'), ('of', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('gene', 'O'), ('lies', 'O'), ('within', 'O'), ('a', 'O'), ('duplicated', 'O'), ('region', 'O'), ('of', 'O'), ('human', 'O'), ('chromosome', 'O'), ('17q21', 'O'), ('.', 'O'))"
"To begin to address the hypothesis that abnormal regulation of the breast / ovarian cancer susceptibility gene BRCA1 is a critical step in sporadic breast / ovarian tumorigenesis , we have determined the detailed structure of the BRCA1 genomic region .","(('To', 'O'), ('begin', 'O'), ('to', 'O'), ('address', 'O'), ('the', 'O'), ('hypothesis', 'O'), ('that', 'O'), ('abnormal', 'O'), ('regulation', 'O'), ('of', 'O'), ('the', 'O'), ('breast', 'B'), ('/', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('susceptibility', 'O'), ('gene', 'O'), ('BRCA1', 'O'), ('is', 'O'), ('a', 'O'), ('critical', 'O'), ('step', 'O'), ('in', 'O'), ('sporadic', 'O'), ('breast', 'B'), ('/', 'I'), ('ovarian', 'I'), ('tumorigenesis', 'I'), (',', 'O'), ('we', 'O'), ('have', 'O'), ('determined', 'O'), ('the', 'O'), ('detailed', 'O'), ('structure', 'O'), ('of', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('genomic', 'O'), ('region', 'O'), ('.', 'O'))"
"We show that this region of the genome contains a tandem duplication of approximately 30 kilobases , which results in two copies of BRCA1 exons 1 and 2 , of exons 1 and 3 of the adjacent 1A1 - 3B gene and of the previously reported 295 base pair intergenic region .","(('We', 'O'), ('show', 'O'), ('that', 'O'), ('this', 'O'), ('region', 'O'), ('of', 'O'), ('the', 'O'), ('genome', 'O'), ('contains', 'O'), ('a', 'O'), ('tandem', 'O'), ('duplication', 'O'), ('of', 'O'), ('approximately', 'O'), ('30', 'O'), ('kilobases', 'O'), (',', 'O'), ('which', 'O'), ('results', 'O'), ('in', 'O'), ('two', 'O'), ('copies', 'O'), ('of', 'O'), ('BRCA1', 'O'), ('exons', 'O'), ('1', 'O'), ('and', 'O'), ('2', 'O'), (',', 'O'), ('of', 'O'), ('exons', 'O'), ('1', 'O'), ('and', 'O'), ('3', 'O'), ('of', 'O'), ('the', 'O'), ('adjacent', 'O'), ('1A1', 'O'), ('-', 'O'), ('3B', 'O'), ('gene', 'O'), ('and', 'O'), ('of', 'O'), ('the', 'O'), ('previously', 'O'), ('reported', 'O'), ('295', 'O'), ('base', 'O'), ('pair', 'O'), ('intergenic', 'O'), ('region', 'O'), ('.', 'O'))"
"Sequence analysis of the duplicated exons of BRCA1 and 1A1 - 3B and flanking genomic DNA reveals maintenance of the intron - exon structure and a high degree of nucleotide sequence identity , suggesting that these are non - processed pseudogenes and that the duplication is a recent event in evolutionary terms .","(('Sequence', 'O'), ('analysis', 'O'), ('of', 'O'), ('the', 'O'), ('duplicated', 'O'), ('exons', 'O'), ('of', 'O'), ('BRCA1', 'O'), ('and', 'O'), ('1A1', 'O'), ('-', 'O'), ('3B', 'O'), ('and', 'O'), ('flanking', 'O'), ('genomic', 'O'), ('DNA', 'O'), ('reveals', 'O'), ('maintenance', 'O'), ('of', 'O'), ('the', 'O'), ('intron', 'O'), ('-', 'O'), ('exon', 'O'), ('structure', 'O'), ('and', 'O'), ('a', 'O'), ('high', 'O'), ('degree', 'O'), ('of', 'O'), ('nucleotide', 'O'), ('sequence', 'O'), ('identity', 'O'), (',', 'O'), ('suggesting', 'O'), ('that', 'O'), ('these', 'O'), ('are', 'O'), ('non', 'O'), ('-', 'O'), ('processed', 'O'), ('pseudogenes', 'O'), ('and', 'O'), ('that', 'O'), ('the', 'O'), ('duplication', 'O'), ('is', 'O'), ('a', 'O'), ('recent', 'O'), ('event', 'O'), ('in', 'O'), ('evolutionary', 'O'), ('terms', 'O'), ('.', 'O'))"
We also show that a processed pseudogene of the acidic ribosomal phosphoprotein P1 ( ARPP1 ) is inserted directly upstream of pseudo - BRCA1 exon 1A .,"(('We', 'O'), ('also', 'O'), ('show', 'O'), ('that', 'O'), ('a', 'O'), ('processed', 'O'), ('pseudogene', 'O'), ('of', 'O'), ('the', 'O'), ('acidic', 'O'), ('ribosomal', 'O'), ('phosphoprotein', 'O'), ('P1', 'O'), ('(', 'O'), ('ARPP1', 'O'), (')', 'O'), ('is', 'O'), ('inserted', 'O'), ('directly', 'O'), ('upstream', 'O'), ('of', 'O'), ('pseudo', 'O'), ('-', 'O'), ('BRCA1', 'O'), ('exon', 'O'), ('1A', 'O'), ('.', 'O'))"
"We believe that these findings could not only confound BRCA1 mutation analysis , but could have implications for the normal and abnormal regulation of BRCA1 transcription , translation and function . .","(('We', 'O'), ('believe', 'O'), ('that', 'O'), ('these', 'O'), ('findings', 'O'), ('could', 'O'), ('not', 'O'), ('only', 'O'), ('confound', 'O'), ('BRCA1', 'O'), ('mutation', 'O'), ('analysis', 'O'), (',', 'O'), ('but', 'O'), ('could', 'O'), ('have', 'O'), ('implications', 'O'), ('for', 'O'), ('the', 'O'), ('normal', 'O'), ('and', 'O'), ('abnormal', 'O'), ('regulation', 'O'), ('of', 'O'), ('BRCA1', 'O'), ('transcription', 'O'), (',', 'O'), ('translation', 'O'), ('and', 'O'), ('function', 'O'), ('.', 'O'), ('.', 'O'))"
"Neither a cytogenetically detectable 15q12 deletion nor a deletion for the D15S11 , D15S10 , and GABRB3 cosmid probes were found in either patient .","(('Neither', 'O'), ('a', 'O'), ('cytogenetically', 'O'), ('detectable', 'O'), ('15q12', 'O'), ('deletion', 'O'), ('nor', 'O'), ('a', 'O'), ('deletion', 'O'), ('for', 'O'), ('the', 'O'), ('D15S11', 'O'), (',', 'O'), ('D15S10', 'O'), (',', 'O'), ('and', 'O'), ('GABRB3', 'O'), ('cosmid', 'O'), ('probes', 'O'), ('were', 'O'), ('found', 'O'), ('in', 'O'), ('either', 'O'), ('patient', 'O'), ('.', 'O'))"
The common hereditary forms of breast cancer have been largely attributed to the inheritance of mutations in the BRCA1 or BRCA2 genes .,"(('The', 'O'), ('common', 'O'), ('hereditary', 'O'), ('forms', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('have', 'O'), ('been', 'O'), ('largely', 'O'), ('attributed', 'O'), ('to', 'O'), ('the', 'O'), ('inheritance', 'O'), ('of', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('or', 'O'), ('BRCA2', 'O'), ('genes', 'O'), ('.', 'O'))"
Twenty - three families were identified through two high - risk breast cancer research programs .,"(('Twenty', 'O'), ('-', 'O'), ('three', 'O'), ('families', 'O'), ('were', 'O'), ('identified', 'O'), ('through', 'O'), ('two', 'O'), ('high', 'O'), ('-', 'O'), ('risk', 'O'), ('breast', 'B'), ('cancer', 'I'), ('research', 'O'), ('programs', 'O'), ('.', 'O'))"
Genetic analysis was undertaken to establish linkage between the breast or ovarian cancer cases and markers on chromosomes 17q ( BRCA1 ) and 13q ( BRCA2 ) .,"(('Genetic', 'O'), ('analysis', 'O'), ('was', 'O'), ('undertaken', 'O'), ('to', 'O'), ('establish', 'O'), ('linkage', 'O'), ('between', 'O'), ('the', 'O'), ('breast', 'B'), ('or', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('cases', 'O'), ('and', 'O'), ('markers', 'O'), ('on', 'O'), ('chromosomes', 'O'), ('17q', 'O'), ('(', 'O'), ('BRCA1', 'O'), (')', 'O'), ('and', 'O'), ('13q', 'O'), ('(', 'O'), ('BRCA2', 'O'), (')', 'O'), ('.', 'O'))"
Mutation analysis in the BRCA1 and BRCA2 genes was also undertaken in all families .,"(('Mutation', 'O'), ('analysis', 'O'), ('in', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('and', 'O'), ('BRCA2', 'O'), ('genes', 'O'), ('was', 'O'), ('also', 'O'), ('undertaken', 'O'), ('in', 'O'), ('all', 'O'), ('families', 'O'), ('.', 'O'))"
No families were attributed to BRCA2 .,"(('No', 'O'), ('families', 'O'), ('were', 'O'), ('attributed', 'O'), ('to', 'O'), ('BRCA2', 'O'), ('.', 'O'))"
Five families ( 22 % ) provided evidence against linkage to both BRCA1 and BRCA2 .,"(('Five', 'O'), ('families', 'O'), ('(', 'O'), ('22', 'O'), ('%', 'O'), (')', 'O'), ('provided', 'O'), ('evidence', 'O'), ('against', 'O'), ('linkage', 'O'), ('to', 'O'), ('both', 'O'), ('BRCA1', 'O'), ('and', 'O'), ('BRCA2', 'O'), ('.', 'O'))"
No BRCA1 or BRCA2 mutations were detected in these five families .,"(('No', 'O'), ('BRCA1', 'O'), ('or', 'O'), ('BRCA2', 'O'), ('mutations', 'O'), ('were', 'O'), ('detected', 'O'), ('in', 'O'), ('these', 'O'), ('five', 'O'), ('families', 'O'), ('.', 'O'))"
The BRCA1 or BRCA2 status of four families ( 17 % ) could not be determined .,"(('The', 'O'), ('BRCA1', 'O'), ('or', 'O'), ('BRCA2', 'O'), ('status', 'O'), ('of', 'O'), ('four', 'O'), ('families', 'O'), ('(', 'O'), ('17', 'O'), ('%', 'O'), (')', 'O'), ('could', 'O'), ('not', 'O'), ('be', 'O'), ('determined', 'O'), ('.', 'O'))"
The first step in the splicing of an intron from nuclear precursors of mRNA results in the formation of a lariat structure .,"(('The', 'O'), ('first', 'O'), ('step', 'O'), ('in', 'O'), ('the', 'O'), ('splicing', 'O'), ('of', 'O'), ('an', 'O'), ('intron', 'O'), ('from', 'O'), ('nuclear', 'O'), ('precursors', 'O'), ('of', 'O'), ('mRNA', 'O'), ('results', 'O'), ('in', 'O'), ('the', 'O'), ('formation', 'O'), ('of', 'O'), ('a', 'O'), ('lariat', 'O'), ('structure', 'O'), ('.', 'O'))"
"A distinct intronic nucleotide sequence , known as the branchpoint region , plays a central role in this process .","(('A', 'O'), ('distinct', 'O'), ('intronic', 'O'), ('nucleotide', 'O'), ('sequence', 'O'), (',', 'O'), ('known', 'O'), ('as', 'O'), ('the', 'O'), ('branchpoint', 'O'), ('region', 'O'), (',', 'O'), ('plays', 'O'), ('a', 'O'), ('central', 'O'), ('role', 'O'), ('in', 'O'), ('this', 'O'), ('process', 'O'), ('.', 'O'))"
We here describe a point mutation in such a sequence .,"(('We', 'O'), ('here', 'O'), ('describe', 'O'), ('a', 'O'), ('point', 'O'), ('mutation', 'O'), ('in', 'O'), ('such', 'O'), ('a', 'O'), ('sequence', 'O'), ('.', 'O'))"
"By performing in vitro expression of LCAT minigenes and reverse transcriptase PCR on mRNA isolated from leukocytes of the patient , this gene defect was shown to cause a null allele as the result of complete intron retention .","(('By', 'O'), ('performing', 'O'), ('in', 'O'), ('vitro', 'O'), ('expression', 'O'), ('of', 'O'), ('LCAT', 'O'), ('minigenes', 'O'), ('and', 'O'), ('reverse', 'O'), ('transcriptase', 'O'), ('PCR', 'O'), ('on', 'O'), ('mRNA', 'O'), ('isolated', 'O'), ('from', 'O'), ('leukocytes', 'O'), ('of', 'O'), ('the', 'O'), ('patient', 'O'), (',', 'O'), ('this', 'O'), ('gene', 'O'), ('defect', 'O'), ('was', 'O'), ('shown', 'O'), ('to', 'O'), ('cause', 'O'), ('a', 'O'), ('null', 'O'), ('allele', 'O'), ('as', 'O'), ('the', 'O'), ('result', 'O'), ('of', 'O'), ('complete', 'O'), ('intron', 'O'), ('retention', 'O'), ('.', 'O'))"
"In addition , our finding illustrates the importance of this sequence for normal human mRNA processing .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('our', 'O'), ('finding', 'O'), ('illustrates', 'O'), ('the', 'O'), ('importance', 'O'), ('of', 'O'), ('this', 'O'), ('sequence', 'O'), ('for', 'O'), ('normal', 'O'), ('human', 'O'), ('mRNA', 'O'), ('processing', 'O'), ('.', 'O'))"
"Finally , this report provides a widely applicable strategy which ensures fast and effective screening for intronic defects that underlie differential gene expression . .","(('Finally', 'O'), (',', 'O'), ('this', 'O'), ('report', 'O'), ('provides', 'O'), ('a', 'O'), ('widely', 'O'), ('applicable', 'O'), ('strategy', 'O'), ('which', 'O'), ('ensures', 'O'), ('fast', 'O'), ('and', 'O'), ('effective', 'O'), ('screening', 'O'), ('for', 'O'), ('intronic', 'O'), ('defects', 'O'), ('that', 'O'), ('underlie', 'O'), ('differential', 'O'), ('gene', 'O'), ('expression', 'O'), ('.', 'O'), ('.', 'O'))"
"In 10 of these families , all the homozygotes have a 137 - bp insertion in their cDNA caused by a point mutation in a sequence resembling a splice - donor site .","(('In', 'O'), ('10', 'O'), ('of', 'O'), ('these', 'O'), ('families', 'O'), (',', 'O'), ('all', 'O'), ('the', 'O'), ('homozygotes', 'O'), ('have', 'O'), ('a', 'O'), ('137', 'O'), ('-', 'O'), ('bp', 'O'), ('insertion', 'O'), ('in', 'O'), ('their', 'O'), ('cDNA', 'O'), ('caused', 'O'), ('by', 'O'), ('a', 'O'), ('point', 'O'), ('mutation', 'O'), ('in', 'O'), ('a', 'O'), ('sequence', 'O'), ('resembling', 'O'), ('a', 'O'), ('splice', 'O'), ('-', 'O'), ('donor', 'O'), ('site', 'O'), ('.', 'O'))"
"We show that the less severe phenotype in these patients is caused by some degree of normal splicing , which occurs as an alternative product from the insertion - containing allele .","(('We', 'O'), ('show', 'O'), ('that', 'O'), ('the', 'O'), ('less', 'O'), ('severe', 'O'), ('phenotype', 'O'), ('in', 'O'), ('these', 'O'), ('patients', 'O'), ('is', 'O'), ('caused', 'O'), ('by', 'O'), ('some', 'O'), ('degree', 'O'), ('of', 'O'), ('normal', 'O'), ('splicing', 'O'), (',', 'O'), ('which', 'O'), ('occurs', 'O'), ('as', 'O'), ('an', 'O'), ('alternative', 'O'), ('product', 'O'), ('from', 'O'), ('the', 'O'), ('insertion', 'O'), ('-', 'O'), ('containing', 'O'), ('allele', 'O'), ('.', 'O'))"
The level of the 137 - bp PCR product containing the insertion was lowest in two patients who showed a later onset of cerebellar ataxia .,"(('The', 'O'), ('level', 'O'), ('of', 'O'), ('the', 'O'), ('137', 'O'), ('-', 'O'), ('bp', 'O'), ('PCR', 'O'), ('product', 'O'), ('containing', 'O'), ('the', 'O'), ('insertion', 'O'), ('was', 'O'), ('lowest', 'O'), ('in', 'O'), ('two', 'O'), ('patients', 'O'), ('who', 'O'), ('showed', 'O'), ('a', 'O'), ('later', 'O'), ('onset', 'O'), ('of', 'O'), ('cerebellar', 'B'), ('ataxia', 'I'), ('.', 'O'))"
A further four families who do not have this insertion have been identified .,"(('A', 'O'), ('further', 'O'), ('four', 'O'), ('families', 'O'), ('who', 'O'), ('do', 'O'), ('not', 'O'), ('have', 'O'), ('this', 'O'), ('insertion', 'O'), ('have', 'O'), ('been', 'O'), ('identified', 'O'), ('.', 'O'))"
One possibility might be that individuals who are compound heterozygotes for ATM mutations are more common than we realize . .,"(('One', 'O'), ('possibility', 'O'), ('might', 'O'), ('be', 'O'), ('that', 'O'), ('individuals', 'O'), ('who', 'O'), ('are', 'O'), ('compound', 'O'), ('heterozygotes', 'O'), ('for', 'O'), ('ATM', 'O'), ('mutations', 'O'), ('are', 'O'), ('more', 'O'), ('common', 'O'), ('than', 'O'), ('we', 'O'), ('realize', 'O'), ('.', 'O'), ('.', 'O'))"
Mutation of the VHL gene is associated exclusively with the development of non - papillary renal cell carcinomas .,"(('Mutation', 'O'), ('of', 'O'), ('the', 'O'), ('VHL', 'O'), ('gene', 'O'), ('is', 'O'), ('associated', 'O'), ('exclusively', 'O'), ('with', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('non', 'B'), ('-', 'I'), ('papillary', 'I'), ('renal', 'I'), ('cell', 'I'), ('carcinomas', 'I'), ('.', 'O'))"
Chromosome 3p deletion was detected in 98 per cent of non - papillary renal cell carcinomas and in 25 per cent of chromophobe renal cell carcinomas .,"(('Chromosome', 'O'), ('3p', 'O'), ('deletion', 'O'), ('was', 'O'), ('detected', 'O'), ('in', 'O'), ('98', 'O'), ('per', 'O'), ('cent', 'O'), ('of', 'O'), ('non', 'O'), ('-', 'O'), ('papillary', 'B'), ('renal', 'I'), ('cell', 'I'), ('carcinomas', 'I'), ('and', 'O'), ('in', 'O'), ('25', 'O'), ('per', 'O'), ('cent', 'O'), ('of', 'O'), ('chromophobe', 'B'), ('renal', 'I'), ('cell', 'I'), ('carcinomas', 'I'), ('.', 'O'))"
"In 22 of the 43 non - papillary renal cell carcinomas , abnormally migrating DNA bands were detected by SSCP and / or HD analysis .","(('In', 'O'), ('22', 'O'), ('of', 'O'), ('the', 'O'), ('43', 'O'), ('non', 'O'), ('-', 'O'), ('papillary', 'B'), ('renal', 'I'), ('cell', 'I'), ('carcinomas', 'I'), (',', 'O'), ('abnormally', 'O'), ('migrating', 'O'), ('DNA', 'O'), ('bands', 'O'), ('were', 'O'), ('detected', 'O'), ('by', 'O'), ('SSCP', 'O'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('HD', 'O'), ('analysis', 'O'), ('.', 'O'))"
No mobility shift was seen in any of the 23 chromophobe renal cell carcinomas .,"(('No', 'O'), ('mobility', 'O'), ('shift', 'O'), ('was', 'O'), ('seen', 'O'), ('in', 'O'), ('any', 'O'), ('of', 'O'), ('the', 'O'), ('23', 'O'), ('chromophobe', 'O'), ('renal', 'B'), ('cell', 'I'), ('carcinomas', 'I'), ('.', 'O'))"
A large fragment of emerin cDNA was prepared by PCR and expressed as a recombinant protein in Escherichia coli .,"(('A', 'O'), ('large', 'O'), ('fragment', 'O'), ('of', 'O'), ('emerin', 'O'), ('cDNA', 'O'), ('was', 'O'), ('prepared', 'O'), ('by', 'O'), ('PCR', 'O'), ('and', 'O'), ('expressed', 'O'), ('as', 'O'), ('a', 'O'), ('recombinant', 'O'), ('protein', 'O'), ('in', 'O'), ('Escherichia', 'O'), ('coli', 'O'), ('.', 'O'))"
"Using this as immunogen , we prepared a panel of 12 monoclonal antibodies which recognise at least four different epitopes on emerin in order to ensure that emerin can be distinguished from non - specific cross - reacting proteins .","(('Using', 'O'), ('this', 'O'), ('as', 'O'), ('immunogen', 'O'), (',', 'O'), ('we', 'O'), ('prepared', 'O'), ('a', 'O'), ('panel', 'O'), ('of', 'O'), ('12', 'O'), ('monoclonal', 'O'), ('antibodies', 'O'), ('which', 'O'), ('recognise', 'O'), ('at', 'O'), ('least', 'O'), ('four', 'O'), ('different', 'O'), ('epitopes', 'O'), ('on', 'O'), ('emerin', 'O'), ('in', 'O'), ('order', 'O'), ('to', 'O'), ('ensure', 'O'), ('that', 'O'), ('emerin', 'O'), ('can', 'O'), ('be', 'O'), ('distinguished', 'O'), ('from', 'O'), ('non', 'O'), ('-', 'O'), ('specific', 'O'), ('cross', 'O'), ('-', 'O'), ('reacting', 'O'), ('proteins', 'O'), ('.', 'O'))"
"All the mAbs recognised a 34 kDa protein in all tissues tested , though minor emerin - related bands were also detected in some tissues .","(('All', 'O'), ('the', 'O'), ('mAbs', 'O'), ('recognised', 'O'), ('a', 'O'), ('34', 'O'), ('kDa', 'O'), ('protein', 'O'), ('in', 'O'), ('all', 'O'), ('tissues', 'O'), ('tested', 'O'), (',', 'O'), ('though', 'O'), ('minor', 'O'), ('emerin', 'O'), ('-', 'O'), ('related', 'O'), ('bands', 'O'), ('were', 'O'), ('also', 'O'), ('detected', 'O'), ('in', 'O'), ('some', 'O'), ('tissues', 'O'), ('.', 'O'))"
Immunofluorescence microscopy showed that emerin is located at the nuclear rim in all tissues examined .,"(('Immunofluorescence', 'O'), ('microscopy', 'O'), ('showed', 'O'), ('that', 'O'), ('emerin', 'O'), ('is', 'O'), ('located', 'O'), ('at', 'O'), ('the', 'O'), ('nuclear', 'O'), ('rim', 'O'), ('in', 'O'), ('all', 'O'), ('tissues', 'O'), ('examined', 'O'), ('.', 'O'))"
"Biochemical fractionation of brain and liver tissues showed that emerin was present in nuclei purified by centrifugation through 65 % sucrose and was absent from soluble fractions ( post - 100 , 000 g ) .","(('Biochemical', 'O'), ('fractionation', 'O'), ('of', 'O'), ('brain', 'O'), ('and', 'O'), ('liver', 'O'), ('tissues', 'O'), ('showed', 'O'), ('that', 'O'), ('emerin', 'O'), ('was', 'O'), ('present', 'O'), ('in', 'O'), ('nuclei', 'O'), ('purified', 'O'), ('by', 'O'), ('centrifugation', 'O'), ('through', 'O'), ('65', 'O'), ('%', 'O'), ('sucrose', 'O'), ('and', 'O'), ('was', 'O'), ('absent', 'O'), ('from', 'O'), ('soluble', 'O'), ('fractions', 'O'), ('(', 'O'), ('post', 'O'), ('-', 'O'), ('100', 'O'), (',', 'O'), ('000', 'O'), ('g', 'O'), (')', 'O'), ('.', 'O'))"
"From these results , together with sequence and structural homologies between emerin , thymopoietins and the nuclear lamina - associated protein , LAP2 , we suggest that emerin will prove to be one member of a family of inner nuclear membrane proteins . .","(('From', 'O'), ('these', 'O'), ('results', 'O'), (',', 'O'), ('together', 'O'), ('with', 'O'), ('sequence', 'O'), ('and', 'O'), ('structural', 'O'), ('homologies', 'O'), ('between', 'O'), ('emerin', 'O'), (',', 'O'), ('thymopoietins', 'O'), ('and', 'O'), ('the', 'O'), ('nuclear', 'O'), ('lamina', 'O'), ('-', 'O'), ('associated', 'O'), ('protein', 'O'), (',', 'O'), ('LAP2', 'O'), (',', 'O'), ('we', 'O'), ('suggest', 'O'), ('that', 'O'), ('emerin', 'O'), ('will', 'O'), ('prove', 'O'), ('to', 'O'), ('be', 'O'), ('one', 'O'), ('member', 'O'), ('of', 'O'), ('a', 'O'), ('family', 'O'), ('of', 'O'), ('inner', 'O'), ('nuclear', 'O'), ('membrane', 'O'), ('proteins', 'O'), ('.', 'O'), ('.', 'O'))"
Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair .,"(('Mutation', 'O'), ('of', 'O'), ('MSH3', 'O'), ('in', 'O'), ('endometrial', 'B'), ('cancer', 'I'), ('and', 'O'), ('evidence', 'O'), ('for', 'O'), ('its', 'O'), ('functional', 'O'), ('role', 'O'), ('in', 'O'), ('heteroduplex', 'O'), ('repair', 'O'), ('.', 'O'))"
It is therefore of interest to identify other genes that contribute to this instability .,"(('It', 'O'), ('is', 'O'), ('therefore', 'O'), ('of', 'O'), ('interest', 'O'), ('to', 'O'), ('identify', 'O'), ('other', 'O'), ('genes', 'O'), ('that', 'O'), ('contribute', 'O'), ('to', 'O'), ('this', 'O'), ('instability', 'O'), ('.', 'O'))"
"In yeast , mutations in several genes , including RTH and MSH3 , cause microsatellite instability .","(('In', 'O'), ('yeast', 'O'), (',', 'O'), ('mutations', 'O'), ('in', 'O'), ('several', 'O'), ('genes', 'O'), (',', 'O'), ('including', 'O'), ('RTH', 'O'), ('and', 'O'), ('MSH3', 'O'), (',', 'O'), ('cause', 'O'), ('microsatellite', 'B'), ('instability', 'O'), ('.', 'O'))"
"Thus , we screened 16 endometrial carcinomas with microsatellite instability for alterations in FEN1 ( the human homolog of RTH ) and in MSH3 ( refs 12 - 14 ) .","(('Thus', 'O'), (',', 'O'), ('we', 'O'), ('screened', 'O'), ('16', 'O'), ('endometrial', 'B'), ('carcinomas', 'I'), ('with', 'O'), ('microsatellite', 'O'), ('instability', 'O'), ('for', 'O'), ('alterations', 'O'), ('in', 'O'), ('FEN1', 'O'), ('(', 'O'), ('the', 'O'), ('human', 'O'), ('homolog', 'O'), ('of', 'O'), ('RTH', 'O'), (')', 'O'), ('and', 'O'), ('in', 'O'), ('MSH3', 'O'), ('(', 'O'), ('refs', 'O'), ('12', 'O'), ('-', 'O'), ('14', 'O'), (')', 'O'), ('.', 'O'))"
"Although we found no FEN1 mutations , a frameshift mutation in MSH3 was observed in an endometrial carcinoma and in an endometrial carcinoma cell line .","(('Although', 'O'), ('we', 'O'), ('found', 'O'), ('no', 'O'), ('FEN1', 'O'), ('mutations', 'O'), (',', 'O'), ('a', 'O'), ('frameshift', 'O'), ('mutation', 'O'), ('in', 'O'), ('MSH3', 'O'), ('was', 'O'), ('observed', 'O'), ('in', 'O'), ('an', 'O'), ('endometrial', 'B'), ('carcinoma', 'I'), ('and', 'O'), ('in', 'O'), ('an', 'O'), ('endometrial', 'B'), ('carcinoma', 'I'), ('cell', 'O'), ('line', 'O'), ('.', 'O'))"
Extracts of the cell line were deficient in repair of DNA substrates containing mismatches or extra nucleotides .,"(('Extracts', 'O'), ('of', 'O'), ('the', 'O'), ('cell', 'O'), ('line', 'O'), ('were', 'O'), ('deficient', 'O'), ('in', 'O'), ('repair', 'O'), ('of', 'O'), ('DNA', 'O'), ('substrates', 'O'), ('containing', 'O'), ('mismatches', 'O'), ('or', 'O'), ('extra', 'O'), ('nucleotides', 'O'), ('.', 'O'))"
"Introducing chromosome 5 , encoding the MSH3 gene , into the mutant cell line increased the stability of some but not all microsatellites .","(('Introducing', 'O'), ('chromosome', 'O'), ('5', 'O'), (',', 'O'), ('encoding', 'O'), ('the', 'O'), ('MSH3', 'O'), ('gene', 'O'), (',', 'O'), ('into', 'O'), ('the', 'O'), ('mutant', 'O'), ('cell', 'O'), ('line', 'O'), ('increased', 'O'), ('the', 'O'), ('stability', 'O'), ('of', 'O'), ('some', 'O'), ('but', 'O'), ('not', 'O'), ('all', 'O'), ('microsatellites', 'O'), ('.', 'O'))"
"Extracts of these cells repaired certain substrates containing extra nucleotides , but were deficient in repair of those containing mismatches or other extra nucleotides .","(('Extracts', 'O'), ('of', 'O'), ('these', 'O'), ('cells', 'O'), ('repaired', 'O'), ('certain', 'O'), ('substrates', 'O'), ('containing', 'O'), ('extra', 'O'), ('nucleotides', 'O'), (',', 'O'), ('but', 'O'), ('were', 'O'), ('deficient', 'O'), ('in', 'O'), ('repair', 'O'), ('of', 'O'), ('those', 'O'), ('containing', 'O'), ('mismatches', 'O'), ('or', 'O'), ('other', 'O'), ('extra', 'O'), ('nucleotides', 'O'), ('.', 'O'))"
"A subsequent search revealed a second gene mutation in HHUA cells , a missense mutation in the MSH6 gene .","(('A', 'O'), ('subsequent', 'O'), ('search', 'O'), ('revealed', 'O'), ('a', 'O'), ('second', 'O'), ('gene', 'O'), ('mutation', 'O'), ('in', 'O'), ('HHUA', 'O'), ('cells', 'O'), (',', 'O'), ('a', 'O'), ('missense', 'O'), ('mutation', 'O'), ('in', 'O'), ('the', 'O'), ('MSH6', 'O'), ('gene', 'O'), ('.', 'O'))"
"Both genes were colocalized to the C - D band of mouse chromosome 9 , the proximal end of q24 .","(('Both', 'O'), ('genes', 'O'), ('were', 'O'), ('colocalized', 'O'), ('to', 'O'), ('the', 'O'), ('C', 'O'), ('-', 'O'), ('D', 'O'), ('band', 'O'), ('of', 'O'), ('mouse', 'O'), ('chromosome', 'O'), ('9', 'O'), (',', 'O'), ('the', 'O'), ('proximal', 'O'), ('end', 'O'), ('of', 'O'), ('q24', 'O'), ('.', 'O'))"
"1 of rat chromosome 8 , and qa4 - qa5 of Syrian hamster chromosome 12 .","(('1', 'O'), ('of', 'O'), ('rat', 'O'), ('chromosome', 'O'), ('8', 'O'), (',', 'O'), ('and', 'O'), ('qa4', 'O'), ('-', 'O'), ('qa5', 'O'), ('of', 'O'), ('Syrian', 'O'), ('hamster', 'O'), ('chromosome', 'O'), ('12', 'O'), ('.', 'O'))"
The regions in the mouse and rat were homologous to human chromosome 11q .,"(('The', 'O'), ('regions', 'O'), ('in', 'O'), ('the', 'O'), ('mouse', 'O'), ('and', 'O'), ('rat', 'O'), ('were', 'O'), ('homologous', 'O'), ('to', 'O'), ('human', 'O'), ('chromosome', 'O'), ('11q', 'O'), ('.', 'O'))"
"Atm , Acat1 , and Npat , which is a new gene isolated from the AT region , and 12 flanking microsatellite DNA markers were examined .","(('Atm', 'O'), (',', 'O'), ('Acat1', 'O'), (',', 'O'), ('and', 'O'), ('Npat', 'O'), (',', 'O'), ('which', 'O'), ('is', 'O'), ('a', 'O'), ('new', 'O'), ('gene', 'O'), ('isolated', 'O'), ('from', 'O'), ('the', 'O'), ('AT', 'O'), ('region', 'O'), (',', 'O'), ('and', 'O'), ('12', 'O'), ('flanking', 'O'), ('microsatellite', 'O'), ('DNA', 'O'), ('markers', 'O'), ('were', 'O'), ('examined', 'O'), ('.', 'O'))"
"No recombinations were found among the Atm , Npat , Acat1 , and D9Mit6 loci , and these loci were mapped 2 .","(('No', 'O'), ('recombinations', 'O'), ('were', 'O'), ('found', 'O'), ('among', 'O'), ('the', 'O'), ('Atm', 'O'), (',', 'O'), ('Npat', 'O'), (',', 'O'), ('Acat1', 'O'), (',', 'O'), ('and', 'O'), ('D9Mit6', 'O'), ('loci', 'O'), (',', 'O'), ('and', 'O'), ('these', 'O'), ('loci', 'O'), ('were', 'O'), ('mapped', 'O'), ('2', 'O'), ('.', 'O'))"
0 cM distal to D9Mit99 and 1 .,"(('0', 'O'), ('cM', 'O'), ('distal', 'O'), ('to', 'O'), ('D9Mit99', 'O'), ('and', 'O'), ('1', 'O'), ('.', 'O'))"
3 cM proximal to D9Mit102 .,"(('3', 'O'), ('cM', 'O'), ('proximal', 'O'), ('to', 'O'), ('D9Mit102', 'O'), ('.', 'O'))"
Comparison of the linkage map of mouse chromosome 9 ( MMU9 ) and that of human chromosome 11 ( HSA11 ) indicates that there is a chromosomal rearrangement due to an inversion between Ets1 and Atm - Npat - Acat1 and that the inversion of MMU9 originated from the chromosomal breakage at the boundary between Gria4 and Atm - Npat - Acat1 on HSA11 .,"(('Comparison', 'O'), ('of', 'O'), ('the', 'O'), ('linkage', 'O'), ('map', 'O'), ('of', 'O'), ('mouse', 'O'), ('chromosome', 'O'), ('9', 'O'), ('(', 'O'), ('MMU9', 'O'), (')', 'O'), ('and', 'O'), ('that', 'O'), ('of', 'O'), ('human', 'O'), ('chromosome', 'O'), ('11', 'O'), ('(', 'O'), ('HSA11', 'O'), (')', 'O'), ('indicates', 'O'), ('that', 'O'), ('there', 'O'), ('is', 'O'), ('a', 'O'), ('chromosomal', 'O'), ('rearrangement', 'O'), ('due', 'O'), ('to', 'O'), ('an', 'O'), ('inversion', 'O'), ('between', 'O'), ('Ets1', 'O'), ('and', 'O'), ('Atm', 'O'), ('-', 'O'), ('Npat', 'O'), ('-', 'O'), ('Acat1', 'O'), ('and', 'O'), ('that', 'O'), ('the', 'O'), ('inversion', 'O'), ('of', 'O'), ('MMU9', 'O'), ('originated', 'O'), ('from', 'O'), ('the', 'O'), ('chromosomal', 'O'), ('breakage', 'O'), ('at', 'O'), ('the', 'O'), ('boundary', 'O'), ('between', 'O'), ('Gria4', 'O'), ('and', 'O'), ('Atm', 'O'), ('-', 'O'), ('Npat', 'O'), ('-', 'O'), ('Acat1', 'O'), ('on', 'O'), ('HSA11', 'O'), ('.', 'O'))"
"This type of inversion appeared to be conserved in the three rodent species , mouse , rat , and Syrian hamster , using additional comparative mapping data with the Rck gene","(('This', 'O'), ('type', 'O'), ('of', 'O'), ('inversion', 'O'), ('appeared', 'O'), ('to', 'O'), ('be', 'O'), ('conserved', 'O'), ('in', 'O'), ('the', 'O'), ('three', 'O'), ('rodent', 'O'), ('species', 'O'), (',', 'O'), ('mouse', 'O'), (',', 'O'), ('rat', 'O'), (',', 'O'), ('and', 'O'), ('Syrian', 'O'), ('hamster', 'O'), (',', 'O'), ('using', 'O'), ('additional', 'O'), ('comparative', 'O'), ('mapping', 'O'), ('data', 'O'), ('with', 'O'), ('the', 'O'), ('Rck', 'O'), ('gene', 'O'))"
"RNA in situ hybridization revealed expression in retina , brain and the olfactory bulb and epithelium of 2 week old mice .","(('RNA', 'O'), ('in', 'O'), ('situ', 'O'), ('hybridization', 'O'), ('revealed', 'O'), ('expression', 'O'), ('in', 'O'), ('retina', 'O'), (',', 'O'), ('brain', 'O'), ('and', 'O'), ('the', 'O'), ('olfactory', 'O'), ('bulb', 'O'), ('and', 'O'), ('epithelium', 'O'), ('of', 'O'), ('2', 'O'), ('week', 'O'), ('old', 'O'), ('mice', 'O'), ('.', 'O'))"
"The outer plexiform layer disappears occasionally , resulting in a juxtaposed inner and outer nuclear layer .","(('The', 'O'), ('outer', 'O'), ('plexiform', 'O'), ('layer', 'O'), ('disappears', 'O'), ('occasionally', 'O'), (',', 'O'), ('resulting', 'O'), ('in', 'O'), ('a', 'O'), ('juxtaposed', 'O'), ('inner', 'O'), ('and', 'O'), ('outer', 'O'), ('nuclear', 'O'), ('layer', 'O'), ('.', 'O'))"
"At the same regions , the outer segments of the photoreceptor cell layer are no longer present .","(('At', 'O'), ('the', 'O'), ('same', 'O'), ('regions', 'O'), (',', 'O'), ('the', 'O'), ('outer', 'O'), ('segments', 'O'), ('of', 'O'), ('the', 'O'), ('photoreceptor', 'O'), ('cell', 'O'), ('layer', 'O'), ('are', 'O'), ('no', 'O'), ('longer', 'O'), ('present', 'O'), ('.', 'O'))"
"PAX3 codes for a transcriptional regulator that controls developmental programs , and FKHR codes for a forkhead - winged helix protein , also a likely transcription factor .","(('PAX3', 'O'), ('codes', 'O'), ('for', 'O'), ('a', 'O'), ('transcriptional', 'O'), ('regulator', 'O'), ('that', 'O'), ('controls', 'O'), ('developmental', 'O'), ('programs', 'O'), (',', 'O'), ('and', 'O'), ('FKHR', 'O'), ('codes', 'O'), ('for', 'O'), ('a', 'O'), ('forkhead', 'O'), ('-', 'O'), ('winged', 'O'), ('helix', 'O'), ('protein', 'O'), (',', 'O'), ('also', 'O'), ('a', 'O'), ('likely', 'O'), ('transcription', 'O'), ('factor', 'O'), ('.', 'O'))"
The PAX3 - FKHR fusion product retains the DNA binding domains of the PAX3 protein and the putative activator domain of the FKHR protein .,"(('The', 'O'), ('PAX3', 'O'), ('-', 'O'), ('FKHR', 'O'), ('fusion', 'O'), ('product', 'O'), ('retains', 'O'), ('the', 'O'), ('DNA', 'O'), ('binding', 'O'), ('domains', 'O'), ('of', 'O'), ('the', 'O'), ('PAX3', 'O'), ('protein', 'O'), ('and', 'O'), ('the', 'O'), ('putative', 'O'), ('activator', 'O'), ('domain', 'O'), ('of', 'O'), ('the', 'O'), ('FKHR', 'O'), ('protein', 'O'), ('.', 'O'))"
The PAX3 - FKHR protein has been shown to function as a transcriptional activator .,"(('The', 'O'), ('PAX3', 'O'), ('-', 'O'), ('FKHR', 'O'), ('protein', 'O'), ('has', 'O'), ('been', 'O'), ('shown', 'O'), ('to', 'O'), ('function', 'O'), ('as', 'O'), ('a', 'O'), ('transcriptional', 'O'), ('activator', 'O'), ('.', 'O'))"
"Using the RCAS retroviral vector , we have introduced the PAX3 - FKHR gene into chicken embryo fibroblasts .","(('Using', 'O'), ('the', 'O'), ('RCAS', 'O'), ('retroviral', 'O'), ('vector', 'O'), (',', 'O'), ('we', 'O'), ('have', 'O'), ('introduced', 'O'), ('the', 'O'), ('PAX3', 'O'), ('-', 'O'), ('FKHR', 'O'), ('gene', 'O'), ('into', 'O'), ('chicken', 'O'), ('embryo', 'O'), ('fibroblasts', 'O'), ('.', 'O'))"
"Expression of the PAX3 - FKHR protein in these cells leads to transformation the cells become enlarged , grow tightly packed and in multiple layers , and acquire the ability for anchorage - independent growth .","(('Expression', 'O'), ('of', 'O'), ('the', 'O'), ('PAX3', 'O'), ('-', 'O'), ('FKHR', 'O'), ('protein', 'O'), ('in', 'O'), ('these', 'O'), ('cells', 'O'), ('leads', 'O'), ('to', 'O'), ('transformation', 'O'), ('the', 'O'), ('cells', 'O'), ('become', 'O'), ('enlarged', 'O'), (',', 'O'), ('grow', 'O'), ('tightly', 'O'), ('packed', 'O'), ('and', 'O'), ('in', 'O'), ('multiple', 'O'), ('layers', 'O'), (',', 'O'), ('and', 'O'), ('acquire', 'O'), ('the', 'O'), ('ability', 'O'), ('for', 'O'), ('anchorage', 'O'), ('-', 'O'), ('independent', 'O'), ('growth', 'O'), ('.', 'O'))"
This cellular transformation in vitro will facilitate studies on the mechanism of PAX3 - FKHR - induced oncogenesis . .,"(('This', 'O'), ('cellular', 'O'), ('transformation', 'O'), ('in', 'O'), ('vitro', 'O'), ('will', 'O'), ('facilitate', 'O'), ('studies', 'O'), ('on', 'O'), ('the', 'O'), ('mechanism', 'O'), ('of', 'O'), ('PAX3', 'O'), ('-', 'O'), ('FKHR', 'O'), ('-', 'O'), ('induced', 'O'), ('oncogenesis', 'B'), ('.', 'O'), ('.', 'O'))"
"X - chromosome inactivation in mammals is regarded as an essentially random process , but the resulting somatic - cell mosaicism creates the opportunity for cell selection .","(('X', 'O'), ('-', 'O'), ('chromosome', 'O'), ('inactivation', 'O'), ('in', 'O'), ('mammals', 'O'), ('is', 'O'), ('regarded', 'O'), ('as', 'O'), ('an', 'O'), ('essentially', 'O'), ('random', 'O'), ('process', 'O'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('resulting', 'O'), ('somatic', 'O'), ('-', 'O'), ('cell', 'O'), ('mosaicism', 'O'), ('creates', 'O'), ('the', 'O'), ('opportunity', 'O'), ('for', 'O'), ('cell', 'O'), ('selection', 'O'), ('.', 'O'))"
In order to test this possibility we have analyzed four heterozygotes for class I G6PD mutations two with G6PD Portici ( 1178G - - > A ) and two with G6PD Bari ( 1187C - - > T ) .,"(('In', 'O'), ('order', 'O'), ('to', 'O'), ('test', 'O'), ('this', 'O'), ('possibility', 'O'), ('we', 'O'), ('have', 'O'), ('analyzed', 'O'), ('four', 'O'), ('heterozygotes', 'O'), ('for', 'O'), ('class', 'O'), ('I', 'O'), ('G6PD', 'O'), ('mutations', 'O'), ('two', 'O'), ('with', 'O'), ('G6PD', 'O'), ('Portici', 'B'), ('(', 'O'), ('1178G', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('A', 'O'), (')', 'O'), ('and', 'O'), ('two', 'O'), ('with', 'O'), ('G6PD', 'O'), ('Bari', 'O'), ('(', 'O'), ('1187C', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('T', 'O'), (')', 'O'), ('.', 'O'))"
"We found that in fractionated blood cell types ( including erythroid , myeloid , and lymphoid cell lineages ) there was a significant excess of G6PD - normal cells .","(('We', 'O'), ('found', 'O'), ('that', 'O'), ('in', 'O'), ('fractionated', 'O'), ('blood', 'O'), ('cell', 'O'), ('types', 'O'), ('(', 'O'), ('including', 'O'), ('erythroid', 'O'), (',', 'O'), ('myeloid', 'O'), (',', 'O'), ('and', 'O'), ('lymphoid', 'O'), ('cell', 'O'), ('lineages', 'O'), (')', 'O'), ('there', 'O'), ('was', 'O'), ('a', 'O'), ('significant', 'O'), ('excess', 'O'), ('of', 'O'), ('G6PD', 'O'), ('-', 'O'), ('normal', 'O'), ('cells', 'O'), ('.', 'O'))"
The significant concordance that we have observed in the degree of imbalance in the different blood - cell lineages indicates that a selective mechanism is likely to operate at the level of pluripotent blood stem cells .,"(('The', 'O'), ('significant', 'O'), ('concordance', 'O'), ('that', 'O'), ('we', 'O'), ('have', 'O'), ('observed', 'O'), ('in', 'O'), ('the', 'O'), ('degree', 'O'), ('of', 'O'), ('imbalance', 'O'), ('in', 'O'), ('the', 'O'), ('different', 'O'), ('blood', 'O'), ('-', 'O'), ('cell', 'O'), ('lineages', 'O'), ('indicates', 'O'), ('that', 'O'), ('a', 'O'), ('selective', 'O'), ('mechanism', 'O'), ('is', 'O'), ('likely', 'O'), ('to', 'O'), ('operate', 'O'), ('at', 'O'), ('the', 'O'), ('level', 'O'), ('of', 'O'), ('pluripotent', 'O'), ('blood', 'O'), ('stem', 'O'), ('cells', 'O'), ('.', 'O'))"
"Using statistical models specifically designed to study single - sperm segregation data , we find no evidence of meiotic segregation distortion .","(('Using', 'O'), ('statistical', 'O'), ('models', 'O'), ('specifically', 'O'), ('designed', 'O'), ('to', 'O'), ('study', 'O'), ('single', 'O'), ('-', 'O'), ('sperm', 'O'), ('segregation', 'O'), ('data', 'O'), (',', 'O'), ('we', 'O'), ('find', 'O'), ('no', 'O'), ('evidence', 'O'), ('of', 'O'), ('meiotic', 'O'), ('segregation', 'O'), ('distortion', 'O'), ('.', 'O'))"
The upper limit of the two - sided 95 % confidence interval for the estimate of the common segregation probability for the three donors is at or below .,"(('The', 'O'), ('upper', 'O'), ('limit', 'O'), ('of', 'O'), ('the', 'O'), ('two', 'O'), ('-', 'O'), ('sided', 'O'), ('95', 'O'), ('%', 'O'), ('confidence', 'O'), ('interval', 'O'), ('for', 'O'), ('the', 'O'), ('estimate', 'O'), ('of', 'O'), ('the', 'O'), ('common', 'O'), ('segregation', 'O'), ('probability', 'O'), ('for', 'O'), ('the', 'O'), ('three', 'O'), ('donors', 'O'), ('is', 'O'), ('at', 'O'), ('or', 'O'), ('below', 'O'), ('.', 'O'))"
"515 for all models considered , and no statistically significant difference from .","(('515', 'O'), ('for', 'O'), ('all', 'O'), ('models', 'O'), ('considered', 'O'), (',', 'O'), ('and', 'O'), ('no', 'O'), ('statistically', 'O'), ('significant', 'O'), ('difference', 'O'), ('from', 'O'), ('.', 'O'))"
5 is detected in any of the models .,"(('5', 'O'), ('is', 'O'), ('detected', 'O'), ('in', 'O'), ('any', 'O'), ('of', 'O'), ('the', 'O'), ('models', 'O'), ('.', 'O'))"
Multiple chromosomes have been found as the translocation partners of chromosome 12 but 3q27 - q28 is preferentially involved .,"(('Multiple', 'O'), ('chromosomes', 'O'), ('have', 'O'), ('been', 'O'), ('found', 'O'), ('as', 'O'), ('the', 'O'), ('translocation', 'O'), ('partners', 'O'), ('of', 'O'), ('chromosome', 'O'), ('12', 'O'), ('but', 'O'), ('3q27', 'O'), ('-', 'O'), ('q28', 'O'), ('is', 'O'), ('preferentially', 'O'), ('involved', 'O'), ('.', 'O'))"
"In previous studies , it has been shown that the high mobility group ( HMG ) protein gene HMGIC at 12q15 is consistently rearranged as a consequence of these translocations .","(('In', 'O'), ('previous', 'O'), ('studies', 'O'), (',', 'O'), ('it', 'O'), ('has', 'O'), ('been', 'O'), ('shown', 'O'), ('that', 'O'), ('the', 'O'), ('high', 'O'), ('mobility', 'O'), ('group', 'O'), ('(', 'O'), ('HMG', 'O'), (')', 'O'), ('protein', 'O'), ('gene', 'O'), ('HMGIC', 'O'), ('at', 'O'), ('12q15', 'O'), ('is', 'O'), ('consistently', 'O'), ('rearranged', 'O'), ('as', 'O'), ('a', 'O'), ('consequence', 'O'), ('of', 'O'), ('these', 'O'), ('translocations', 'O'), ('.', 'O'))"
"In Northern blot analysis , an mRNA of over 10 kb was detected by these ectopic sequences in a variety of human tissues but not in brain and peripheral blood leukocytes .","(('In', 'O'), ('Northern', 'O'), ('blot', 'O'), ('analysis', 'O'), (',', 'O'), ('an', 'O'), ('mRNA', 'O'), ('of', 'O'), ('over', 'O'), ('10', 'O'), ('kb', 'O'), ('was', 'O'), ('detected', 'O'), ('by', 'O'), ('these', 'O'), ('ectopic', 'O'), ('sequences', 'O'), ('in', 'O'), ('a', 'O'), ('variety', 'O'), ('of', 'O'), ('human', 'O'), ('tissues', 'O'), ('but', 'O'), ('not', 'O'), ('in', 'O'), ('brain', 'O'), ('and', 'O'), ('peripheral', 'O'), ('blood', 'O'), ('leukocytes', 'O'), ('.', 'O'))"
"Upon partial cDNA cloning , features of the genetic organization of LPP were established .","(('Upon', 'O'), ('partial', 'O'), ('cDNA', 'O'), ('cloning', 'O'), (',', 'O'), ('features', 'O'), ('of', 'O'), ('the', 'O'), ('genetic', 'O'), ('organization', 'O'), ('of', 'O'), ('LPP', 'O'), ('were', 'O'), ('established', 'O'), ('.', 'O'))"
The gene was found to span a genomic region of over 400 kb .,"(('The', 'O'), ('gene', 'O'), ('was', 'O'), ('found', 'O'), ('to', 'O'), ('span', 'O'), ('a', 'O'), ('genomic', 'O'), ('region', 'O'), ('of', 'O'), ('over', 'O'), ('400', 'O'), ('kb', 'O'), ('.', 'O'))"
Nucleotide sequence analysis of a composite cDNA of LPP revealed an open reading frame of 1836 nucleotides encoding a proline - rich protein containing a leucine - zipper motif in its amino - terminal region and three LIM domains in its carboxy - terminal region .,"(('Nucleotide', 'O'), ('sequence', 'O'), ('analysis', 'O'), ('of', 'O'), ('a', 'O'), ('composite', 'O'), ('cDNA', 'O'), ('of', 'O'), ('LPP', 'O'), ('revealed', 'O'), ('an', 'O'), ('open', 'O'), ('reading', 'O'), ('frame', 'O'), ('of', 'O'), ('1836', 'O'), ('nucleotides', 'O'), ('encoding', 'O'), ('a', 'O'), ('proline', 'O'), ('-', 'O'), ('rich', 'O'), ('protein', 'O'), ('containing', 'O'), ('a', 'O'), ('leucine', 'O'), ('-', 'O'), ('zipper', 'O'), ('motif', 'O'), ('in', 'O'), ('its', 'O'), ('amino', 'O'), ('-', 'O'), ('terminal', 'O'), ('region', 'O'), ('and', 'O'), ('three', 'O'), ('LIM', 'O'), ('domains', 'O'), ('in', 'O'), ('its', 'O'), ('carboxy', 'O'), ('-', 'O'), ('terminal', 'O'), ('region', 'O'), ('.', 'O'))"
The LPP - encoded protein should be classified as a novel member of the group 3 proteins of the LIM protein gene family .,"(('The', 'O'), ('LPP', 'O'), ('-', 'O'), ('encoded', 'O'), ('protein', 'O'), ('should', 'O'), ('be', 'O'), ('classified', 'O'), ('as', 'O'), ('a', 'O'), ('novel', 'O'), ('member', 'O'), ('of', 'O'), ('the', 'O'), ('group', 'O'), ('3', 'O'), ('proteins', 'O'), ('of', 'O'), ('the', 'O'), ('LIM', 'O'), ('protein', 'O'), ('gene', 'O'), ('family', 'O'), ('.', 'O'))"
Two alternative HMGIC / LPP hybrid transcripts have been detected ; the difference between them is mainly the presence of either two or three LIM domains in the predicted HMGI - C / LPP fusion proteins . .,"(('Two', 'O'), ('alternative', 'O'), ('HMGIC', 'O'), ('/', 'O'), ('LPP', 'O'), ('hybrid', 'O'), ('transcripts', 'O'), ('have', 'O'), ('been', 'O'), ('detected', 'O'), (';', 'O'), ('the', 'O'), ('difference', 'O'), ('between', 'O'), ('them', 'O'), ('is', 'O'), ('mainly', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('either', 'O'), ('two', 'O'), ('or', 'O'), ('three', 'O'), ('LIM', 'O'), ('domains', 'O'), ('in', 'O'), ('the', 'O'), ('predicted', 'O'), ('HMGI', 'O'), ('-', 'O'), ('C', 'O'), ('/', 'O'), ('LPP', 'O'), ('fusion', 'O'), ('proteins', 'O'), ('.', 'O'), ('.', 'O'))"
"By 1 year , these mice have no behavioral abnormalities and morphometric analysis at 6 ( one animal ) and 9 ( two animals ) months age revealed no changes .","(('By', 'O'), ('1', 'O'), ('year', 'O'), (',', 'O'), ('these', 'O'), ('mice', 'O'), ('have', 'O'), ('no', 'O'), ('behavioral', 'B'), ('abnormalities', 'I'), ('and', 'O'), ('morphometric', 'O'), ('analysis', 'O'), ('at', 'O'), ('6', 'O'), ('(', 'O'), ('one', 'O'), ('animal', 'O'), (')', 'O'), ('and', 'O'), ('9', 'O'), ('(', 'O'), ('two', 'O'), ('animals', 'O'), (')', 'O'), ('months', 'O'), ('age', 'O'), ('revealed', 'O'), ('no', 'O'), ('changes', 'O'), ('.', 'O'))"
"In contrast to that seen in humans , the CAG repeat in these mice was remarkably stable in 97 meioses .","(('In', 'O'), ('contrast', 'O'), ('to', 'O'), ('that', 'O'), ('seen', 'O'), ('in', 'O'), ('humans', 'O'), (',', 'O'), ('the', 'O'), ('CAG', 'O'), ('repeat', 'O'), ('in', 'O'), ('these', 'O'), ('mice', 'O'), ('was', 'O'), ('remarkably', 'O'), ('stable', 'O'), ('in', 'O'), ('97', 'O'), ('meioses', 'O'), ('.', 'O'))"
This suggests that genomic sequences may play a critical role in influencing repeat instability . .,"(('This', 'O'), ('suggests', 'O'), ('that', 'O'), ('genomic', 'O'), ('sequences', 'O'), ('may', 'O'), ('play', 'O'), ('a', 'O'), ('critical', 'O'), ('role', 'O'), ('in', 'O'), ('influencing', 'O'), ('repeat', 'O'), ('instability', 'O'), ('.', 'O'), ('.', 'O'))"
G6PD activity was detected in samples obtained from biopsies on the quadriceps muscle of seven males and one female .,"(('G6PD', 'O'), ('activity', 'O'), ('was', 'O'), ('detected', 'O'), ('in', 'O'), ('samples', 'O'), ('obtained', 'O'), ('from', 'O'), ('biopsies', 'O'), ('on', 'O'), ('the', 'O'), ('quadriceps', 'O'), ('muscle', 'O'), ('of', 'O'), ('seven', 'O'), ('males', 'O'), ('and', 'O'), ('one', 'O'), ('female', 'O'), ('.', 'O'))"
"The type of genetic variant was determined by molecular analysis of DNA , extracted from blood samples .","(('The', 'O'), ('type', 'O'), ('of', 'O'), ('genetic', 'O'), ('variant', 'O'), ('was', 'O'), ('determined', 'O'), ('by', 'O'), ('molecular', 'O'), ('analysis', 'O'), ('of', 'O'), ('DNA', 'O'), (',', 'O'), ('extracted', 'O'), ('from', 'O'), ('blood', 'O'), ('samples', 'O'), ('.', 'O'))"
All variants showed the enzyme defect in muscle .,"(('All', 'O'), ('variants', 'O'), ('showed', 'O'), ('the', 'O'), ('enzyme', 'O'), ('defect', 'O'), ('in', 'O'), ('muscle', 'O'), ('.', 'O'))"
A statistically significant relationship was found in the activity of G6PD between erythrocytes and muscle of the male subjects ( r = 0 . 968 ; p = 0 . 00008 ) .,"(('A', 'O'), ('statistically', 'O'), ('significant', 'O'), ('relationship', 'O'), ('was', 'O'), ('found', 'O'), ('in', 'O'), ('the', 'O'), ('activity', 'O'), ('of', 'O'), ('G6PD', 'O'), ('between', 'O'), ('erythrocytes', 'O'), ('and', 'O'), ('muscle', 'O'), ('of', 'O'), ('the', 'O'), ('male', 'O'), ('subjects', 'O'), ('(', 'O'), ('r', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('968', 'O'), (';', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('00008', 'O'), (')', 'O'), ('.', 'O'))"
The equation for the best fit line was Y = 0 .,"(('The', 'O'), ('equation', 'O'), ('for', 'O'), ('the', 'O'), ('best', 'O'), ('fit', 'O'), ('line', 'O'), ('was', 'O'), ('Y', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'))"
390X + 0 .,"(('390X', 'O'), ('+', 'O'), ('0', 'O'), ('.', 'O'))"
198 198 .,"(('198', 'O'), ('198', 'O'), ('.', 'O'))"
"The results suggest that , for a given variant , the extent of the enzyme defect in muscle may be determined , using this equation , from the G6PD activity of erythrocytes","(('The', 'O'), ('results', 'O'), ('suggest', 'O'), ('that', 'O'), (',', 'O'), ('for', 'O'), ('a', 'O'), ('given', 'O'), ('variant', 'O'), (',', 'O'), ('the', 'O'), ('extent', 'O'), ('of', 'O'), ('the', 'O'), ('enzyme', 'O'), ('defect', 'O'), ('in', 'O'), ('muscle', 'O'), ('may', 'O'), ('be', 'O'), ('determined', 'O'), (',', 'O'), ('using', 'O'), ('this', 'O'), ('equation', 'O'), (',', 'O'), ('from', 'O'), ('the', 'O'), ('G6PD', 'O'), ('activity', 'O'), ('of', 'O'), ('erythrocytes', 'O'))"
Three different vector systems have been examined .,"(('Three', 'O'), ('different', 'O'), ('vector', 'O'), ('systems', 'O'), ('have', 'O'), ('been', 'O'), ('examined', 'O'), ('.', 'O'))"
This treatment is transient and cannot be effectively re - administered due to the presence of neutralizing antibodies directed against the recombinant adenoviral vector .,"(('This', 'O'), ('treatment', 'O'), ('is', 'O'), ('transient', 'O'), ('and', 'O'), ('cannot', 'O'), ('be', 'O'), ('effectively', 'O'), ('re', 'O'), ('-', 'O'), ('administered', 'O'), ('due', 'O'), ('to', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('neutralizing', 'O'), ('antibodies', 'O'), ('directed', 'O'), ('against', 'O'), ('the', 'O'), ('recombinant', 'O'), ('adenoviral', 'O'), ('vector', 'O'), ('.', 'O'))"
Exon - intron structure of the human neuronal nicotinic acetylcholine receptor alpha 4 subunit ( CHRNA4 ) .,"(('Exon', 'O'), ('-', 'O'), ('intron', 'O'), ('structure', 'O'), ('of', 'O'), ('the', 'O'), ('human', 'O'), ('neuronal', 'O'), ('nicotinic', 'O'), ('acetylcholine', 'O'), ('receptor', 'O'), ('alpha', 'O'), ('4', 'O'), ('subunit', 'O'), ('(', 'O'), ('CHRNA4', 'O'), (')', 'O'), ('.', 'O'))"
"We have determined the genomic organization of CHRNA4 , which consists of six exons distributed over approximately 17 kb of genomic DNA .","(('We', 'O'), ('have', 'O'), ('determined', 'O'), ('the', 'O'), ('genomic', 'O'), ('organization', 'O'), ('of', 'O'), ('CHRNA4', 'O'), (',', 'O'), ('which', 'O'), ('consists', 'O'), ('of', 'O'), ('six', 'O'), ('exons', 'O'), ('distributed', 'O'), ('over', 'O'), ('approximately', 'O'), ('17', 'O'), ('kb', 'O'), ('of', 'O'), ('genomic', 'O'), ('DNA', 'O'), ('.', 'O'))"
The nucleotide sequence obtained from the genomic regions adjacent to the exon boundaries enabled us to develop a set of primer pairs for PCR amplification of the complete coding region .,"(('The', 'O'), ('nucleotide', 'O'), ('sequence', 'O'), ('obtained', 'O'), ('from', 'O'), ('the', 'O'), ('genomic', 'O'), ('regions', 'O'), ('adjacent', 'O'), ('to', 'O'), ('the', 'O'), ('exon', 'O'), ('boundaries', 'O'), ('enabled', 'O'), ('us', 'O'), ('to', 'O'), ('develop', 'O'), ('a', 'O'), ('set', 'O'), ('of', 'O'), ('primer', 'O'), ('pairs', 'O'), ('for', 'O'), ('PCR', 'O'), ('amplification', 'O'), ('of', 'O'), ('the', 'O'), ('complete', 'O'), ('coding', 'O'), ('region', 'O'), ('.', 'O'))"
Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 .,"(('Ashkenazi', 'O'), ('Jewish', 'O'), ('population', 'O'), ('frequencies', 'O'), ('for', 'O'), ('common', 'O'), ('mutations', 'O'), ('in', 'O'), ('BRCA1', 'O'), ('and', 'O'), ('BRCA2', 'O'), ('.', 'O'))"
"Over 85 distinct BRCA1 mutations and a growing list of BRCA2 mutations have been identified , with the majority resulting in protein truncation .","(('Over', 'O'), ('85', 'O'), ('distinct', 'O'), ('BRCA1', 'O'), ('mutations', 'O'), ('and', 'O'), ('a', 'O'), ('growing', 'O'), ('list', 'O'), ('of', 'O'), ('BRCA2', 'O'), ('mutations', 'O'), ('have', 'O'), ('been', 'O'), ('identified', 'O'), (',', 'O'), ('with', 'O'), ('the', 'O'), ('majority', 'O'), ('resulting', 'O'), ('in', 'O'), ('protein', 'O'), ('truncation', 'O'), ('.', 'O'))"
"A specific BRCA1 mutation , 185delAG , has a reported increased carrier frequency of approximately 0 .","(('A', 'O'), ('specific', 'O'), ('BRCA1', 'O'), ('mutation', 'O'), (',', 'O'), ('185delAG', 'O'), (',', 'O'), ('has', 'O'), ('a', 'O'), ('reported', 'O'), ('increased', 'O'), ('carrier', 'O'), ('frequency', 'O'), ('of', 'O'), ('approximately', 'O'), ('0', 'O'), ('.', 'O'))"
"9 % in the Ashkenazi Jewish population , but is also found in rare non - Jewish patients with a different haplotype .","(('9', 'O'), ('%', 'O'), ('in', 'O'), ('the', 'O'), ('Ashkenazi', 'O'), ('Jewish', 'O'), ('population', 'O'), (',', 'O'), ('but', 'O'), ('is', 'O'), ('also', 'O'), ('found', 'O'), ('in', 'O'), ('rare', 'O'), ('non', 'O'), ('-', 'O'), ('Jewish', 'O'), ('patients', 'O'), ('with', 'O'), ('a', 'O'), ('different', 'O'), ('haplotype', 'O'), ('.', 'O'))"
We have conducted a large - scale population study to investigate the prevalence of specific BRCA1 and BRCA2 mutations in Ashkenazi Jewish individuals who were unselected for breast cancer .,"(('We', 'O'), ('have', 'O'), ('conducted', 'O'), ('a', 'O'), ('large', 'O'), ('-', 'O'), ('scale', 'O'), ('population', 'O'), ('study', 'O'), ('to', 'O'), ('investigate', 'O'), ('the', 'O'), ('prevalence', 'O'), ('of', 'O'), ('specific', 'O'), ('BRCA1', 'O'), ('and', 'O'), ('BRCA2', 'O'), ('mutations', 'O'), ('in', 'O'), ('Ashkenazi', 'O'), ('Jewish', 'O'), ('individuals', 'O'), ('who', 'O'), ('were', 'O'), ('unselected', 'O'), ('for', 'O'), ('breast', 'B'), ('cancer', 'I'), ('.', 'O'))"
"BRCA1 mutation screening on approximately 3 , 000 Ashkenazi Jewish samples determined a carrier frequency of 1 .","(('BRCA1', 'O'), ('mutation', 'O'), ('screening', 'O'), ('on', 'O'), ('approximately', 'O'), ('3', 'O'), (',', 'O'), ('000', 'O'), ('Ashkenazi', 'O'), ('Jewish', 'O'), ('samples', 'O'), ('determined', 'O'), ('a', 'O'), ('carrier', 'O'), ('frequency', 'O'), ('of', 'O'), ('1', 'O'), ('.', 'O'))"
09 % for the 185delAG mutation and 0 .,"(('09', 'O'), ('%', 'O'), ('for', 'O'), ('the', 'O'), ('185delAG', 'O'), ('mutation', 'O'), ('and', 'O'), ('0', 'O'), ('.', 'O'))"
13 % for the 5382insC mutation .,"(('13', 'O'), ('%', 'O'), ('for', 'O'), ('the', 'O'), ('5382insC', 'O'), ('mutation', 'O'), ('.', 'O'))"
"BRCA2 analysis on 3 , 085 individuals from the same population showed a carrier frequency of 1 .","(('BRCA2', 'O'), ('analysis', 'O'), ('on', 'O'), ('3', 'O'), (',', 'O'), ('085', 'O'), ('individuals', 'O'), ('from', 'O'), ('the', 'O'), ('same', 'O'), ('population', 'O'), ('showed', 'O'), ('a', 'O'), ('carrier', 'O'), ('frequency', 'O'), ('of', 'O'), ('1', 'O'), ('.', 'O'))"
52 % for the 6174delT mutation .,"(('52', 'O'), ('%', 'O'), ('for', 'O'), ('the', 'O'), ('6174delT', 'O'), ('mutation', 'O'), ('.', 'O'))"
Dual roles of ATM in the cellular response to radiation and in cell growth control .,"(('Dual', 'O'), ('roles', 'O'), ('of', 'O'), ('ATM', 'O'), ('in', 'O'), ('the', 'O'), ('cellular', 'O'), ('response', 'O'), ('to', 'O'), ('radiation', 'O'), ('and', 'O'), ('in', 'O'), ('cell', 'O'), ('growth', 'O'), ('control', 'O'), ('.', 'O'))"
"To elucidate the functions of ATM , we disrupted the mouse ATM gene through homologous recombination in mice .","(('To', 'O'), ('elucidate', 'O'), ('the', 'O'), ('functions', 'O'), ('of', 'O'), ('ATM', 'O'), (',', 'O'), ('we', 'O'), ('disrupted', 'O'), ('the', 'O'), ('mouse', 'O'), ('ATM', 'O'), ('gene', 'O'), ('through', 'O'), ('homologous', 'O'), ('recombination', 'O'), ('in', 'O'), ('mice', 'O'), ('.', 'O'))"
"In addition , ATM - / - mouse thymocytes are more resistant to apoptosis induced by gamma - irradiation than normal thymocytes .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('ATM', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), ('mouse', 'O'), ('thymocytes', 'O'), ('are', 'O'), ('more', 'O'), ('resistant', 'O'), ('to', 'O'), ('apoptosis', 'O'), ('induced', 'O'), ('by', 'O'), ('gamma', 'O'), ('-', 'O'), ('irradiation', 'O'), ('than', 'O'), ('normal', 'O'), ('thymocytes', 'O'), ('.', 'O'))"
ATM - / - fibroblasts are inefficient in G1 to S - phase progression following serum stimulation and senesce after only a few passages in culture .,"(('ATM', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), ('fibroblasts', 'O'), ('are', 'O'), ('inefficient', 'O'), ('in', 'O'), ('G1', 'O'), ('to', 'O'), ('S', 'O'), ('-', 'O'), ('phase', 'O'), ('progression', 'O'), ('following', 'O'), ('serum', 'O'), ('stimulation', 'O'), ('and', 'O'), ('senesce', 'O'), ('after', 'O'), ('only', 'O'), ('a', 'O'), ('few', 'O'), ('passages', 'O'), ('in', 'O'), ('culture', 'O'), ('.', 'O'))"
They have an increased constitutive level of p21CP1 / WAF1 .,"(('They', 'O'), ('have', 'O'), ('an', 'O'), ('increased', 'O'), ('constitutive', 'O'), ('level', 'O'), ('of', 'O'), ('p21CP1', 'O'), ('/', 'O'), ('WAF1', 'O'), ('.', 'O'))"
The ATM protein is therefore critical both for cellular responses to ionizing radiation and for normal cell - cycle progression .,"(('The', 'O'), ('ATM', 'O'), ('protein', 'O'), ('is', 'O'), ('therefore', 'O'), ('critical', 'O'), ('both', 'O'), ('for', 'O'), ('cellular', 'O'), ('responses', 'O'), ('to', 'O'), ('ionizing', 'O'), ('radiation', 'O'), ('and', 'O'), ('for', 'O'), ('normal', 'O'), ('cell', 'O'), ('-', 'O'), ('cycle', 'O'), ('progression', 'O'), ('.', 'O'))"
"To help clarify the physiological roles of the ATM protein , we disrupted the ATM gene in mice through homologous recombination .","(('To', 'O'), ('help', 'O'), ('clarify', 'O'), ('the', 'O'), ('physiological', 'O'), ('roles', 'O'), ('of', 'O'), ('the', 'O'), ('ATM', 'O'), ('protein', 'O'), (',', 'O'), ('we', 'O'), ('disrupted', 'O'), ('the', 'O'), ('ATM', 'O'), ('gene', 'O'), ('in', 'O'), ('mice', 'O'), ('through', 'O'), ('homologous', 'O'), ('recombination', 'O'), ('.', 'O'))"
"The homozygous mutant ( ATM - / - ) mice are viable , growth - retarded , and infertile .","(('The', 'O'), ('homozygous', 'O'), ('mutant', 'O'), ('(', 'O'), ('ATM', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('mice', 'O'), ('are', 'O'), ('viable', 'O'), (',', 'O'), ('growth', 'B'), ('-', 'I'), ('retarded', 'I'), (',', 'O'), ('and', 'O'), ('infertile', 'B'), ('.', 'O'))"
The infertility of ATM - / - mice results from meiotic failure .,"(('The', 'O'), ('infertility', 'B'), ('of', 'O'), ('ATM', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), ('mice', 'O'), ('results', 'O'), ('from', 'O'), ('meiotic', 'O'), ('failure', 'O'), ('.', 'O'))"
Meiosis is arrested at the zygotene / pachytene stage of prophase I as a result of abnormal chromosomal synapsis and subsequent chromosome fragmentation .,"(('Meiosis', 'O'), ('is', 'O'), ('arrested', 'O'), ('at', 'O'), ('the', 'O'), ('zygotene', 'O'), ('/', 'O'), ('pachytene', 'O'), ('stage', 'O'), ('of', 'O'), ('prophase', 'O'), ('I', 'O'), ('as', 'O'), ('a', 'O'), ('result', 'O'), ('of', 'O'), ('abnormal', 'O'), ('chromosomal', 'O'), ('synapsis', 'O'), ('and', 'O'), ('subsequent', 'O'), ('chromosome', 'O'), ('fragmentation', 'O'), ('.', 'O'))"
The cerebella of ATM - / - mice appear normal by histologic examination at 3 to 4 months and the mice have no gross behavioral abnormalities .,"(('The', 'O'), ('cerebella', 'O'), ('of', 'O'), ('ATM', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), ('mice', 'O'), ('appear', 'O'), ('normal', 'O'), ('by', 'O'), ('histologic', 'O'), ('examination', 'O'), ('at', 'O'), ('3', 'O'), ('to', 'O'), ('4', 'O'), ('months', 'O'), ('and', 'O'), ('the', 'O'), ('mice', 'O'), ('have', 'O'), ('no', 'O'), ('gross', 'O'), ('behavioral', 'B'), ('abnormalities', 'I'), ('.', 'O'))"
"These findings indicate that the ATM gene product plays an essential role in a diverse group of cellular processes , including meiosis , the normal growth of somatic tissues , immune development , and tumor suppression . .","(('These', 'O'), ('findings', 'O'), ('indicate', 'O'), ('that', 'O'), ('the', 'O'), ('ATM', 'O'), ('gene', 'O'), ('product', 'O'), ('plays', 'O'), ('an', 'O'), ('essential', 'O'), ('role', 'O'), ('in', 'O'), ('a', 'O'), ('diverse', 'O'), ('group', 'O'), ('of', 'O'), ('cellular', 'O'), ('processes', 'O'), (',', 'O'), ('including', 'O'), ('meiosis', 'O'), (',', 'O'), ('the', 'O'), ('normal', 'O'), ('growth', 'O'), ('of', 'O'), ('somatic', 'O'), ('tissues', 'O'), (',', 'O'), ('immune', 'O'), ('development', 'O'), (',', 'O'), ('and', 'O'), ('tumor', 'B'), ('suppression', 'O'), ('.', 'O'), ('.', 'O'))"
"Cloning and characterization of human very - long - chain acyl - CoA dehydrogenase cDNA , chromosomal assignment of the gene and identification in four patients of nine different mutations within the VLCAD gene .","(('Cloning', 'O'), ('and', 'O'), ('characterization', 'O'), ('of', 'O'), ('human', 'O'), ('very', 'O'), ('-', 'O'), ('long', 'O'), ('-', 'O'), ('chain', 'O'), ('acyl', 'O'), ('-', 'O'), ('CoA', 'O'), ('dehydrogenase', 'O'), ('cDNA', 'O'), (',', 'O'), ('chromosomal', 'O'), ('assignment', 'O'), ('of', 'O'), ('the', 'O'), ('gene', 'O'), ('and', 'O'), ('identification', 'O'), ('in', 'O'), ('four', 'O'), ('patients', 'O'), ('of', 'O'), ('nine', 'O'), ('different', 'O'), ('mutations', 'O'), ('within', 'O'), ('the', 'O'), ('VLCAD', 'O'), ('gene', 'O'), ('.', 'O'))"
"Very - long - chain acyl - CoA dehydrogenase ( VLCAD ) is one of four straight - chain acyl - CoA dehydrogenase ( ACD ) enzymes , which are all nuclear encoded mitochondrial flavoproteins catalyzing the initial step in fatty acid beta - oxidation .","(('Very', 'O'), ('-', 'O'), ('long', 'O'), ('-', 'O'), ('chain', 'O'), ('acyl', 'O'), ('-', 'O'), ('CoA', 'O'), ('dehydrogenase', 'O'), ('(', 'O'), ('VLCAD', 'O'), (')', 'O'), ('is', 'O'), ('one', 'O'), ('of', 'O'), ('four', 'O'), ('straight', 'O'), ('-', 'O'), ('chain', 'O'), ('acyl', 'O'), ('-', 'O'), ('CoA', 'O'), ('dehydrogenase', 'O'), ('(', 'O'), ('ACD', 'O'), (')', 'O'), ('enzymes', 'O'), (',', 'O'), ('which', 'O'), ('are', 'O'), ('all', 'O'), ('nuclear', 'O'), ('encoded', 'O'), ('mitochondrial', 'O'), ('flavoproteins', 'O'), ('catalyzing', 'O'), ('the', 'O'), ('initial', 'O'), ('step', 'O'), ('in', 'O'), ('fatty', 'O'), ('acid', 'O'), ('beta', 'O'), ('-', 'O'), ('oxidation', 'O'), ('.', 'O'))"
"We have used the very fast , Rapid Amplification of cDNA Ends ( RACE ) based strategy to obtain the sequence of cDNAs encoding human VLCAD from placenta and fibroblasts .","(('We', 'O'), ('have', 'O'), ('used', 'O'), ('the', 'O'), ('very', 'O'), ('fast', 'O'), (',', 'O'), ('Rapid', 'O'), ('Amplification', 'O'), ('of', 'O'), ('cDNA', 'O'), ('Ends', 'O'), ('(', 'O'), ('RACE', 'O'), (')', 'O'), ('based', 'O'), ('strategy', 'O'), ('to', 'O'), ('obtain', 'O'), ('the', 'O'), ('sequence', 'O'), ('of', 'O'), ('cDNAs', 'O'), ('encoding', 'O'), ('human', 'O'), ('VLCAD', 'O'), ('from', 'O'), ('placenta', 'O'), ('and', 'O'), ('fibroblasts', 'O'), ('.', 'O'))"
Alignment of the predicted amino acid sequence of human VLCAD with those of the other human ACD enzymes revealed extensive sequence homology .,"(('Alignment', 'O'), ('of', 'O'), ('the', 'O'), ('predicted', 'O'), ('amino', 'O'), ('acid', 'O'), ('sequence', 'O'), ('of', 'O'), ('human', 'O'), ('VLCAD', 'O'), ('with', 'O'), ('those', 'O'), ('of', 'O'), ('the', 'O'), ('other', 'O'), ('human', 'O'), ('ACD', 'O'), ('enzymes', 'O'), ('revealed', 'O'), ('extensive', 'O'), ('sequence', 'O'), ('homology', 'O'), ('.', 'O'))"
"Moreover , human VLCAD and human acyl - CoA oxidase showed extensive sequence homology corroborating the notion that these genes are evolutionarily related .","(('Moreover', 'O'), (',', 'O'), ('human', 'O'), ('VLCAD', 'O'), ('and', 'O'), ('human', 'O'), ('acyl', 'O'), ('-', 'O'), ('CoA', 'O'), ('oxidase', 'O'), ('showed', 'O'), ('extensive', 'O'), ('sequence', 'O'), ('homology', 'O'), ('corroborating', 'O'), ('the', 'O'), ('notion', 'O'), ('that', 'O'), ('these', 'O'), ('genes', 'O'), ('are', 'O'), ('evolutionarily', 'O'), ('related', 'O'), ('.', 'O'))"
Southern blot analysis of genomic DNA from hybrid cell lines was used to localize the VLCAD gene to human chromosome 17p11 .,"(('Southern', 'O'), ('blot', 'O'), ('analysis', 'O'), ('of', 'O'), ('genomic', 'O'), ('DNA', 'O'), ('from', 'O'), ('hybrid', 'O'), ('cell', 'O'), ('lines', 'O'), ('was', 'O'), ('used', 'O'), ('to', 'O'), ('localize', 'O'), ('the', 'O'), ('VLCAD', 'O'), ('gene', 'O'), ('to', 'O'), ('human', 'O'), ('chromosome', 'O'), ('17p11', 'O'), ('.', 'O'))"
2 - p11 .,"(('2', 'O'), ('-', 'O'), ('p11', 'O'), ('.', 'O'))"
13105 .,"(('13105', 'O'), ('.', 'O'))"
Using Northern and Western blot analysis to investigate the tissue specific distribution of VLCAD mRNA and protein in several human tissues we showed that VLCAD is most abundant in heart and skeletal muscle .,"(('Using', 'O'), ('Northern', 'O'), ('and', 'O'), ('Western', 'O'), ('blot', 'O'), ('analysis', 'O'), ('to', 'O'), ('investigate', 'O'), ('the', 'O'), ('tissue', 'O'), ('specific', 'O'), ('distribution', 'O'), ('of', 'O'), ('VLCAD', 'O'), ('mRNA', 'O'), ('and', 'O'), ('protein', 'O'), ('in', 'O'), ('several', 'O'), ('human', 'O'), ('tissues', 'O'), ('we', 'O'), ('showed', 'O'), ('that', 'O'), ('VLCAD', 'O'), ('is', 'O'), ('most', 'O'), ('abundant', 'O'), ('in', 'O'), ('heart', 'O'), ('and', 'O'), ('skeletal', 'O'), ('muscle', 'O'), ('.', 'O'))"
Western blot analysis of patient fibroblasts showed that the identified mutations result in severely reduced amounts of VLCAD protein .,"(('Western', 'O'), ('blot', 'O'), ('analysis', 'O'), ('of', 'O'), ('patient', 'O'), ('fibroblasts', 'O'), ('showed', 'O'), ('that', 'O'), ('the', 'O'), ('identified', 'O'), ('mutations', 'O'), ('result', 'O'), ('in', 'O'), ('severely', 'O'), ('reduced', 'O'), ('amounts', 'O'), ('of', 'O'), ('VLCAD', 'O'), ('protein', 'O'), ('.', 'O'))"
A defect at the 5 splice donor site of intron 15 of the C6 gene explains the low molecular weight of the C6 protein and is probably responsible for its low expressed concentration .,"(('A', 'O'), ('defect', 'O'), ('at', 'O'), ('the', 'O'), ('5', 'O'), ('splice', 'O'), ('donor', 'O'), ('site', 'O'), ('of', 'O'), ('intron', 'O'), ('15', 'O'), ('of', 'O'), ('the', 'O'), ('C6', 'O'), ('gene', 'O'), ('explains', 'O'), ('the', 'O'), ('low', 'O'), ('molecular', 'O'), ('weight', 'O'), ('of', 'O'), ('the', 'O'), ('C6', 'O'), ('protein', 'O'), ('and', 'O'), ('is', 'O'), ('probably', 'O'), ('responsible', 'O'), ('for', 'O'), ('its', 'O'), ('low', 'O'), ('expressed', 'O'), ('concentration', 'O'), ('.', 'O'))"
"The C7 defect is more enigmatic the protein is of normal molecular weight , low circulating concentration , and altered isoelectric point .","(('The', 'O'), ('C7', 'O'), ('defect', 'O'), ('is', 'O'), ('more', 'O'), ('enigmatic', 'O'), ('the', 'O'), ('protein', 'O'), ('is', 'O'), ('of', 'O'), ('normal', 'O'), ('molecular', 'O'), ('weight', 'O'), (',', 'O'), ('low', 'O'), ('circulating', 'O'), ('concentration', 'O'), (',', 'O'), ('and', 'O'), ('altered', 'O'), ('isoelectric', 'O'), ('point', 'O'), ('.', 'O'))"
An Arg > Ser codon substitution in exon 11 is the only molecular alteration within the mature C7 protein .,"(('An', 'O'), ('Arg', 'O'), ('>', 'O'), ('Ser', 'O'), ('codon', 'O'), ('substitution', 'O'), ('in', 'O'), ('exon', 'O'), ('11', 'O'), ('is', 'O'), ('the', 'O'), ('only', 'O'), ('molecular', 'O'), ('alteration', 'O'), ('within', 'O'), ('the', 'O'), ('mature', 'O'), ('C7', 'O'), ('protein', 'O'), ('.', 'O'))"
"These defects are associated with a characteristic set of polymorphic DNA markers in the C6 / C7 region , forming a distinct haplotype .","(('These', 'O'), ('defects', 'O'), ('are', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('characteristic', 'O'), ('set', 'O'), ('of', 'O'), ('polymorphic', 'O'), ('DNA', 'O'), ('markers', 'O'), ('in', 'O'), ('the', 'O'), ('C6', 'O'), ('/', 'O'), ('C7', 'O'), ('region', 'O'), (',', 'O'), ('forming', 'O'), ('a', 'O'), ('distinct', 'O'), ('haplotype', 'O'), ('.', 'O'))"
"In contrast , where the C7 genes are both defective ( but still partially functional ) , there may be a profound deficit of circulating C7 because there is ample C6 to produce C56 and consume the already small amount of C7 .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('where', 'O'), ('the', 'O'), ('C7', 'O'), ('genes', 'O'), ('are', 'O'), ('both', 'O'), ('defective', 'O'), ('(', 'O'), ('but', 'O'), ('still', 'O'), ('partially', 'O'), ('functional', 'O'), (')', 'O'), (',', 'O'), ('there', 'O'), ('may', 'O'), ('be', 'O'), ('a', 'O'), ('profound', 'O'), ('deficit', 'O'), ('of', 'O'), ('circulating', 'O'), ('C7', 'O'), ('because', 'O'), ('there', 'O'), ('is', 'O'), ('ample', 'O'), ('C6', 'O'), ('to', 'O'), ('produce', 'O'), ('C56', 'O'), ('and', 'O'), ('consume', 'O'), ('the', 'O'), ('already', 'O'), ('small', 'O'), ('amount', 'O'), ('of', 'O'), ('C7', 'O'), ('.', 'O'))"
Each molecular defect has also been found in isolation and has the expected effect . .,"(('Each', 'O'), ('molecular', 'O'), ('defect', 'O'), ('has', 'O'), ('also', 'O'), ('been', 'O'), ('found', 'O'), ('in', 'O'), ('isolation', 'O'), ('and', 'O'), ('has', 'O'), ('the', 'O'), ('expected', 'O'), ('effect', 'O'), ('.', 'O'), ('.', 'O'))"
We used exon - specific PCR / single - strand conformation polymorphism analysis as a screening step for mutations .,"(('We', 'O'), ('used', 'O'), ('exon', 'O'), ('-', 'O'), ('specific', 'O'), ('PCR', 'O'), ('/', 'O'), ('single', 'O'), ('-', 'O'), ('strand', 'O'), ('conformation', 'O'), ('polymorphism', 'O'), ('analysis', 'O'), ('as', 'O'), ('a', 'O'), ('screening', 'O'), ('step', 'O'), ('for', 'O'), ('mutations', 'O'), ('.', 'O'))"
Subsequent direct sequencing of the target exons identified homozygous mutations in exon 16 of case 1 and in exon 15 of case 2 .,"(('Subsequent', 'O'), ('direct', 'O'), ('sequencing', 'O'), ('of', 'O'), ('the', 'O'), ('target', 'O'), ('exons', 'O'), ('identified', 'O'), ('homozygous', 'O'), ('mutations', 'O'), ('in', 'O'), ('exon', 'O'), ('16', 'O'), ('of', 'O'), ('case', 'O'), ('1', 'O'), ('and', 'O'), ('in', 'O'), ('exon', 'O'), ('15', 'O'), ('of', 'O'), ('case', 'O'), ('2', 'O'), ('.', 'O'))"
"The mutation of case 1 was a homozygous T to A transversion at nucleotide 2250 , the third nucleotide of the codon TGT for Cys728 , leading to a stop codon TGA ( C728X ) .","(('The', 'O'), ('mutation', 'O'), ('of', 'O'), ('case', 'O'), ('1', 'O'), ('was', 'O'), ('a', 'O'), ('homozygous', 'O'), ('T', 'O'), ('to', 'O'), ('A', 'O'), ('transversion', 'O'), ('at', 'O'), ('nucleotide', 'O'), ('2250', 'O'), (',', 'O'), ('the', 'O'), ('third', 'O'), ('nucleotide', 'O'), ('of', 'O'), ('the', 'O'), ('codon', 'O'), ('TGT', 'O'), ('for', 'O'), ('Cys728', 'O'), (',', 'O'), ('leading', 'O'), ('to', 'O'), ('a', 'O'), ('stop', 'O'), ('codon', 'O'), ('TGA', 'O'), ('(', 'O'), ('C728X', 'O'), (')', 'O'), ('.', 'O'))"
"In case 2 , a homozygous 2 - bp deletion ( 2137delTG / 2138delGT / 2139delTG ) caused a frameshift , generating a premature termination codon 4 to 6 nucleotides downstream .","(('In', 'O'), ('case', 'O'), ('2', 'O'), (',', 'O'), ('a', 'O'), ('homozygous', 'O'), ('2', 'O'), ('-', 'O'), ('bp', 'O'), ('deletion', 'O'), ('(', 'O'), ('2137delTG', 'O'), ('/', 'O'), ('2138delGT', 'O'), ('/', 'O'), ('2139delTG', 'O'), (')', 'O'), ('caused', 'O'), ('a', 'O'), ('frameshift', 'O'), (',', 'O'), ('generating', 'O'), ('a', 'O'), ('premature', 'O'), ('termination', 'O'), ('codon', 'O'), ('4', 'O'), ('to', 'O'), ('6', 'O'), ('nucleotides', 'O'), ('downstream', 'O'), ('.', 'O'))"
Family study in case 1 confirmed the genetic nature of the defect .,"(('Family', 'O'), ('study', 'O'), ('in', 'O'), ('case', 'O'), ('1', 'O'), ('confirmed', 'O'), ('the', 'O'), ('genetic', 'O'), ('nature', 'O'), ('of', 'O'), ('the', 'O'), ('defect', 'O'), ('.', 'O'))"
Somatic alterations of the DPC4 gene in human colorectal cancers in vivo .,"(('Somatic', 'O'), ('alterations', 'O'), ('of', 'O'), ('the', 'O'), ('DPC4', 'O'), ('gene', 'O'), ('in', 'O'), ('human', 'O'), ('colorectal', 'B'), ('cancers', 'I'), ('in', 'O'), ('vivo', 'O'), ('.', 'O'))"
"BACKGROUND & AIMS The chromosome region 18q21 has been shown to be frequently deleted in colorectal cancers , and such frequent allelic loss is a hallmark of the presence of a tumor - suppressor gene .","(('BACKGROUND', 'O'), ('&', 'O'), ('AIMS', 'O'), ('The', 'O'), ('chromosome', 'O'), ('region', 'O'), ('18q21', 'O'), ('has', 'O'), ('been', 'O'), ('shown', 'O'), ('to', 'O'), ('be', 'O'), ('frequently', 'O'), ('deleted', 'O'), ('in', 'O'), ('colorectal', 'B'), ('cancers', 'I'), (',', 'O'), ('and', 'O'), ('such', 'O'), ('frequent', 'O'), ('allelic', 'O'), ('loss', 'O'), ('is', 'O'), ('a', 'O'), ('hallmark', 'O'), ('of', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('a', 'O'), ('tumor', 'O'), ('-', 'O'), ('suppressor', 'O'), ('gene', 'O'), ('.', 'O'))"
The aim of the present study was to determine if it might also be altered in colorectal cancers .,"(('The', 'O'), ('aim', 'O'), ('of', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('determine', 'O'), ('if', 'O'), ('it', 'O'), ('might', 'O'), ('also', 'O'), ('be', 'O'), ('altered', 'O'), ('in', 'O'), ('colorectal', 'B'), ('cancers', 'I'), ('.', 'O'))"
"METHODS Mutation analyses of the DPC4 gene were performed on complementary DNA samples from 31 primary colorectal cancer specimens using a combination of polymerase chain reaction , single - strand conformation polymorphism , and DNA sequencing .","(('METHODS', 'O'), ('Mutation', 'O'), ('analyses', 'O'), ('of', 'O'), ('the', 'O'), ('DPC4', 'O'), ('gene', 'O'), ('were', 'O'), ('performed', 'O'), ('on', 'O'), ('complementary', 'O'), ('DNA', 'O'), ('samples', 'O'), ('from', 'O'), ('31', 'O'), ('primary', 'O'), ('colorectal', 'B'), ('cancer', 'I'), ('specimens', 'O'), ('using', 'O'), ('a', 'O'), ('combination', 'O'), ('of', 'O'), ('polymerase', 'O'), ('chain', 'O'), ('reaction', 'O'), (',', 'O'), ('single', 'O'), ('-', 'O'), ('strand', 'O'), ('conformation', 'O'), ('polymorphism', 'O'), (',', 'O'), ('and', 'O'), ('DNA', 'O'), ('sequencing', 'O'), ('.', 'O'))"
RESULTS Four missense mutations producing amino acid substitutions and a somatic 12 - base pair deletion in the coding region of the DPC4 gene were detected in the 31 cancers ( 16 % ; 5 of 31 ) .,"(('RESULTS', 'O'), ('Four', 'O'), ('missense', 'O'), ('mutations', 'O'), ('producing', 'O'), ('amino', 'O'), ('acid', 'O'), ('substitutions', 'O'), ('and', 'O'), ('a', 'O'), ('somatic', 'O'), ('12', 'O'), ('-', 'O'), ('base', 'O'), ('pair', 'O'), ('deletion', 'O'), ('in', 'O'), ('the', 'O'), ('coding', 'O'), ('region', 'O'), ('of', 'O'), ('the', 'O'), ('DPC4', 'O'), ('gene', 'O'), ('were', 'O'), ('detected', 'O'), ('in', 'O'), ('the', 'O'), ('31', 'O'), ('cancers', 'B'), ('(', 'O'), ('16', 'O'), ('%', 'O'), (';', 'O'), ('5', 'O'), ('of', 'O'), ('31', 'O'), (')', 'O'), ('.', 'O'))"
"CONCLUSIONS The DPC4 gene may play a role as a tumor - suppressor gene in a fraction of colorectal cancers ; however , while allelic loss at 18q21 is very often seen in colorectal cancers , only a minority show DPC4 mutations , suggesting that there might be another tumor - suppressor gene in this chromosome region . .","(('CONCLUSIONS', 'O'), ('The', 'O'), ('DPC4', 'O'), ('gene', 'O'), ('may', 'O'), ('play', 'O'), ('a', 'O'), ('role', 'O'), ('as', 'O'), ('a', 'O'), ('tumor', 'O'), ('-', 'O'), ('suppressor', 'O'), ('gene', 'O'), ('in', 'O'), ('a', 'O'), ('fraction', 'O'), ('of', 'O'), ('colorectal', 'B'), ('cancers', 'I'), (';', 'O'), ('however', 'O'), (',', 'O'), ('while', 'O'), ('allelic', 'O'), ('loss', 'O'), ('at', 'O'), ('18q21', 'O'), ('is', 'O'), ('very', 'O'), ('often', 'O'), ('seen', 'O'), ('in', 'O'), ('colorectal', 'B'), ('cancers', 'I'), (',', 'O'), ('only', 'O'), ('a', 'O'), ('minority', 'O'), ('show', 'O'), ('DPC4', 'O'), ('mutations', 'O'), (',', 'O'), ('suggesting', 'O'), ('that', 'O'), ('there', 'O'), ('might', 'O'), ('be', 'O'), ('another', 'O'), ('tumor', 'O'), ('-', 'O'), ('suppressor', 'O'), ('gene', 'O'), ('in', 'O'), ('this', 'O'), ('chromosome', 'O'), ('region', 'O'), ('.', 'O'), ('.', 'O'))"
Atm - deficient fibroblasts grow poorly in culture and display a high level of double - stranded chromosome breaks .,"(('Atm', 'O'), ('-', 'O'), ('deficient', 'O'), ('fibroblasts', 'O'), ('grow', 'O'), ('poorly', 'O'), ('in', 'O'), ('culture', 'O'), ('and', 'O'), ('display', 'O'), ('a', 'O'), ('high', 'O'), ('level', 'O'), ('of', 'O'), ('double', 'O'), ('-', 'O'), ('stranded', 'O'), ('chromosome', 'O'), ('breaks', 'O'), ('.', 'O'))"
Atm - deficient thymocytes undergo spontaneous apoptosis in vitro significantly more than controls .,"(('Atm', 'O'), ('-', 'O'), ('deficient', 'O'), ('thymocytes', 'O'), ('undergo', 'O'), ('spontaneous', 'O'), ('apoptosis', 'O'), ('in', 'O'), ('vitro', 'O'), ('significantly', 'O'), ('more', 'O'), ('than', 'O'), ('controls', 'O'), ('.', 'O'))"
"Furthermore , we demonstrate that the Atm protein exists as two discrete molecular species , and that loss of one or of both of these can lead to the development of the disease . .","(('Furthermore', 'O'), (',', 'O'), ('we', 'O'), ('demonstrate', 'O'), ('that', 'O'), ('the', 'O'), ('Atm', 'O'), ('protein', 'O'), ('exists', 'O'), ('as', 'O'), ('two', 'O'), ('discrete', 'O'), ('molecular', 'O'), ('species', 'O'), (',', 'O'), ('and', 'O'), ('that', 'O'), ('loss', 'O'), ('of', 'O'), ('one', 'O'), ('or', 'O'), ('of', 'O'), ('both', 'O'), ('of', 'O'), ('these', 'O'), ('can', 'O'), ('lead', 'O'), ('to', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('the', 'O'), ('disease', 'O'), ('.', 'O'), ('.', 'O'))"
The DCC protein and prognosis in colorectal cancer .,"(('The', 'O'), ('DCC', 'O'), ('protein', 'O'), ('and', 'O'), ('prognosis', 'O'), ('in', 'O'), ('colorectal', 'B'), ('cancer', 'I'), ('.', 'O'))"
BACKGROUND Allelic loss of chromosome 18q predicts a poor outcome in patients with stage II colorectal cancer .,"(('BACKGROUND', 'O'), ('Allelic', 'O'), ('loss', 'O'), ('of', 'O'), ('chromosome', 'O'), ('18q', 'O'), ('predicts', 'O'), ('a', 'O'), ('poor', 'O'), ('outcome', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('stage', 'O'), ('II', 'O'), ('colorectal', 'B'), ('cancer', 'I'), ('.', 'O'))"
"Although the specific gene inactivated by this allelic loss has not been elucidated , the DCC ( deleted in colorectal cancer ) gene is a candidate .","(('Although', 'O'), ('the', 'O'), ('specific', 'O'), ('gene', 'O'), ('inactivated', 'O'), ('by', 'O'), ('this', 'O'), ('allelic', 'O'), ('loss', 'O'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('elucidated', 'O'), (',', 'O'), ('the', 'O'), ('DCC', 'O'), ('(', 'O'), ('deleted', 'O'), ('in', 'O'), ('colorectal', 'B'), ('cancer', 'I'), (')', 'O'), ('gene', 'O'), ('is', 'O'), ('a', 'O'), ('candidate', 'O'), ('.', 'O'))"
We investigated whether the expression of the DCC protein in tumor cells is a prognostic marker in colorectal carcinoma .,"(('We', 'O'), ('investigated', 'O'), ('whether', 'O'), ('the', 'O'), ('expression', 'O'), ('of', 'O'), ('the', 'O'), ('DCC', 'O'), ('protein', 'O'), ('in', 'O'), ('tumor', 'B'), ('cells', 'O'), ('is', 'O'), ('a', 'O'), ('prognostic', 'O'), ('marker', 'O'), ('in', 'O'), ('colorectal', 'B'), ('carcinoma', 'I'), ('.', 'O'))"
"The Cox proportional - hazards model was used to adjust for covariates including age , sex , tumor site , degree of tumor differentiation , and use of adjuvant therapy .","(('The', 'O'), ('Cox', 'O'), ('proportional', 'O'), ('-', 'O'), ('hazards', 'O'), ('model', 'O'), ('was', 'O'), ('used', 'O'), ('to', 'O'), ('adjust', 'O'), ('for', 'O'), ('covariates', 'O'), ('including', 'O'), ('age', 'O'), (',', 'O'), ('sex', 'O'), (',', 'O'), ('tumor', 'B'), ('site', 'O'), (',', 'O'), ('degree', 'O'), ('of', 'O'), ('tumor', 'B'), ('differentiation', 'O'), (',', 'O'), ('and', 'O'), ('use', 'O'), ('of', 'O'), ('adjuvant', 'O'), ('therapy', 'O'), ('.', 'O'))"
"In patients with stage II disease whose tumors expressed DCC , the five - year survival rate was 94 .","(('In', 'O'), ('patients', 'O'), ('with', 'O'), ('stage', 'O'), ('II', 'O'), ('disease', 'O'), ('whose', 'O'), ('tumors', 'B'), ('expressed', 'O'), ('DCC', 'O'), (',', 'O'), ('the', 'O'), ('five', 'O'), ('-', 'O'), ('year', 'O'), ('survival', 'O'), ('rate', 'O'), ('was', 'O'), ('94', 'O'), ('.', 'O'))"
6 percent ( P < 0 . 001 ) .,"(('6', 'O'), ('percent', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('.', 'O'))"
3 percent and 33 .,"(('3', 'O'), ('percent', 'O'), ('and', 'O'), ('33', 'O'), ('.', 'O'))"
2 percent ( P = 0 . 03 ) .,"(('2', 'O'), ('percent', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('03', 'O'), (')', 'O'), ('.', 'O'))"
These findings may thus have therapeutic implications in this group of patients,"(('These', 'O'), ('findings', 'O'), ('may', 'O'), ('thus', 'O'), ('have', 'O'), ('therapeutic', 'O'), ('implications', 'O'), ('in', 'O'), ('this', 'O'), ('group', 'O'), ('of', 'O'), ('patients', 'O'))"
Transporter - facilitated uptake of serotonin ( 5 - hydroxytryptamine or 5 - HT ) has been implicated in anxiety in humans and animal models and is the site of action of widely used uptake - inhibiting antidepressant and antianxiety drugs .,"(('Transporter', 'O'), ('-', 'O'), ('facilitated', 'O'), ('uptake', 'O'), ('of', 'O'), ('serotonin', 'O'), ('(', 'O'), ('5', 'O'), ('-', 'O'), ('hydroxytryptamine', 'O'), ('or', 'O'), ('5', 'O'), ('-', 'O'), ('HT', 'O'), (')', 'O'), ('has', 'O'), ('been', 'O'), ('implicated', 'O'), ('in', 'O'), ('anxiety', 'B'), ('in', 'O'), ('humans', 'O'), ('and', 'O'), ('animal', 'O'), ('models', 'O'), ('and', 'O'), ('is', 'O'), ('the', 'O'), ('site', 'O'), ('of', 'O'), ('action', 'O'), ('of', 'O'), ('widely', 'O'), ('used', 'O'), ('uptake', 'O'), ('-', 'O'), ('inhibiting', 'O'), ('antidepressant', 'O'), ('and', 'O'), ('antianxiety', 'O'), ('drugs', 'O'), ('.', 'O'))"
Human 5 - HT transporter ( 5 - HTT ) gene transcription is modulated by a common polymorphism in its upstream regulatory region .,"(('Human', 'O'), ('5', 'O'), ('-', 'O'), ('HT', 'O'), ('transporter', 'O'), ('(', 'O'), ('5', 'O'), ('-', 'O'), ('HTT', 'O'), (')', 'O'), ('gene', 'O'), ('transcription', 'O'), ('is', 'O'), ('modulated', 'O'), ('by', 'O'), ('a', 'O'), ('common', 'O'), ('polymorphism', 'O'), ('in', 'O'), ('its', 'O'), ('upstream', 'O'), ('regulatory', 'O'), ('region', 'O'), ('.', 'O'))"
"The short variant of the polymorphism reduces the transcriptional efficiency of the 5 - HTT gene promoter , resulting in decreased 5 - HTT expression and 5 - HT uptake in lymphoblasts .","(('The', 'O'), ('short', 'O'), ('variant', 'O'), ('of', 'O'), ('the', 'O'), ('polymorphism', 'O'), ('reduces', 'O'), ('the', 'O'), ('transcriptional', 'O'), ('efficiency', 'O'), ('of', 'O'), ('the', 'O'), ('5', 'O'), ('-', 'O'), ('HTT', 'O'), ('gene', 'O'), ('promoter', 'O'), (',', 'O'), ('resulting', 'O'), ('in', 'O'), ('decreased', 'O'), ('5', 'O'), ('-', 'O'), ('HTT', 'O'), ('expression', 'O'), ('and', 'O'), ('5', 'O'), ('-', 'O'), ('HT', 'O'), ('uptake', 'O'), ('in', 'O'), ('lymphoblasts', 'O'), ('.', 'O'))"
Reduced incorporation of inorganic sulfate into macromolecules was found in all three .,"(('Reduced', 'O'), ('incorporation', 'O'), ('of', 'O'), ('inorganic', 'O'), ('sulfate', 'O'), ('into', 'O'), ('macromolecules', 'O'), ('was', 'O'), ('found', 'O'), ('in', 'O'), ('all', 'O'), ('three', 'O'), ('.', 'O'))"
Each of the three patients was found to be heterozygous for a c862t transition predicting a R279W substitution in the third extracellular loop of DTDST .,"(('Each', 'O'), ('of', 'O'), ('the', 'O'), ('three', 'O'), ('patients', 'O'), ('was', 'O'), ('found', 'O'), ('to', 'O'), ('be', 'O'), ('heterozygous', 'O'), ('for', 'O'), ('a', 'O'), ('c862t', 'O'), ('transition', 'O'), ('predicting', 'O'), ('a', 'O'), ('R279W', 'O'), ('substitution', 'O'), ('in', 'O'), ('the', 'O'), ('third', 'O'), ('extracellular', 'O'), ('loop', 'O'), ('of', 'O'), ('DTDST', 'O'), ('.', 'O'))"
"Also the delta c418 allele was underrepresented in the cDNA , in accordance with previous observations that premature stop codons reduce mRNA levels .","(('Also', 'O'), ('the', 'O'), ('delta', 'O'), ('c418', 'O'), ('allele', 'O'), ('was', 'O'), ('underrepresented', 'O'), ('in', 'O'), ('the', 'O'), ('cDNA', 'O'), (',', 'O'), ('in', 'O'), ('accordance', 'O'), ('with', 'O'), ('previous', 'O'), ('observations', 'O'), ('that', 'O'), ('premature', 'O'), ('stop', 'O'), ('codons', 'O'), ('reduce', 'O'), ('mRNA', 'O'), ('levels', 'O'), ('.', 'O'))"
"By analysis of these compiled mutation data , we demonstrated clustering of WASP mutations within the four most N - terminal exons of the gene and also identified several sites within this region as hotspots for WASP mutation .","(('By', 'O'), ('analysis', 'O'), ('of', 'O'), ('these', 'O'), ('compiled', 'O'), ('mutation', 'O'), ('data', 'O'), (',', 'O'), ('we', 'O'), ('demonstrated', 'O'), ('clustering', 'O'), ('of', 'O'), ('WASP', 'O'), ('mutations', 'O'), ('within', 'O'), ('the', 'O'), ('four', 'O'), ('most', 'O'), ('N', 'O'), ('-', 'O'), ('terminal', 'O'), ('exons', 'O'), ('of', 'O'), ('the', 'O'), ('gene', 'O'), ('and', 'O'), ('also', 'O'), ('identified', 'O'), ('several', 'O'), ('sites', 'O'), ('within', 'O'), ('this', 'O'), ('region', 'O'), ('as', 'O'), ('hotspots', 'O'), ('for', 'O'), ('WASP', 'O'), ('mutation', 'O'), ('.', 'O'))"
"These characteristics were observed , however , in both severe and mild cases of the disease .","(('These', 'O'), ('characteristics', 'O'), ('were', 'O'), ('observed', 'O'), (',', 'O'), ('however', 'O'), (',', 'O'), ('in', 'O'), ('both', 'O'), ('severe', 'O'), ('and', 'O'), ('mild', 'O'), ('cases', 'O'), ('of', 'O'), ('the', 'O'), ('disease', 'O'), ('.', 'O'))"
Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1 .,"(('Complete', 'O'), ('genomic', 'O'), ('sequence', 'O'), ('and', 'O'), ('analysis', 'O'), ('of', 'O'), ('117', 'O'), ('kb', 'O'), ('of', 'O'), ('human', 'O'), ('DNA', 'O'), ('containing', 'O'), ('the', 'O'), ('gene', 'O'), ('BRCA1', 'O'), ('.', 'O'))"
Over 100 distinct disease - associated mutations have been identified in the breast - ovarian cancer susceptibility gene BRCA1 .,"(('Over', 'O'), ('100', 'O'), ('distinct', 'O'), ('disease', 'O'), ('-', 'O'), ('associated', 'O'), ('mutations', 'O'), ('have', 'O'), ('been', 'O'), ('identified', 'O'), ('in', 'O'), ('the', 'O'), ('breast', 'B'), ('-', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('susceptibility', 'O'), ('gene', 'O'), ('BRCA1', 'O'), ('.', 'O'))"
Loss of the wild - type allele in > 90 % of tumors from patients with inherited BRCA1 mutations indicates tumor suppressive function .,"(('Loss', 'O'), ('of', 'O'), ('the', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('allele', 'O'), ('in', 'O'), ('>', 'O'), ('90', 'O'), ('%', 'O'), ('of', 'O'), ('tumors', 'B'), ('from', 'O'), ('patients', 'O'), ('with', 'O'), ('inherited', 'O'), ('BRCA1', 'O'), ('mutations', 'O'), ('indicates', 'O'), ('tumor', 'B'), ('suppressive', 'O'), ('function', 'O'), ('.', 'O'))"
"The low incidence of somatic mutations suggests that BRCA1 inactivation in sporadic tumors occurs by alternative mechanisms , such as interstitial chromosomal deletion or reduced transcription .","(('The', 'O'), ('low', 'O'), ('incidence', 'O'), ('of', 'O'), ('somatic', 'O'), ('mutations', 'O'), ('suggests', 'O'), ('that', 'O'), ('BRCA1', 'O'), ('inactivation', 'O'), ('in', 'O'), ('sporadic', 'O'), ('tumors', 'B'), ('occurs', 'O'), ('by', 'O'), ('alternative', 'O'), ('mechanisms', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('interstitial', 'O'), ('chromosomal', 'O'), ('deletion', 'O'), ('or', 'O'), ('reduced', 'O'), ('transcription', 'O'), ('.', 'O'))"
"To identify possible features of the BRCA1 genomic region that may contribute to chromosomal instability as well as potential transcriptional regulatory elements , a 117 , 143 - bp DNA sequence encompassing BRCA1 was obtained by random sequencing of four cosmids identified from a human chromosome 17 specific library .","(('To', 'O'), ('identify', 'O'), ('possible', 'O'), ('features', 'O'), ('of', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('genomic', 'O'), ('region', 'O'), ('that', 'O'), ('may', 'O'), ('contribute', 'O'), ('to', 'O'), ('chromosomal', 'B'), ('instability', 'I'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('potential', 'O'), ('transcriptional', 'O'), ('regulatory', 'O'), ('elements', 'O'), (',', 'O'), ('a', 'O'), ('117', 'O'), (',', 'O'), ('143', 'O'), ('-', 'O'), ('bp', 'O'), ('DNA', 'O'), ('sequence', 'O'), ('encompassing', 'O'), ('BRCA1', 'O'), ('was', 'O'), ('obtained', 'O'), ('by', 'O'), ('random', 'O'), ('sequencing', 'O'), ('of', 'O'), ('four', 'O'), ('cosmids', 'O'), ('identified', 'O'), ('from', 'O'), ('a', 'O'), ('human', 'O'), ('chromosome', 'O'), ('17', 'O'), ('specific', 'O'), ('library', 'O'), ('.', 'O'))"
"The 24 exons of BRCA1 span an 81 - kb region that has an unusually high density of Alu repetitive DNA ( 41 . 5 % ) , but relatively low density ( 4 . 8 % ) of other repetitive sequences .","(('The', 'O'), ('24', 'O'), ('exons', 'O'), ('of', 'O'), ('BRCA1', 'O'), ('span', 'O'), ('an', 'O'), ('81', 'O'), ('-', 'O'), ('kb', 'O'), ('region', 'O'), ('that', 'O'), ('has', 'O'), ('an', 'O'), ('unusually', 'O'), ('high', 'O'), ('density', 'O'), ('of', 'O'), ('Alu', 'O'), ('repetitive', 'O'), ('DNA', 'O'), ('(', 'O'), ('41', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('but', 'O'), ('relatively', 'O'), ('low', 'O'), ('density', 'O'), ('(', 'O'), ('4', 'O'), ('.', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), ('of', 'O'), ('other', 'O'), ('repetitive', 'O'), ('sequences', 'O'), ('.', 'O'))"
BRCA1 intron lengths range in size from 403 bp to 9 .,"(('BRCA1', 'O'), ('intron', 'O'), ('lengths', 'O'), ('range', 'O'), ('in', 'O'), ('size', 'O'), ('from', 'O'), ('403', 'O'), ('bp', 'O'), ('to', 'O'), ('9', 'O'), ('.', 'O'))"
"2 kb and contain the intragenic microsatellite markers D17S1323 , D17S1322 , and D17S855 , which localize to introns 12 , 19 , and 20 , respectively .","(('2', 'O'), ('kb', 'O'), ('and', 'O'), ('contain', 'O'), ('the', 'O'), ('intragenic', 'O'), ('microsatellite', 'O'), ('markers', 'O'), ('D17S1323', 'O'), (',', 'O'), ('D17S1322', 'O'), (',', 'O'), ('and', 'O'), ('D17S855', 'O'), (',', 'O'), ('which', 'O'), ('localize', 'O'), ('to', 'O'), ('introns', 'O'), ('12', 'O'), (',', 'O'), ('19', 'O'), (',', 'O'), ('and', 'O'), ('20', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"In addition to BRCA1 , the contig contains two complete genes Rho7 , a member of the rho family of GTP binding proteins , and VAT1 , an abundant membrane protein of cholinergic synaptic vesicles .","(('In', 'O'), ('addition', 'O'), ('to', 'O'), ('BRCA1', 'O'), (',', 'O'), ('the', 'O'), ('contig', 'O'), ('contains', 'O'), ('two', 'O'), ('complete', 'O'), ('genes', 'O'), ('Rho7', 'O'), (',', 'O'), ('a', 'O'), ('member', 'O'), ('of', 'O'), ('the', 'O'), ('rho', 'O'), ('family', 'O'), ('of', 'O'), ('GTP', 'O'), ('binding', 'O'), ('proteins', 'O'), (',', 'O'), ('and', 'O'), ('VAT1', 'O'), (',', 'O'), ('an', 'O'), ('abundant', 'O'), ('membrane', 'O'), ('protein', 'O'), ('of', 'O'), ('cholinergic', 'O'), ('synaptic', 'O'), ('vesicles', 'O'), ('.', 'O'))"
"Partial sequences of the 1A1 - 3B B - box protein pseudogene and IFP 35 , an interferon induced leucine zipper protein , reside within the contig .","(('Partial', 'O'), ('sequences', 'O'), ('of', 'O'), ('the', 'O'), ('1A1', 'O'), ('-', 'O'), ('3B', 'O'), ('B', 'O'), ('-', 'O'), ('box', 'O'), ('protein', 'O'), ('pseudogene', 'O'), ('and', 'O'), ('IFP', 'O'), ('35', 'O'), (',', 'O'), ('an', 'O'), ('interferon', 'O'), ('induced', 'O'), ('leucine', 'O'), ('zipper', 'O'), ('protein', 'O'), (',', 'O'), ('reside', 'O'), ('within', 'O'), ('the', 'O'), ('contig', 'O'), ('.', 'O'))"
An L21 ribosomal protein pseudogene is embedded in BRCA1 intron 13 .,"(('An', 'O'), ('L21', 'O'), ('ribosomal', 'O'), ('protein', 'O'), ('pseudogene', 'O'), ('is', 'O'), ('embedded', 'O'), ('in', 'O'), ('BRCA1', 'O'), ('intron', 'O'), ('13', 'O'), ('.', 'O'))"
The order of genes on the chromosome is centromere - 1FP 35 - VAT1 - Rho7 - BRCA1 - 1A1 - 3B - telomere,"(('The', 'O'), ('order', 'O'), ('of', 'O'), ('genes', 'O'), ('on', 'O'), ('the', 'O'), ('chromosome', 'O'), ('is', 'O'), ('centromere', 'O'), ('-', 'O'), ('1FP', 'O'), ('35', 'O'), ('-', 'O'), ('VAT1', 'O'), ('-', 'O'), ('Rho7', 'O'), ('-', 'O'), ('BRCA1', 'O'), ('-', 'O'), ('1A1', 'O'), ('-', 'O'), ('3B', 'O'), ('-', 'O'), ('telomere', 'O'))"
Identification of a RING protein that can interact in vivo with the BRCA1 gene product .,"(('Identification', 'O'), ('of', 'O'), ('a', 'O'), ('RING', 'O'), ('protein', 'O'), ('that', 'O'), ('can', 'O'), ('interact', 'O'), ('in', 'O'), ('vivo', 'O'), ('with', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('gene', 'O'), ('product', 'O'), ('.', 'O'))"
Here we describe a novel protein that interacts in vivo with the N - terminal region of BRCA1 .,"(('Here', 'O'), ('we', 'O'), ('describe', 'O'), ('a', 'O'), ('novel', 'O'), ('protein', 'O'), ('that', 'O'), ('interacts', 'O'), ('in', 'O'), ('vivo', 'O'), ('with', 'O'), ('the', 'O'), ('N', 'O'), ('-', 'O'), ('terminal', 'O'), ('region', 'O'), ('of', 'O'), ('BRCA1', 'O'), ('.', 'O'))"
"This BRCA1 - associated RING domain ( BARD1 ) protein contains an N - terminal RING motif , three tandem ankyrin repeats , and a C - terminal sequence with significant homology to the phylogenetically conserved BRCT domains that lie near the C terminus of BRCA1 .","(('This', 'O'), ('BRCA1', 'O'), ('-', 'O'), ('associated', 'O'), ('RING', 'O'), ('domain', 'O'), ('(', 'O'), ('BARD1', 'O'), (')', 'O'), ('protein', 'O'), ('contains', 'O'), ('an', 'O'), ('N', 'O'), ('-', 'O'), ('terminal', 'O'), ('RING', 'O'), ('motif', 'O'), (',', 'O'), ('three', 'O'), ('tandem', 'O'), ('ankyrin', 'O'), ('repeats', 'O'), (',', 'O'), ('and', 'O'), ('a', 'O'), ('C', 'O'), ('-', 'O'), ('terminal', 'O'), ('sequence', 'O'), ('with', 'O'), ('significant', 'O'), ('homology', 'O'), ('to', 'O'), ('the', 'O'), ('phylogenetically', 'O'), ('conserved', 'O'), ('BRCT', 'O'), ('domains', 'O'), ('that', 'O'), ('lie', 'O'), ('near', 'O'), ('the', 'O'), ('C', 'O'), ('terminus', 'O'), ('of', 'O'), ('BRCA1', 'O'), ('.', 'O'))"
"The BARD1 / BRCA1 interaction is disrupted by BRCA1 missense mutations that segregate with breast cancer susceptibility , indicating that BARD1 may be involved in mediating tumour suppression by BRCA1 . .","(('The', 'O'), ('BARD1', 'O'), ('/', 'O'), ('BRCA1', 'O'), ('interaction', 'O'), ('is', 'O'), ('disrupted', 'O'), ('by', 'O'), ('BRCA1', 'O'), ('missense', 'O'), ('mutations', 'O'), ('that', 'O'), ('segregate', 'O'), ('with', 'O'), ('breast', 'B'), ('cancer', 'I'), ('susceptibility', 'O'), (',', 'O'), ('indicating', 'O'), ('that', 'O'), ('BARD1', 'O'), ('may', 'O'), ('be', 'O'), ('involved', 'O'), ('in', 'O'), ('mediating', 'O'), ('tumour', 'B'), ('suppression', 'O'), ('by', 'O'), ('BRCA1', 'O'), ('.', 'O'), ('.', 'O'))"
Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two - colour fluorescence analysis .,"(('Detection', 'O'), ('of', 'O'), ('heterozygous', 'O'), ('mutations', 'O'), ('in', 'O'), ('BRCA1', 'O'), ('using', 'O'), ('high', 'O'), ('density', 'O'), ('oligonucleotide', 'O'), ('arrays', 'O'), ('and', 'O'), ('two', 'O'), ('-', 'O'), ('colour', 'O'), ('fluorescence', 'O'), ('analysis', 'O'), ('.', 'O'))"
The ability to scan a large gene rapidly and accurately for all possible heterozygous mutations in large numbers of patient samples will be critical for the future of medicine .,"(('The', 'O'), ('ability', 'O'), ('to', 'O'), ('scan', 'O'), ('a', 'O'), ('large', 'O'), ('gene', 'O'), ('rapidly', 'O'), ('and', 'O'), ('accurately', 'O'), ('for', 'O'), ('all', 'O'), ('possible', 'O'), ('heterozygous', 'O'), ('mutations', 'O'), ('in', 'O'), ('large', 'O'), ('numbers', 'O'), ('of', 'O'), ('patient', 'O'), ('samples', 'O'), ('will', 'O'), ('be', 'O'), ('critical', 'O'), ('for', 'O'), ('the', 'O'), ('future', 'O'), ('of', 'O'), ('medicine', 'O'), ('.', 'O'))"
"We have designed high - density arrays consisting of over 96 , 600 oligonucleotides 20 - nucleotides ( nt ) in length to screen for a wide range of heterozygous mutations in the 3 .","(('We', 'O'), ('have', 'O'), ('designed', 'O'), ('high', 'O'), ('-', 'O'), ('density', 'O'), ('arrays', 'O'), ('consisting', 'O'), ('of', 'O'), ('over', 'O'), ('96', 'O'), (',', 'O'), ('600', 'O'), ('oligonucleotides', 'O'), ('20', 'O'), ('-', 'O'), ('nucleotides', 'O'), ('(', 'O'), ('nt', 'O'), (')', 'O'), ('in', 'O'), ('length', 'O'), ('to', 'O'), ('screen', 'O'), ('for', 'O'), ('a', 'O'), ('wide', 'O'), ('range', 'O'), ('of', 'O'), ('heterozygous', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('3', 'O'), ('.', 'O'))"
Reference and test samples were co - hybridized to these arrays and differences in hybridization patterns quantitated by two - colour analysis .,"(('Reference', 'O'), ('and', 'O'), ('test', 'O'), ('samples', 'O'), ('were', 'O'), ('co', 'O'), ('-', 'O'), ('hybridized', 'O'), ('to', 'O'), ('these', 'O'), ('arrays', 'O'), ('and', 'O'), ('differences', 'O'), ('in', 'O'), ('hybridization', 'O'), ('patterns', 'O'), ('quantitated', 'O'), ('by', 'O'), ('two', 'O'), ('-', 'O'), ('colour', 'O'), ('analysis', 'O'), ('.', 'O'))"
"Fourteen of fifteen patient samples with known mutations were accurately diagnosed , and no false positive mutations were identified in 20 control samples .","(('Fourteen', 'O'), ('of', 'O'), ('fifteen', 'O'), ('patient', 'O'), ('samples', 'O'), ('with', 'O'), ('known', 'O'), ('mutations', 'O'), ('were', 'O'), ('accurately', 'O'), ('diagnosed', 'O'), (',', 'O'), ('and', 'O'), ('no', 'O'), ('false', 'O'), ('positive', 'O'), ('mutations', 'O'), ('were', 'O'), ('identified', 'O'), ('in', 'O'), ('20', 'O'), ('control', 'O'), ('samples', 'O'), ('.', 'O'))"
Eight single nucleotide polymorphisms were also readily detected .,"(('Eight', 'O'), ('single', 'O'), ('nucleotide', 'O'), ('polymorphisms', 'O'), ('were', 'O'), ('also', 'O'), ('readily', 'O'), ('detected', 'O'), ('.', 'O'))"
DNA chip - based assays may provide a valuable new technology for high - throughput cost - efficient detection of genetic alterations .,"(('DNA', 'O'), ('chip', 'O'), ('-', 'O'), ('based', 'O'), ('assays', 'O'), ('may', 'O'), ('provide', 'O'), ('a', 'O'), ('valuable', 'O'), ('new', 'O'), ('technology', 'O'), ('for', 'O'), ('high', 'O'), ('-', 'O'), ('throughput', 'O'), ('cost', 'O'), ('-', 'O'), ('efficient', 'O'), ('detection', 'O'), ('of', 'O'), ('genetic', 'O'), ('alterations', 'O'), ('.', 'O'))"
The possibility of the latter cosegregating as a separate autosomal dominant gene can not be ruled out .,"(('The', 'O'), ('possibility', 'O'), ('of', 'O'), ('the', 'O'), ('latter', 'O'), ('cosegregating', 'O'), ('as', 'O'), ('a', 'O'), ('separate', 'O'), ('autosomal', 'O'), ('dominant', 'O'), ('gene', 'O'), ('can', 'O'), ('not', 'O'), ('be', 'O'), ('ruled', 'O'), ('out', 'O'), ('.', 'O'))"
"Meiotic recombinations detected in affected individuals placed the locus telomeric of D1S215 , thus narrowing the HRPT2 region from > 60 to approximately 34 centimorgans .","(('Meiotic', 'O'), ('recombinations', 'O'), ('detected', 'O'), ('in', 'O'), ('affected', 'O'), ('individuals', 'O'), ('placed', 'O'), ('the', 'O'), ('locus', 'O'), ('telomeric', 'O'), ('of', 'O'), ('D1S215', 'O'), (',', 'O'), ('thus', 'O'), ('narrowing', 'O'), ('the', 'O'), ('HRPT2', 'O'), ('region', 'O'), ('from', 'O'), ('>', 'O'), ('60', 'O'), ('to', 'O'), ('approximately', 'O'), ('34', 'O'), ('centimorgans', 'O'), ('.', 'O'))"
"The losses invariably involved the wild type allele derived from the unaffected parent , suggesting the inactivation of a tumor suppressor gene in this region","(('The', 'O'), ('losses', 'O'), ('invariably', 'O'), ('involved', 'O'), ('the', 'O'), ('wild', 'O'), ('type', 'O'), ('allele', 'O'), ('derived', 'O'), ('from', 'O'), ('the', 'O'), ('unaffected', 'O'), ('parent', 'O'), (',', 'O'), ('suggesting', 'O'), ('the', 'O'), ('inactivation', 'O'), ('of', 'O'), ('a', 'O'), ('tumor', 'O'), ('suppressor', 'O'), ('gene', 'O'), ('in', 'O'), ('this', 'O'), ('region', 'O'))"
Independent origin of single and double mutations in the human glucose 6 - phosphate dehydrogenase gene .,"(('Independent', 'O'), ('origin', 'O'), ('of', 'O'), ('single', 'O'), ('and', 'O'), ('double', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('human', 'O'), ('glucose', 'O'), ('6', 'O'), ('-', 'O'), ('phosphate', 'O'), ('dehydrogenase', 'O'), ('gene', 'O'), ('.', 'O'))"
The vast majority of both polymorphic and sporadic G6PD variants are due to single missense mutations .,"(('The', 'O'), ('vast', 'O'), ('majority', 'O'), ('of', 'O'), ('both', 'O'), ('polymorphic', 'O'), ('and', 'O'), ('sporadic', 'O'), ('G6PD', 'O'), ('variants', 'O'), ('are', 'O'), ('due', 'O'), ('to', 'O'), ('single', 'O'), ('missense', 'O'), ('mutations', 'O'), ('.', 'O'))"
"In the four polymorphic variants that have two point mutations , one of the mutations is always 376 A - - > G ( 126 Asn - - > Asp ) , which on its own gives rise to the nondeficient polymorphic variant , G6PD A .","(('In', 'O'), ('the', 'O'), ('four', 'O'), ('polymorphic', 'O'), ('variants', 'O'), ('that', 'O'), ('have', 'O'), ('two', 'O'), ('point', 'O'), ('mutations', 'O'), (',', 'O'), ('one', 'O'), ('of', 'O'), ('the', 'O'), ('mutations', 'O'), ('is', 'O'), ('always', 'O'), ('376', 'O'), ('A', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('G', 'O'), ('(', 'O'), ('126', 'O'), ('Asn', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('Asp', 'O'), (')', 'O'), (',', 'O'), ('which', 'O'), ('on', 'O'), ('its', 'O'), ('own', 'O'), ('gives', 'O'), ('rise', 'O'), ('to', 'O'), ('the', 'O'), ('nondeficient', 'O'), ('polymorphic', 'O'), ('variant', 'O'), (',', 'O'), ('G6PD', 'O'), ('A', 'O'), ('.', 'O'))"
"This is the same mutation as previously found in association with the mutation of G6PD A in the double mutant , G6PD Santamaria .","(('This', 'O'), ('is', 'O'), ('the', 'O'), ('same', 'O'), ('mutation', 'O'), ('as', 'O'), ('previously', 'O'), ('found', 'O'), ('in', 'O'), ('association', 'O'), ('with', 'O'), ('the', 'O'), ('mutation', 'O'), ('of', 'O'), ('G6PD', 'O'), ('A', 'O'), ('in', 'O'), ('the', 'O'), ('double', 'O'), ('mutant', 'O'), (',', 'O'), ('G6PD', 'O'), ('Santamaria', 'O'), ('.', 'O'))"
"G6PD Santamaria might have been produced by recombination between G6PD A and G6PD Malaga ; however haplotype analysis , including the use of a new silent polymorphism , suggests that the same 542 A - - > T mutation has taken place independently in a G6PD B gene to give G6PD Malaga and in a G6PD A gene to give G6PD Santamaria .","(('G6PD', 'O'), ('Santamaria', 'O'), ('might', 'O'), ('have', 'O'), ('been', 'O'), ('produced', 'O'), ('by', 'O'), ('recombination', 'O'), ('between', 'O'), ('G6PD', 'O'), ('A', 'O'), ('and', 'O'), ('G6PD', 'O'), ('Malaga', 'O'), (';', 'O'), ('however', 'O'), ('haplotype', 'O'), ('analysis', 'O'), (',', 'O'), ('including', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('a', 'O'), ('new', 'O'), ('silent', 'O'), ('polymorphism', 'O'), (',', 'O'), ('suggests', 'O'), ('that', 'O'), ('the', 'O'), ('same', 'O'), ('542', 'O'), ('A', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('T', 'O'), ('mutation', 'O'), ('has', 'O'), ('taken', 'O'), ('place', 'O'), ('independently', 'O'), ('in', 'O'), ('a', 'O'), ('G6PD', 'O'), ('B', 'O'), ('gene', 'O'), ('to', 'O'), ('give', 'O'), ('G6PD', 'O'), ('Malaga', 'O'), ('and', 'O'), ('in', 'O'), ('a', 'O'), ('G6PD', 'O'), ('A', 'O'), ('gene', 'O'), ('to', 'O'), ('give', 'O'), ('G6PD', 'O'), ('Santamaria', 'O'), ('.', 'O'))"
These findings help to outline the relationship and evolution of mutations in the human G6PD locus . .,"(('These', 'O'), ('findings', 'O'), ('help', 'O'), ('to', 'O'), ('outline', 'O'), ('the', 'O'), ('relationship', 'O'), ('and', 'O'), ('evolution', 'O'), ('of', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('human', 'O'), ('G6PD', 'O'), ('locus', 'O'), ('.', 'O'), ('.', 'O'))"
BRCA1 R841W : a strong candidate for a common mutation with moderate phenotype .,"(('BRCA1', 'O'), ('R841W', 'O'), (':', 'O'), ('a', 'O'), ('strong', 'O'), ('candidate', 'O'), ('for', 'O'), ('a', 'O'), ('common', 'O'), ('mutation', 'O'), ('with', 'O'), ('moderate', 'O'), ('phenotype', 'O'), ('.', 'O'))"
"BRCA1 mutations cause increased risk for breast and ovarian cancer , frequently of early onset .","(('BRCA1', 'O'), ('mutations', 'O'), ('cause', 'O'), ('increased', 'O'), ('risk', 'O'), ('for', 'O'), ('breast', 'B'), ('and', 'I'), ('ovarian', 'I'), ('cancer', 'I'), (',', 'O'), ('frequently', 'O'), ('of', 'O'), ('early', 'O'), ('onset', 'O'), ('.', 'O'))"
"Many different mutations occur in BRCA1 , including several examples of recurrent mutations , each of which accounts for a significant number of families with heritable cancer predisposition .","(('Many', 'O'), ('different', 'O'), ('mutations', 'O'), ('occur', 'O'), ('in', 'O'), ('BRCA1', 'O'), (',', 'O'), ('including', 'O'), ('several', 'O'), ('examples', 'O'), ('of', 'O'), ('recurrent', 'O'), ('mutations', 'O'), (',', 'O'), ('each', 'O'), ('of', 'O'), ('which', 'O'), ('accounts', 'O'), ('for', 'O'), ('a', 'O'), ('significant', 'O'), ('number', 'O'), ('of', 'O'), ('families', 'O'), ('with', 'O'), ('heritable', 'O'), ('cancer', 'B'), ('predisposition', 'O'), ('.', 'O'))"
These common mutations have an etiological role in many breast and ovarian cancer cases and provide the opportunity to examine genotype - phenotype correlations and genotype - environment interactions in individuals with the identical BRCA1 lesion .,"(('These', 'O'), ('common', 'O'), ('mutations', 'O'), ('have', 'O'), ('an', 'O'), ('etiological', 'O'), ('role', 'O'), ('in', 'O'), ('many', 'O'), ('breast', 'B'), ('and', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('cases', 'O'), ('and', 'O'), ('provide', 'O'), ('the', 'O'), ('opportunity', 'O'), ('to', 'O'), ('examine', 'O'), ('genotype', 'O'), ('-', 'O'), ('phenotype', 'O'), ('correlations', 'O'), ('and', 'O'), ('genotype', 'O'), ('-', 'O'), ('environment', 'O'), ('interactions', 'O'), ('in', 'O'), ('individuals', 'O'), ('with', 'O'), ('the', 'O'), ('identical', 'O'), ('BRCA1', 'O'), ('lesion', 'O'), ('.', 'O'))"
"These are consecutive , population - based cases not selected for age or family history .","(('These', 'O'), ('are', 'O'), ('consecutive', 'O'), (',', 'O'), ('population', 'O'), ('-', 'O'), ('based', 'O'), ('cases', 'O'), ('not', 'O'), ('selected', 'O'), ('for', 'O'), ('age', 'O'), ('or', 'O'), ('family', 'O'), ('history', 'O'), ('.', 'O'))"
The age of cancer onset was not always distinct from typical sporadic cases .,"(('The', 'O'), ('age', 'O'), ('of', 'O'), ('cancer', 'B'), ('onset', 'O'), ('was', 'O'), ('not', 'O'), ('always', 'O'), ('distinct', 'O'), ('from', 'O'), ('typical', 'O'), ('sporadic', 'O'), ('cases', 'O'), ('.', 'O'))"
"Testing of a sample of 413 unrelated individuals to examine the hypothesis that R841W might be a rare polymorphism detected one additional instance in a woman with breast cancer diagnosed at age 77 years , and cancer in one parent .","(('Testing', 'O'), ('of', 'O'), ('a', 'O'), ('sample', 'O'), ('of', 'O'), ('413', 'O'), ('unrelated', 'O'), ('individuals', 'O'), ('to', 'O'), ('examine', 'O'), ('the', 'O'), ('hypothesis', 'O'), ('that', 'O'), ('R841W', 'O'), ('might', 'O'), ('be', 'O'), ('a', 'O'), ('rare', 'O'), ('polymorphism', 'O'), ('detected', 'O'), ('one', 'O'), ('additional', 'O'), ('instance', 'O'), ('in', 'O'), ('a', 'O'), ('woman', 'O'), ('with', 'O'), ('breast', 'B'), ('cancer', 'I'), ('diagnosed', 'O'), ('at', 'O'), ('age', 'O'), ('77', 'O'), ('years', 'O'), (',', 'O'), ('and', 'O'), ('cancer', 'B'), ('in', 'O'), ('one', 'O'), ('parent', 'O'), ('.', 'O'))"
R841W is likely to be an etiologically significant lesion with involvement in close to 1 % ( 95 % confidence interval of 0 - 1 . 7 % ) of all breast and ovarian cancers in this population .,"(('R841W', 'O'), ('is', 'O'), ('likely', 'O'), ('to', 'O'), ('be', 'O'), ('an', 'O'), ('etiologically', 'O'), ('significant', 'O'), ('lesion', 'O'), ('with', 'O'), ('involvement', 'O'), ('in', 'O'), ('close', 'O'), ('to', 'O'), ('1', 'O'), ('%', 'O'), ('(', 'O'), ('95', 'O'), ('%', 'O'), ('confidence', 'O'), ('interval', 'O'), ('of', 'O'), ('0', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('7', 'O'), ('%', 'O'), (')', 'O'), ('of', 'O'), ('all', 'O'), ('breast', 'B'), ('and', 'I'), ('ovarian', 'I'), ('cancers', 'I'), ('in', 'O'), ('this', 'O'), ('population', 'O'), ('.', 'O'))"
"This mutation , 103C - - > T , results in a stop codon at position 35 of the ATM protein .","(('This', 'O'), ('mutation', 'O'), (',', 'O'), ('103C', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('T', 'O'), (',', 'O'), ('results', 'O'), ('in', 'O'), ('a', 'O'), ('stop', 'O'), ('codon', 'O'), ('at', 'O'), ('position', 'O'), ('35', 'O'), ('of', 'O'), ('the', 'O'), ('ATM', 'O'), ('protein', 'O'), ('.', 'O'))"
"In keeping with the nature of this mutation , various antibodies directed against the ATM protein failed to defect this protein in patient cells .","(('In', 'O'), ('keeping', 'O'), ('with', 'O'), ('the', 'O'), ('nature', 'O'), ('of', 'O'), ('this', 'O'), ('mutation', 'O'), (',', 'O'), ('various', 'O'), ('antibodies', 'O'), ('directed', 'O'), ('against', 'O'), ('the', 'O'), ('ATM', 'O'), ('protein', 'O'), ('failed', 'O'), ('to', 'O'), ('defect', 'O'), ('this', 'O'), ('protein', 'O'), ('in', 'O'), ('patient', 'O'), ('cells', 'O'), ('.', 'O'))"
A rapid carrier detection assay detected this mutation in three out of 488 ATM alleles of Jewish Moroccan or Tunisian origin .,"(('A', 'O'), ('rapid', 'O'), ('carrier', 'O'), ('detection', 'O'), ('assay', 'O'), ('detected', 'O'), ('this', 'O'), ('mutation', 'O'), ('in', 'O'), ('three', 'O'), ('out', 'O'), ('of', 'O'), ('488', 'O'), ('ATM', 'O'), ('alleles', 'O'), ('of', 'O'), ('Jewish', 'O'), ('Moroccan', 'O'), ('or', 'O'), ('Tunisian', 'O'), ('origin', 'O'), ('.', 'O'))"
Nine ( 17 % ) of the patients had a family history of breast and / or ovarian cancer in at least one first - degree relative .,"(('Nine', 'O'), ('(', 'O'), ('17', 'O'), ('%', 'O'), (')', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('had', 'O'), ('a', 'O'), ('family', 'O'), ('history', 'O'), ('of', 'O'), ('breast', 'B'), ('and', 'I'), ('/', 'I'), ('or', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('in', 'O'), ('at', 'O'), ('least', 'O'), ('one', 'O'), ('first', 'O'), ('-', 'O'), ('degree', 'O'), ('relative', 'O'), ('.', 'O'))"
A further seven ( 13 % ) of the patients reported breast / ovarian cancer in at least one second - degree relative and in no first - degree relatives .,"(('A', 'O'), ('further', 'O'), ('seven', 'O'), ('(', 'O'), ('13', 'O'), ('%', 'O'), (')', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('reported', 'O'), ('breast', 'B'), ('/', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('in', 'O'), ('at', 'O'), ('least', 'O'), ('one', 'O'), ('second', 'O'), ('-', 'O'), ('degree', 'O'), ('relative', 'O'), ('and', 'O'), ('in', 'O'), ('no', 'O'), ('first', 'O'), ('-', 'O'), ('degree', 'O'), ('relatives', 'O'), ('.', 'O'))"
No germ - line BRCA1 mutations were found .,"(('No', 'O'), ('germ', 'O'), ('-', 'O'), ('line', 'O'), ('BRCA1', 'O'), ('mutations', 'O'), ('were', 'O'), ('found', 'O'), ('.', 'O'))"
The Duarte biochemical phenotype has a molecular genotype of N314D / N314D .,"(('The', 'O'), ('Duarte', 'O'), ('biochemical', 'O'), ('phenotype', 'O'), ('has', 'O'), ('a', 'O'), ('molecular', 'O'), ('genotype', 'O'), ('of', 'O'), ('N314D', 'O'), ('/', 'O'), ('N314D', 'O'), ('.', 'O'))"
"The characteristic Duarte isoform is also associated with a variant called the "" Los Angeles ( LA ) phenotype , "" which has increased GALT enzyme activity .","(('The', 'O'), ('characteristic', 'O'), ('Duarte', 'O'), ('isoform', 'O'), ('is', 'O'), ('also', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('variant', 'O'), ('called', 'O'), ('the', 'O'), ('""', 'O'), ('Los', 'O'), ('Angeles', 'O'), ('(', 'O'), ('LA', 'O'), (')', 'O'), ('phenotype', 'O'), (',', 'O'), ('""', 'O'), ('which', 'O'), ('has', 'O'), ('increased', 'O'), ('GALT', 'O'), ('enzyme', 'O'), ('activity', 'O'), ('.', 'O'))"
We evaluated GALT enzyme activity and screened the GALT genes of 145 patients with one or more N314D - containing alleles .,"(('We', 'O'), ('evaluated', 'O'), ('GALT', 'O'), ('enzyme', 'O'), ('activity', 'O'), ('and', 'O'), ('screened', 'O'), ('the', 'O'), ('GALT', 'O'), ('genes', 'O'), ('of', 'O'), ('145', 'O'), ('patients', 'O'), ('with', 'O'), ('one', 'O'), ('or', 'O'), ('more', 'O'), ('N314D', 'O'), ('-', 'O'), ('containing', 'O'), ('alleles', 'O'), ('.', 'O'))"
"We found seven with the LA biochemical phenotype , and all had a 1721C - - > T transition in exon 7 in cis with the N314D missense mutation .","(('We', 'O'), ('found', 'O'), ('seven', 'O'), ('with', 'O'), ('the', 'O'), ('LA', 'O'), ('biochemical', 'O'), ('phenotype', 'O'), (',', 'O'), ('and', 'O'), ('all', 'O'), ('had', 'O'), ('a', 'O'), ('1721C', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('T', 'O'), ('transition', 'O'), ('in', 'O'), ('exon', 'O'), ('7', 'O'), ('in', 'O'), ('cis', 'O'), ('with', 'O'), ('the', 'O'), ('N314D', 'O'), ('missense', 'O'), ('mutation', 'O'), ('.', 'O'))"
The 1721C - - > T transition is a neutral polymorphism for leucine at amino acid 218 ( L218L ) .,"(('The', 'O'), ('1721C', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('T', 'O'), ('transition', 'O'), ('is', 'O'), ('a', 'O'), ('neutral', 'O'), ('polymorphism', 'O'), ('for', 'O'), ('leucine', 'O'), ('at', 'O'), ('amino', 'O'), ('acid', 'O'), ('218', 'O'), ('(', 'O'), ('L218L', 'O'), (')', 'O'), ('.', 'O'))"
"In pedigree analyses , this 1721C - - > T transition segregated with the LA phenotype of increased GALT activity in three different biochemical phenotypes ( LA / N , LA / G , and LA / D ) .","(('In', 'O'), ('pedigree', 'O'), ('analyses', 'O'), (',', 'O'), ('this', 'O'), ('1721C', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('T', 'O'), ('transition', 'O'), ('segregated', 'O'), ('with', 'O'), ('the', 'O'), ('LA', 'O'), ('phenotype', 'O'), ('of', 'O'), ('increased', 'O'), ('GALT', 'O'), ('activity', 'O'), ('in', 'O'), ('three', 'O'), ('different', 'O'), ('biochemical', 'O'), ('phenotypes', 'O'), ('(', 'O'), ('LA', 'O'), ('/', 'O'), ('N', 'O'), (',', 'O'), ('LA', 'O'), ('/', 'O'), ('G', 'O'), (',', 'O'), ('and', 'O'), ('LA', 'O'), ('/', 'O'), ('D', 'O'), (')', 'O'), ('.', 'O'))"
"To determine the mechanism for increased activity of the LA variant , we compared GALT mRNA , protein abundance , and enzyme thermal stability in lymphoblast cell lines of D and LA phenotypes with comparable genotypes .","(('To', 'O'), ('determine', 'O'), ('the', 'O'), ('mechanism', 'O'), ('for', 'O'), ('increased', 'O'), ('activity', 'O'), ('of', 'O'), ('the', 'O'), ('LA', 'O'), ('variant', 'O'), (',', 'O'), ('we', 'O'), ('compared', 'O'), ('GALT', 'O'), ('mRNA', 'O'), (',', 'O'), ('protein', 'O'), ('abundance', 'O'), (',', 'O'), ('and', 'O'), ('enzyme', 'O'), ('thermal', 'O'), ('stability', 'O'), ('in', 'O'), ('lymphoblast', 'O'), ('cell', 'O'), ('lines', 'O'), ('of', 'O'), ('D', 'O'), ('and', 'O'), ('LA', 'O'), ('phenotypes', 'O'), ('with', 'O'), ('comparable', 'O'), ('genotypes', 'O'), ('.', 'O'))"
"GALT protein abundance was increased in LA compared to D alleles , but mRNA was similar among all genotypes .","(('GALT', 'O'), ('protein', 'O'), ('abundance', 'O'), ('was', 'O'), ('increased', 'O'), ('in', 'O'), ('LA', 'O'), ('compared', 'O'), ('to', 'O'), ('D', 'O'), ('alleles', 'O'), (',', 'O'), ('but', 'O'), ('mRNA', 'O'), ('was', 'O'), ('similar', 'O'), ('among', 'O'), ('all', 'O'), ('genotypes', 'O'), ('.', 'O'))"
"When LA / D and D / D GALT biochemical phenotypes were compared to N / N GALT phenotypes , both had 50 % , as compared to 21 % , reduction in GALT activity in the wild type ( N / N ) after exposure at identical initial enzyme activity to 50 degrees C for 15 min .","(('When', 'O'), ('LA', 'O'), ('/', 'O'), ('D', 'O'), ('and', 'O'), ('D', 'O'), ('/', 'O'), ('D', 'O'), ('GALT', 'O'), ('biochemical', 'O'), ('phenotypes', 'O'), ('were', 'O'), ('compared', 'O'), ('to', 'O'), ('N', 'O'), ('/', 'O'), ('N', 'O'), ('GALT', 'O'), ('phenotypes', 'O'), (',', 'O'), ('both', 'O'), ('had', 'O'), ('50', 'O'), ('%', 'O'), (',', 'O'), ('as', 'O'), ('compared', 'O'), ('to', 'O'), ('21', 'O'), ('%', 'O'), (',', 'O'), ('reduction', 'O'), ('in', 'O'), ('GALT', 'O'), ('activity', 'O'), ('in', 'O'), ('the', 'O'), ('wild', 'O'), ('type', 'O'), ('(', 'O'), ('N', 'O'), ('/', 'O'), ('N', 'O'), (')', 'O'), ('after', 'O'), ('exposure', 'O'), ('at', 'O'), ('identical', 'O'), ('initial', 'O'), ('enzyme', 'O'), ('activity', 'O'), ('to', 'O'), ('50', 'O'), ('degrees', 'O'), ('C', 'O'), ('for', 'O'), ('15', 'O'), ('min', 'O'), ('.', 'O'))"
A favorable codon bias for the mutated codon with consequently increased translation rates is postulated as the mechanism . .,"(('A', 'O'), ('favorable', 'O'), ('codon', 'O'), ('bias', 'O'), ('for', 'O'), ('the', 'O'), ('mutated', 'O'), ('codon', 'O'), ('with', 'O'), ('consequently', 'O'), ('increased', 'O'), ('translation', 'O'), ('rates', 'O'), ('is', 'O'), ('postulated', 'O'), ('as', 'O'), ('the', 'O'), ('mechanism', 'O'), ('.', 'O'), ('.', 'O'))"
The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer .,"(('The', 'O'), ('TSG101', 'O'), ('tumor', 'B'), ('susceptibility', 'O'), ('gene', 'O'), ('is', 'O'), ('located', 'O'), ('in', 'O'), ('chromosome', 'O'), ('11', 'O'), ('band', 'O'), ('p15', 'O'), ('and', 'O'), ('is', 'O'), ('mutated', 'O'), ('in', 'O'), ('human', 'O'), ('breast', 'B'), ('cancer', 'I'), ('.', 'O'))"
"Here , we report that the human homolog , TSG101 , which we isolated and mapped to chromosome 11 , bands 15 .","(('Here', 'O'), (',', 'O'), ('we', 'O'), ('report', 'O'), ('that', 'O'), ('the', 'O'), ('human', 'O'), ('homolog', 'O'), (',', 'O'), ('TSG101', 'O'), (',', 'O'), ('which', 'O'), ('we', 'O'), ('isolated', 'O'), ('and', 'O'), ('mapped', 'O'), ('to', 'O'), ('chromosome', 'O'), ('11', 'O'), (',', 'O'), ('bands', 'O'), ('15', 'O'), ('.', 'O'))"
1 - 15 1 - 15 .,"(('1', 'O'), ('-', 'O'), ('15', 'O'), ('1', 'O'), ('-', 'O'), ('15', 'O'), ('.', 'O'))"
"2 , a region proposed to contain tumor suppressor gene ( s ) , is mutated at high frequency in human breast cancer .","(('2', 'O'), (',', 'O'), ('a', 'O'), ('region', 'O'), ('proposed', 'O'), ('to', 'O'), ('contain', 'O'), ('tumor', 'O'), ('suppressor', 'O'), ('gene', 'O'), ('(', 'O'), ('s', 'O'), (')', 'O'), (',', 'O'), ('is', 'O'), ('mutated', 'O'), ('at', 'O'), ('high', 'O'), ('frequency', 'O'), ('in', 'O'), ('human', 'O'), ('breast', 'B'), ('cancer', 'I'), ('.', 'O'))"
"In 7 of 15 uncultured primary human breast carcinomas , intragenic deletions were shown in TSG101 genomic DNA and transcripts by gel and sequence analysis , and mutations affecting two TSG101 alleles were identified in four of these cancers .","(('In', 'O'), ('7', 'O'), ('of', 'O'), ('15', 'O'), ('uncultured', 'O'), ('primary', 'O'), ('human', 'O'), ('breast', 'B'), ('carcinomas', 'I'), (',', 'O'), ('intragenic', 'O'), ('deletions', 'O'), ('were', 'O'), ('shown', 'O'), ('in', 'O'), ('TSG101', 'O'), ('genomic', 'O'), ('DNA', 'O'), ('and', 'O'), ('transcripts', 'O'), ('by', 'O'), ('gel', 'O'), ('and', 'O'), ('sequence', 'O'), ('analysis', 'O'), (',', 'O'), ('and', 'O'), ('mutations', 'O'), ('affecting', 'O'), ('two', 'O'), ('TSG101', 'O'), ('alleles', 'O'), ('were', 'O'), ('identified', 'O'), ('in', 'O'), ('four', 'O'), ('of', 'O'), ('these', 'O'), ('cancers', 'B'), ('.', 'O'))"
No TSG101 defects were found in matched normal breast tissue from the breast cancer patients .,"(('No', 'O'), ('TSG101', 'O'), ('defects', 'O'), ('were', 'O'), ('found', 'O'), ('in', 'O'), ('matched', 'O'), ('normal', 'O'), ('breast', 'O'), ('tissue', 'O'), ('from', 'O'), ('the', 'O'), ('breast', 'B'), ('cancer', 'I'), ('patients', 'O'), ('.', 'O'))"
These findings strongly implicate TSG101 mutations in human breast cancer,"(('These', 'O'), ('findings', 'O'), ('strongly', 'O'), ('implicate', 'O'), ('TSG101', 'O'), ('mutations', 'O'), ('in', 'O'), ('human', 'O'), ('breast', 'B'), ('cancer', 'I'))"
Moderate intergenerational and somatic instability of a 55 - CTG repeat in transgenic mice .,"(('Moderate', 'O'), ('intergenerational', 'O'), ('and', 'O'), ('somatic', 'O'), ('instability', 'O'), ('of', 'O'), ('a', 'O'), ('55', 'O'), ('-', 'O'), ('CTG', 'O'), ('repeat', 'O'), ('in', 'O'), ('transgenic', 'O'), ('mice', 'O'), ('.', 'O'))"
"The ( CTG ) n repeat is polymorphic and varies in size between 5 and 37 repeats in unaffected individuals whereas in affected patients there are between 50 and 4 , 000 CTGs .","(('The', 'O'), ('(', 'O'), ('CTG', 'O'), (')', 'O'), ('n', 'O'), ('repeat', 'O'), ('is', 'O'), ('polymorphic', 'O'), ('and', 'O'), ('varies', 'O'), ('in', 'O'), ('size', 'O'), ('between', 'O'), ('5', 'O'), ('and', 'O'), ('37', 'O'), ('repeats', 'O'), ('in', 'O'), ('unaffected', 'O'), ('individuals', 'O'), ('whereas', 'O'), ('in', 'O'), ('affected', 'O'), ('patients', 'O'), ('there', 'O'), ('are', 'O'), ('between', 'O'), ('50', 'O'), ('and', 'O'), ('4', 'O'), (',', 'O'), ('000', 'O'), ('CTGs', 'O'), ('.', 'O'))"
"The size of the ( CTG ) n repeat , which increases through generations , generally correlates with clinical severity and age of onset .","(('The', 'O'), ('size', 'O'), ('of', 'O'), ('the', 'O'), ('(', 'O'), ('CTG', 'O'), (')', 'O'), ('n', 'O'), ('repeat', 'O'), (',', 'O'), ('which', 'O'), ('increases', 'O'), ('through', 'O'), ('generations', 'O'), (',', 'O'), ('generally', 'O'), ('correlates', 'O'), ('with', 'O'), ('clinical', 'O'), ('severity', 'O'), ('and', 'O'), ('age', 'O'), ('of', 'O'), ('onset', 'O'), ('.', 'O'))"
The instability of the CTG repeat appears to depend on its size as well as on the sex of the transmitting parent .,"(('The', 'O'), ('instability', 'O'), ('of', 'O'), ('the', 'O'), ('CTG', 'O'), ('repeat', 'O'), ('appears', 'O'), ('to', 'O'), ('depend', 'O'), ('on', 'O'), ('its', 'O'), ('size', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('on', 'O'), ('the', 'O'), ('sex', 'O'), ('of', 'O'), ('the', 'O'), ('transmitting', 'O'), ('parent', 'O'), ('.', 'O'))"
The molecular mechanisms of triplet instability remain elusive .,"(('The', 'O'), ('molecular', 'O'), ('mechanisms', 'O'), ('of', 'O'), ('triplet', 'O'), ('instability', 'O'), ('remain', 'O'), ('elusive', 'O'), ('.', 'O'))"
"To investigate the role of genomic sequences in instability , we produced transgenic mice containing a 45 - kb genomic segment with a 55 - CTG repeat cloned from a mildly affected patient .","(('To', 'O'), ('investigate', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('genomic', 'O'), ('sequences', 'O'), ('in', 'O'), ('instability', 'O'), (',', 'O'), ('we', 'O'), ('produced', 'O'), ('transgenic', 'O'), ('mice', 'O'), ('containing', 'O'), ('a', 'O'), ('45', 'O'), ('-', 'O'), ('kb', 'O'), ('genomic', 'O'), ('segment', 'O'), ('with', 'O'), ('a', 'O'), ('55', 'O'), ('-', 'O'), ('CTG', 'O'), ('repeat', 'O'), ('cloned', 'O'), ('from', 'O'), ('a', 'O'), ('mildly', 'O'), ('affected', 'O'), ('patient', 'O'), ('.', 'O'))"
"In contrast to other mouse models containing CAG repeats within cDNAs , these mice showed both intergenerational and somatic repeat instability . .","(('In', 'O'), ('contrast', 'O'), ('to', 'O'), ('other', 'O'), ('mouse', 'O'), ('models', 'O'), ('containing', 'O'), ('CAG', 'O'), ('repeats', 'O'), ('within', 'O'), ('cDNAs', 'O'), (',', 'O'), ('these', 'O'), ('mice', 'O'), ('showed', 'O'), ('both', 'O'), ('intergenerational', 'O'), ('and', 'O'), ('somatic', 'O'), ('repeat', 'O'), ('instability', 'O'), ('.', 'O'), ('.', 'O'))"
Programmed cell death ( or apoptosis ) is a physiological process essential to the normal development and homeostatic maintenance of the immune system .,"(('Programmed', 'O'), ('cell', 'O'), ('death', 'O'), ('(', 'O'), ('or', 'O'), ('apoptosis', 'O'), (')', 'O'), ('is', 'O'), ('a', 'O'), ('physiological', 'O'), ('process', 'O'), ('essential', 'O'), ('to', 'O'), ('the', 'O'), ('normal', 'O'), ('development', 'O'), ('and', 'O'), ('homeostatic', 'O'), ('maintenance', 'O'), ('of', 'O'), ('the', 'O'), ('immune', 'O'), ('system', 'O'), ('.', 'O'))"
"In all three siblings , we demonstrated the presence of anergic CD3 + CD4 - CD8 - ( double negative , [ DN ] ) T cells ; moreover , a chronic lymphocyte activation was found , as demonstrated by the presence of high levels of HLA - DR expression on peripheral CD3 + cells and by the presence of high levels of serum activation markers such as soluble interleukin - 2 receptor ( slL - 2R ) and soluble CD30 ( sCD30 ) . .","(('In', 'O'), ('all', 'O'), ('three', 'O'), ('siblings', 'O'), (',', 'O'), ('we', 'O'), ('demonstrated', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('anergic', 'O'), ('CD3', 'O'), ('+', 'O'), ('CD4', 'O'), ('-', 'O'), ('CD8', 'O'), ('-', 'O'), ('(', 'O'), ('double', 'O'), ('negative', 'O'), (',', 'O'), ('[', 'O'), ('DN', 'O'), (']', 'O'), (')', 'O'), ('T', 'O'), ('cells', 'O'), (';', 'O'), ('moreover', 'O'), (',', 'O'), ('a', 'O'), ('chronic', 'O'), ('lymphocyte', 'O'), ('activation', 'O'), ('was', 'O'), ('found', 'O'), (',', 'O'), ('as', 'O'), ('demonstrated', 'O'), ('by', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('high', 'O'), ('levels', 'O'), ('of', 'O'), ('HLA', 'O'), ('-', 'O'), ('DR', 'O'), ('expression', 'O'), ('on', 'O'), ('peripheral', 'O'), ('CD3', 'O'), ('+', 'O'), ('cells', 'O'), ('and', 'O'), ('by', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('high', 'O'), ('levels', 'O'), ('of', 'O'), ('serum', 'O'), ('activation', 'O'), ('markers', 'O'), ('such', 'O'), ('as', 'O'), ('soluble', 'O'), ('interleukin', 'O'), ('-', 'O'), ('2', 'O'), ('receptor', 'O'), ('(', 'O'), ('slL', 'O'), ('-', 'O'), ('2R', 'O'), (')', 'O'), ('and', 'O'), ('soluble', 'O'), ('CD30', 'O'), ('(', 'O'), ('sCD30', 'O'), (')', 'O'), ('.', 'O'), ('.', 'O'))"
"The ATM protein is a single , high - molecular weight protein predominantly confined to the nucleus of human fibroblasts , but is present in both nuclear and microsomal fractions from human lymphoblast cells and peripheral blood lymphocytes .","(('The', 'O'), ('ATM', 'O'), ('protein', 'O'), ('is', 'O'), ('a', 'O'), ('single', 'O'), (',', 'O'), ('high', 'O'), ('-', 'O'), ('molecular', 'O'), ('weight', 'O'), ('protein', 'O'), ('predominantly', 'O'), ('confined', 'O'), ('to', 'O'), ('the', 'O'), ('nucleus', 'O'), ('of', 'O'), ('human', 'O'), ('fibroblasts', 'O'), (',', 'O'), ('but', 'O'), ('is', 'O'), ('present', 'O'), ('in', 'O'), ('both', 'O'), ('nuclear', 'O'), ('and', 'O'), ('microsomal', 'O'), ('fractions', 'O'), ('from', 'O'), ('human', 'O'), ('lymphoblast', 'O'), ('cells', 'O'), ('and', 'O'), ('peripheral', 'O'), ('blood', 'O'), ('lymphocytes', 'O'), ('.', 'O'))"
ATM protein levels and localization remain constant throughout all stages of the cell cycle .,"(('ATM', 'O'), ('protein', 'O'), ('levels', 'O'), ('and', 'O'), ('localization', 'O'), ('remain', 'O'), ('constant', 'O'), ('throughout', 'O'), ('all', 'O'), ('stages', 'O'), ('of', 'O'), ('the', 'O'), ('cell', 'O'), ('cycle', 'O'), ('.', 'O'))"
"Exposure of normal human cells to gamma - irradiation and the radiomimetic drug neocarzinostatin had no effect on ATM protein levels , in contrast to a noted rise in p53 levels over the same time interval .","(('Exposure', 'O'), ('of', 'O'), ('normal', 'O'), ('human', 'O'), ('cells', 'O'), ('to', 'O'), ('gamma', 'O'), ('-', 'O'), ('irradiation', 'O'), ('and', 'O'), ('the', 'O'), ('radiomimetic', 'O'), ('drug', 'O'), ('neocarzinostatin', 'O'), ('had', 'O'), ('no', 'O'), ('effect', 'O'), ('on', 'O'), ('ATM', 'O'), ('protein', 'O'), ('levels', 'O'), (',', 'O'), ('in', 'O'), ('contrast', 'O'), ('to', 'O'), ('a', 'O'), ('noted', 'O'), ('rise', 'O'), ('in', 'O'), ('p53', 'O'), ('levels', 'O'), ('over', 'O'), ('the', 'O'), ('same', 'O'), ('time', 'O'), ('interval', 'O'), ('.', 'O'))"
These findings are consistent with a role for the ATM protein in ensuring the fidelity of DNA repair and cell cycle regulation following genome damage . .,"(('These', 'O'), ('findings', 'O'), ('are', 'O'), ('consistent', 'O'), ('with', 'O'), ('a', 'O'), ('role', 'O'), ('for', 'O'), ('the', 'O'), ('ATM', 'O'), ('protein', 'O'), ('in', 'O'), ('ensuring', 'O'), ('the', 'O'), ('fidelity', 'O'), ('of', 'O'), ('DNA', 'O'), ('repair', 'O'), ('and', 'O'), ('cell', 'O'), ('cycle', 'O'), ('regulation', 'O'), ('following', 'O'), ('genome', 'O'), ('damage', 'O'), ('.', 'O'), ('.', 'O'))"
Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development .,"(('Type', 'O'), ('III', 'O'), ('collagen', 'O'), ('is', 'O'), ('crucial', 'O'), ('for', 'O'), ('collagen', 'O'), ('I', 'O'), ('fibrillogenesis', 'O'), ('and', 'O'), ('for', 'O'), ('normal', 'O'), ('cardiovascular', 'O'), ('development', 'O'), ('.', 'O'))"
Type III collagen is a fibrillar forming collagen comprising three alpha1 ( III ) chains and is expressed in early embryos and throughout embryogenesis .,"(('Type', 'O'), ('III', 'O'), ('collagen', 'O'), ('is', 'O'), ('a', 'O'), ('fibrillar', 'O'), ('forming', 'O'), ('collagen', 'O'), ('comprising', 'O'), ('three', 'O'), ('alpha1', 'O'), ('(', 'O'), ('III', 'O'), (')', 'O'), ('chains', 'O'), ('and', 'O'), ('is', 'O'), ('expressed', 'O'), ('in', 'O'), ('early', 'O'), ('embryos', 'O'), ('and', 'O'), ('throughout', 'O'), ('embryogenesis', 'O'), ('.', 'O'))"
"In the adult , type III collagen is a major component of the extracellular matrix in a variety of internal organs and skin .","(('In', 'O'), ('the', 'O'), ('adult', 'O'), (',', 'O'), ('type', 'O'), ('III', 'O'), ('collagen', 'O'), ('is', 'O'), ('a', 'O'), ('major', 'O'), ('component', 'O'), ('of', 'O'), ('the', 'O'), ('extracellular', 'O'), ('matrix', 'O'), ('in', 'O'), ('a', 'O'), ('variety', 'O'), ('of', 'O'), ('internal', 'O'), ('organs', 'O'), ('and', 'O'), ('skin', 'O'), ('.', 'O'))"
"To directly study the role of Col3a1 in development and disease , we have inactivated the Col3a1 gene in embryonic stem cells by homologous recombination .","(('To', 'O'), ('directly', 'O'), ('study', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('Col3a1', 'O'), ('in', 'O'), ('development', 'O'), ('and', 'O'), ('disease', 'O'), (',', 'O'), ('we', 'O'), ('have', 'O'), ('inactivated', 'O'), ('the', 'O'), ('Col3a1', 'O'), ('gene', 'O'), ('in', 'O'), ('embryonic', 'O'), ('stem', 'O'), ('cells', 'O'), ('by', 'O'), ('homologous', 'O'), ('recombination', 'O'), ('.', 'O'))"
The mutated allele was transmitted through the mouse germ line and homozygous mutant animals were derived from heterozygous intercrosses .,"(('The', 'O'), ('mutated', 'O'), ('allele', 'O'), ('was', 'O'), ('transmitted', 'O'), ('through', 'O'), ('the', 'O'), ('mouse', 'O'), ('germ', 'O'), ('line', 'O'), ('and', 'O'), ('homozygous', 'O'), ('mutant', 'O'), ('animals', 'O'), ('were', 'O'), ('derived', 'O'), ('from', 'O'), ('heterozygous', 'O'), ('intercrosses', 'O'), ('.', 'O'))"
About 10 % of the homozygous mutant animals survived to adulthood but have a much shorter life span compared with wild - type mice .,"(('About', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('homozygous', 'O'), ('mutant', 'O'), ('animals', 'O'), ('survived', 'O'), ('to', 'O'), ('adulthood', 'O'), ('but', 'O'), ('have', 'O'), ('a', 'O'), ('much', 'O'), ('shorter', 'O'), ('life', 'O'), ('span', 'O'), ('compared', 'O'), ('with', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('mice', 'O'), ('.', 'O'))"
Ultrastructural analysis of tissues from mutant mice revealed that type III collagen is essential for normal collagen I fibrillogenesis in the cardiovascular system and other organs . .,"(('Ultrastructural', 'O'), ('analysis', 'O'), ('of', 'O'), ('tissues', 'O'), ('from', 'O'), ('mutant', 'O'), ('mice', 'O'), ('revealed', 'O'), ('that', 'O'), ('type', 'O'), ('III', 'O'), ('collagen', 'O'), ('is', 'O'), ('essential', 'O'), ('for', 'O'), ('normal', 'O'), ('collagen', 'O'), ('I', 'O'), ('fibrillogenesis', 'O'), ('in', 'O'), ('the', 'O'), ('cardiovascular', 'O'), ('system', 'O'), ('and', 'O'), ('other', 'O'), ('organs', 'O'), ('.', 'O'), ('.', 'O'))"
"The mutation , which creates a second AluI restriction site , results in a nonsense mutation in PLP .","(('The', 'O'), ('mutation', 'O'), (',', 'O'), ('which', 'O'), ('creates', 'O'), ('a', 'O'), ('second', 'O'), ('AluI', 'O'), ('restriction', 'O'), ('site', 'O'), (',', 'O'), ('results', 'O'), ('in', 'O'), ('a', 'O'), ('nonsense', 'O'), ('mutation', 'O'), ('in', 'O'), ('PLP', 'O'), ('.', 'O'))"
Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population .,"(('Common', 'O'), ('BRCA1', 'O'), ('variants', 'O'), ('and', 'O'), ('susceptibility', 'O'), ('to', 'O'), ('breast', 'B'), ('and', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('in', 'O'), ('the', 'O'), ('general', 'O'), ('population', 'O'), ('.', 'O'))"
Most multiple case families of young onset breast cancer and ovarian cancer are thought to be due to highly penetrant mutations in the predisposing genes BRCA1 and BRCA2 .,"(('Most', 'O'), ('multiple', 'O'), ('case', 'O'), ('families', 'O'), ('of', 'O'), ('young', 'O'), ('onset', 'O'), ('breast', 'B'), ('cancer', 'I'), ('and', 'O'), ('ovarian', 'B'), ('cancer', 'I'), ('are', 'O'), ('thought', 'O'), ('to', 'O'), ('be', 'O'), ('due', 'O'), ('to', 'O'), ('highly', 'O'), ('penetrant', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('predisposing', 'O'), ('genes', 'O'), ('BRCA1', 'O'), ('and', 'O'), ('BRCA2', 'O'), ('.', 'O'))"
"However , these mutations are uncommon in the population and they probably account for only a few percent of all breast cancer incidence .","(('However', 'O'), (',', 'O'), ('these', 'O'), ('mutations', 'O'), ('are', 'O'), ('uncommon', 'O'), ('in', 'O'), ('the', 'O'), ('population', 'O'), ('and', 'O'), ('they', 'O'), ('probably', 'O'), ('account', 'O'), ('for', 'O'), ('only', 'O'), ('a', 'O'), ('few', 'O'), ('percent', 'O'), ('of', 'O'), ('all', 'O'), ('breast', 'B'), ('cancer', 'I'), ('incidence', 'O'), ('.', 'O'))"
"A much larger fraction of breast cancer might , in principle , be due to common variants which confer more modest individual risks .","(('A', 'O'), ('much', 'O'), ('larger', 'O'), ('fraction', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('might', 'O'), (',', 'O'), ('in', 'O'), ('principle', 'O'), (',', 'O'), ('be', 'O'), ('due', 'O'), ('to', 'O'), ('common', 'O'), ('variants', 'O'), ('which', 'O'), ('confer', 'O'), ('more', 'O'), ('modest', 'O'), ('individual', 'O'), ('risks', 'O'), ('.', 'O'))"
There are several common polymorphisms in the BRCA1 gene which generate amino acid substitutions .,"(('There', 'O'), ('are', 'O'), ('several', 'O'), ('common', 'O'), ('polymorphisms', 'O'), ('in', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('gene', 'O'), ('which', 'O'), ('generate', 'O'), ('amino', 'O'), ('acid', 'O'), ('substitutions', 'O'), ('.', 'O'))"
"We have examined the frequency of four of these polymorphisms Gln356Arg , Pro871Leu , Glu1038Gly and Ser1613Gly in large series of breast and ovarian cancer cases and matched controls .","(('We', 'O'), ('have', 'O'), ('examined', 'O'), ('the', 'O'), ('frequency', 'O'), ('of', 'O'), ('four', 'O'), ('of', 'O'), ('these', 'O'), ('polymorphisms', 'O'), ('Gln356Arg', 'O'), (',', 'O'), ('Pro871Leu', 'O'), (',', 'O'), ('Glu1038Gly', 'O'), ('and', 'O'), ('Ser1613Gly', 'O'), ('in', 'O'), ('large', 'O'), ('series', 'O'), ('of', 'O'), ('breast', 'B'), ('and', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('cases', 'O'), ('and', 'O'), ('matched', 'O'), ('controls', 'O'), ('.', 'O'))"
"Due to strong linkage disequilibrium , these four sites generate only three haplotypes with a frequency > 1 .","(('Due', 'O'), ('to', 'O'), ('strong', 'O'), ('linkage', 'O'), ('disequilibrium', 'O'), (',', 'O'), ('these', 'O'), ('four', 'O'), ('sites', 'O'), ('generate', 'O'), ('only', 'O'), ('three', 'O'), ('haplotypes', 'O'), ('with', 'O'), ('a', 'O'), ('frequency', 'O'), ('>', 'O'), ('1', 'O'), ('.', 'O'))"
3 % .,"(('3', 'O'), ('%', 'O'), ('.', 'O'))"
"The most common haplotypes , defined by the alleles Gln356Pro871Glu1038Ser1613 and Gln356Leu871Gly1038Gly1613 , have frequencies of 0 .","(('The', 'O'), ('most', 'O'), ('common', 'O'), ('haplotypes', 'O'), (',', 'O'), ('defined', 'O'), ('by', 'O'), ('the', 'O'), ('alleles', 'O'), ('Gln356Pro871Glu1038Ser1613', 'O'), ('and', 'O'), ('Gln356Leu871Gly1038Gly1613', 'O'), (',', 'O'), ('have', 'O'), ('frequencies', 'O'), ('of', 'O'), ('0', 'O'), ('.', 'O'))"
57 and 0 .,"(('57', 'O'), ('and', 'O'), ('0', 'O'), ('.', 'O'))"
"32 respectively , and these frequencies do not differ significantly between patient and control groups .","(('32', 'O'), ('respectively', 'O'), (',', 'O'), ('and', 'O'), ('these', 'O'), ('frequencies', 'O'), ('do', 'O'), ('not', 'O'), ('differ', 'O'), ('significantly', 'O'), ('between', 'O'), ('patient', 'O'), ('and', 'O'), ('control', 'O'), ('groups', 'O'), ('.', 'O'))"
Thus the most common polymorphisms of the BRCA1 gene do not make a significant contribution to breast or ovarian cancer risk .,"(('Thus', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('polymorphisms', 'O'), ('of', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('gene', 'O'), ('do', 'O'), ('not', 'O'), ('make', 'O'), ('a', 'O'), ('significant', 'O'), ('contribution', 'O'), ('to', 'O'), ('breast', 'B'), ('or', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('risk', 'O'), ('.', 'O'))"
"However , our data suggest that the Arg356 allele may have a different genotype distribution in breast cancer patients from that in controls ( Arg356 homozygotes are more frequent in the control groups , P = 0 . 01 ) , indicating that it may be protective against breast cancer .","(('However', 'O'), (',', 'O'), ('our', 'O'), ('data', 'O'), ('suggest', 'O'), ('that', 'O'), ('the', 'O'), ('Arg356', 'O'), ('allele', 'O'), ('may', 'O'), ('have', 'O'), ('a', 'O'), ('different', 'O'), ('genotype', 'O'), ('distribution', 'O'), ('in', 'O'), ('breast', 'B'), ('cancer', 'I'), ('patients', 'O'), ('from', 'O'), ('that', 'O'), ('in', 'O'), ('controls', 'O'), ('(', 'O'), ('Arg356', 'O'), ('homozygotes', 'O'), ('are', 'O'), ('more', 'O'), ('frequent', 'O'), ('in', 'O'), ('the', 'O'), ('control', 'O'), ('groups', 'O'), (',', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), (',', 'O'), ('indicating', 'O'), ('that', 'O'), ('it', 'O'), ('may', 'O'), ('be', 'O'), ('protective', 'O'), ('against', 'O'), ('breast', 'B'), ('cancer', 'I'), ('.', 'O'))"
"If this finding can be confirmed , it may provide an insight into the structural features of the BRCA1 protein that are important for its function .","(('If', 'O'), ('this', 'O'), ('finding', 'O'), ('can', 'O'), ('be', 'O'), ('confirmed', 'O'), (',', 'O'), ('it', 'O'), ('may', 'O'), ('provide', 'O'), ('an', 'O'), ('insight', 'O'), ('into', 'O'), ('the', 'O'), ('structural', 'O'), ('features', 'O'), ('of', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('protein', 'O'), ('that', 'O'), ('are', 'O'), ('important', 'O'), ('for', 'O'), ('its', 'O'), ('function', 'O'), ('.', 'O'))"
"Kniest , his patient , the molecular defect .","(('Kniest', 'O'), (',', 'O'), ('his', 'O'), ('patient', 'O'), (',', 'O'), ('the', 'O'), ('molecular', 'O'), ('defect', 'O'), ('.', 'O'))"
Molecular analysis of the patients DNA showed a single base ( G ) deletion involving the GT dinucleotide at the start of intron 18 destroying a splice site of the COL2A1 gene .,"(('Molecular', 'O'), ('analysis', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('DNA', 'O'), ('showed', 'O'), ('a', 'O'), ('single', 'O'), ('base', 'O'), ('(', 'O'), ('G', 'O'), (')', 'O'), ('deletion', 'O'), ('involving', 'O'), ('the', 'O'), ('GT', 'O'), ('dinucleotide', 'O'), ('at', 'O'), ('the', 'O'), ('start', 'O'), ('of', 'O'), ('intron', 'O'), ('18', 'O'), ('destroying', 'O'), ('a', 'O'), ('splice', 'O'), ('site', 'O'), ('of', 'O'), ('the', 'O'), ('COL2A1', 'O'), ('gene', 'O'), ('.', 'O'))"
"We determined 48 amino acid residues from five peptides from the homogeneous monomer of homogentisate 1 , 2 - dioxygenase ( HGO ; E . C . 1 . 13 . 11 . 15 ) of mouse liver .","(('We', 'O'), ('determined', 'O'), ('48', 'O'), ('amino', 'O'), ('acid', 'O'), ('residues', 'O'), ('from', 'O'), ('five', 'O'), ('peptides', 'O'), ('from', 'O'), ('the', 'O'), ('homogeneous', 'O'), ('monomer', 'O'), ('of', 'O'), ('homogentisate', 'O'), ('1', 'O'), (',', 'O'), ('2', 'O'), ('-', 'O'), ('dioxygenase', 'O'), ('(', 'O'), ('HGO', 'O'), (';', 'O'), ('E', 'O'), ('.', 'O'), ('C', 'O'), ('.', 'O'), ('1', 'O'), ('.', 'O'), ('13', 'O'), ('.', 'O'), ('11', 'O'), ('.', 'O'), ('15', 'O'), (')', 'O'), ('of', 'O'), ('mouse', 'O'), ('liver', 'O'), ('.', 'O'))"
"After digestion with trypsin , peptides were separated by reversed phase chromatography and amino acid sequenced .","(('After', 'O'), ('digestion', 'O'), ('with', 'O'), ('trypsin', 'O'), (',', 'O'), ('peptides', 'O'), ('were', 'O'), ('separated', 'O'), ('by', 'O'), ('reversed', 'O'), ('phase', 'O'), ('chromatography', 'O'), ('and', 'O'), ('amino', 'O'), ('acid', 'O'), ('sequenced', 'O'), ('.', 'O'))"
The deduced codon sequence of three peptides was used to derive degenerated oligomeres .,"(('The', 'O'), ('deduced', 'O'), ('codon', 'O'), ('sequence', 'O'), ('of', 'O'), ('three', 'O'), ('peptides', 'O'), ('was', 'O'), ('used', 'O'), ('to', 'O'), ('derive', 'O'), ('degenerated', 'O'), ('oligomeres', 'O'), ('.', 'O'))"
"By combining these oligos , we were able to amplify fragments from 100 to 300 bases ( b ) from mouse liver cDNA by polymerase chain reaction after reverse transcription ( RT - PCR ) .","(('By', 'O'), ('combining', 'O'), ('these', 'O'), ('oligos', 'O'), (',', 'O'), ('we', 'O'), ('were', 'O'), ('able', 'O'), ('to', 'O'), ('amplify', 'O'), ('fragments', 'O'), ('from', 'O'), ('100', 'O'), ('to', 'O'), ('300', 'O'), ('bases', 'O'), ('(', 'O'), ('b', 'O'), (')', 'O'), ('from', 'O'), ('mouse', 'O'), ('liver', 'O'), ('cDNA', 'O'), ('by', 'O'), ('polymerase', 'O'), ('chain', 'O'), ('reaction', 'O'), ('after', 'O'), ('reverse', 'O'), ('transcription', 'O'), ('(', 'O'), ('RT', 'O'), ('-', 'O'), ('PCR', 'O'), (')', 'O'), ('.', 'O'))"
A fragment of 200 b was cloned and used as a probe to screen a mouse liver cDNA library .,"(('A', 'O'), ('fragment', 'O'), ('of', 'O'), ('200', 'O'), ('b', 'O'), ('was', 'O'), ('cloned', 'O'), ('and', 'O'), ('used', 'O'), ('as', 'O'), ('a', 'O'), ('probe', 'O'), ('to', 'O'), ('screen', 'O'), ('a', 'O'), ('mouse', 'O'), ('liver', 'O'), ('cDNA', 'O'), ('library', 'O'), ('.', 'O'))"
One clone from this library contained the complete cDNA - insert for HGO as determined by sequencing .,"(('One', 'O'), ('clone', 'O'), ('from', 'O'), ('this', 'O'), ('library', 'O'), ('contained', 'O'), ('the', 'O'), ('complete', 'O'), ('cDNA', 'O'), ('-', 'O'), ('insert', 'O'), ('for', 'O'), ('HGO', 'O'), ('as', 'O'), ('determined', 'O'), ('by', 'O'), ('sequencing', 'O'), ('.', 'O'))"
"The cDNA encodes for a protein of 50 kDa , as predicted .","(('The', 'O'), ('cDNA', 'O'), ('encodes', 'O'), ('for', 'O'), ('a', 'O'), ('protein', 'O'), ('of', 'O'), ('50', 'O'), ('kDa', 'O'), (',', 'O'), ('as', 'O'), ('predicted', 'O'), ('.', 'O'))"
The cDNA of mouse HGO has an overall identity of 41 % to the corresponding gene hmgA from Aspergillus .,"(('The', 'O'), ('cDNA', 'O'), ('of', 'O'), ('mouse', 'O'), ('HGO', 'O'), ('has', 'O'), ('an', 'O'), ('overall', 'O'), ('identity', 'O'), ('of', 'O'), ('41', 'O'), ('%', 'O'), ('to', 'O'), ('the', 'O'), ('corresponding', 'O'), ('gene', 'O'), ('hmgA', 'O'), ('from', 'O'), ('Aspergillus', 'B'), ('.', 'O'))"
Sequence similarities to human expressed sequence tags ( EST ) clones ranged from 70 % to 20 % .,"(('Sequence', 'O'), ('similarities', 'O'), ('to', 'O'), ('human', 'O'), ('expressed', 'O'), ('sequence', 'O'), ('tags', 'O'), ('(', 'O'), ('EST', 'O'), (')', 'O'), ('clones', 'O'), ('ranged', 'O'), ('from', 'O'), ('70', 'O'), ('%', 'O'), ('to', 'O'), ('20', 'O'), ('%', 'O'), ('.', 'O'))"
The positions of 122 conserved amino acids could be determined by multiple sequence alignment .,"(('The', 'O'), ('positions', 'O'), ('of', 'O'), ('122', 'O'), ('conserved', 'O'), ('amino', 'O'), ('acids', 'O'), ('could', 'O'), ('be', 'O'), ('determined', 'O'), ('by', 'O'), ('multiple', 'O'), ('sequence', 'O'), ('alignment', 'O'), ('.', 'O'))"
We identified one first intron of 928 b in the mouse gene .,"(('We', 'O'), ('identified', 'O'), ('one', 'O'), ('first', 'O'), ('intron', 'O'), ('of', 'O'), ('928', 'O'), ('b', 'O'), ('in', 'O'), ('the', 'O'), ('mouse', 'O'), ('gene', 'O'), ('.', 'O'))"
"The gene for HGO seems to be expressed in various tissues , as shown by RT - PCR on different cDNAs .","(('The', 'O'), ('gene', 'O'), ('for', 'O'), ('HGO', 'O'), ('seems', 'O'), ('to', 'O'), ('be', 'O'), ('expressed', 'O'), ('in', 'O'), ('various', 'O'), ('tissues', 'O'), (',', 'O'), ('as', 'O'), ('shown', 'O'), ('by', 'O'), ('RT', 'O'), ('-', 'O'), ('PCR', 'O'), ('on', 'O'), ('different', 'O'), ('cDNAs', 'O'), ('.', 'O'))"
FISH experiments with the whole murine cDNA as probe clearly revealed signals at the human chromosomal band 3q13 .,"(('FISH', 'O'), ('experiments', 'O'), ('with', 'O'), ('the', 'O'), ('whole', 'O'), ('murine', 'O'), ('cDNA', 'O'), ('as', 'O'), ('probe', 'O'), ('clearly', 'O'), ('revealed', 'O'), ('signals', 'O'), ('at', 'O'), ('the', 'O'), ('human', 'O'), ('chromosomal', 'O'), ('band', 'O'), ('3q13', 'O'), ('.', 'O'))"
3 - q21 .,"(('3', 'O'), ('-', 'O'), ('q21', 'O'), ('.', 'O'))"
"PTEN , a putative protein tyrosine phosphatase gene mutated in human brain , breast , and prostate cancer .","(('PTEN', 'O'), (',', 'O'), ('a', 'O'), ('putative', 'O'), ('protein', 'O'), ('tyrosine', 'O'), ('phosphatase', 'O'), ('gene', 'O'), ('mutated', 'O'), ('in', 'O'), ('human', 'O'), ('brain', 'B'), (',', 'I'), ('breast', 'I'), (',', 'I'), ('and', 'I'), ('prostate', 'I'), ('cancer', 'I'), ('.', 'O'))"
"Mapping of homozygous deletions on human chromosome 10q23 has led to the isolation of a candidate tumor suppressor gene , PTEN , that appears to be mutated at considerable frequency in human cancers .","(('Mapping', 'O'), ('of', 'O'), ('homozygous', 'O'), ('deletions', 'O'), ('on', 'O'), ('human', 'O'), ('chromosome', 'O'), ('10q23', 'O'), ('has', 'O'), ('led', 'O'), ('to', 'O'), ('the', 'O'), ('isolation', 'O'), ('of', 'O'), ('a', 'O'), ('candidate', 'O'), ('tumor', 'O'), ('suppressor', 'O'), ('gene', 'O'), (',', 'O'), ('PTEN', 'O'), (',', 'O'), ('that', 'O'), ('appears', 'O'), ('to', 'O'), ('be', 'O'), ('mutated', 'O'), ('at', 'O'), ('considerable', 'O'), ('frequency', 'O'), ('in', 'O'), ('human', 'O'), ('cancers', 'B'), ('.', 'O'))"
"In preliminary screens , mutations of PTEN were detected in 31 % ( 13 / 42 ) of glioblastoma cell lines and xenografts , 100 % ( 4 / 4 ) of prostate cancer cell lines , 6 % ( 4 / 65 ) of breast cancer cell lines and xenografts , and 17 % ( 3 / 18 ) of primary glioblastomas .","(('In', 'O'), ('preliminary', 'O'), ('screens', 'O'), (',', 'O'), ('mutations', 'O'), ('of', 'O'), ('PTEN', 'O'), ('were', 'O'), ('detected', 'O'), ('in', 'O'), ('31', 'O'), ('%', 'O'), ('(', 'O'), ('13', 'O'), ('/', 'O'), ('42', 'O'), (')', 'O'), ('of', 'O'), ('glioblastoma', 'B'), ('cell', 'O'), ('lines', 'O'), ('and', 'O'), ('xenografts', 'O'), (',', 'O'), ('100', 'O'), ('%', 'O'), ('(', 'O'), ('4', 'O'), ('/', 'O'), ('4', 'O'), (')', 'O'), ('of', 'O'), ('prostate', 'B'), ('cancer', 'I'), ('cell', 'O'), ('lines', 'O'), (',', 'O'), ('6', 'O'), ('%', 'O'), ('(', 'O'), ('4', 'O'), ('/', 'O'), ('65', 'O'), (')', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('cell', 'O'), ('lines', 'O'), ('and', 'O'), ('xenografts', 'O'), (',', 'O'), ('and', 'O'), ('17', 'O'), ('%', 'O'), ('(', 'O'), ('3', 'O'), ('/', 'O'), ('18', 'O'), (')', 'O'), ('of', 'O'), ('primary', 'O'), ('glioblastomas', 'B'), ('.', 'O'))"
"The predicted PTEN product has a protein tyrosine phosphatase domain and extensive homology to tensin , a protein that interacts with actin filaments at focal adhesions .","(('The', 'O'), ('predicted', 'O'), ('PTEN', 'O'), ('product', 'O'), ('has', 'O'), ('a', 'O'), ('protein', 'O'), ('tyrosine', 'O'), ('phosphatase', 'O'), ('domain', 'O'), ('and', 'O'), ('extensive', 'O'), ('homology', 'O'), ('to', 'O'), ('tensin', 'O'), (',', 'O'), ('a', 'O'), ('protein', 'O'), ('that', 'O'), ('interacts', 'O'), ('with', 'O'), ('actin', 'O'), ('filaments', 'O'), ('at', 'O'), ('focal', 'O'), ('adhesions', 'O'), ('.', 'O'))"
We studied the clinical and radiological features in 81 patients from the literature and 5 own patients trying to identify distinct subgroups .,"(('We', 'O'), ('studied', 'O'), ('the', 'O'), ('clinical', 'O'), ('and', 'O'), ('radiological', 'O'), ('features', 'O'), ('in', 'O'), ('81', 'O'), ('patients', 'O'), ('from', 'O'), ('the', 'O'), ('literature', 'O'), ('and', 'O'), ('5', 'O'), ('own', 'O'), ('patients', 'O'), ('trying', 'O'), ('to', 'O'), ('identify', 'O'), ('distinct', 'O'), ('subgroups', 'O'), ('.', 'O'))"
"Within this latter group , there are differences in age of manifestation , clinical course and pattern of bone changes .","(('Within', 'O'), ('this', 'O'), ('latter', 'O'), ('group', 'O'), (',', 'O'), ('there', 'O'), ('are', 'O'), ('differences', 'O'), ('in', 'O'), ('age', 'O'), ('of', 'O'), ('manifestation', 'O'), (',', 'O'), ('clinical', 'O'), ('course', 'O'), ('and', 'O'), ('pattern', 'O'), ('of', 'O'), ('bone', 'O'), ('changes', 'O'), ('.', 'O'))"
A tentative clinico - radiological classification can be useful for the characterization of patients and the development of genotype - phenotype correlations . .,"(('A', 'O'), ('tentative', 'O'), ('clinico', 'O'), ('-', 'O'), ('radiological', 'O'), ('classification', 'O'), ('can', 'O'), ('be', 'O'), ('useful', 'O'), ('for', 'O'), ('the', 'O'), ('characterization', 'O'), ('of', 'O'), ('patients', 'O'), ('and', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('genotype', 'O'), ('-', 'O'), ('phenotype', 'O'), ('correlations', 'O'), ('.', 'O'), ('.', 'O'))"
A clinical overview of WT1 gene mutations .,"(('A', 'O'), ('clinical', 'O'), ('overview', 'O'), ('of', 'O'), ('WT1', 'O'), ('gene', 'O'), ('mutations', 'O'), ('.', 'O'))"
"Six years on , we review 100 reports of intragenic WT1 mutations and examine the accompanying clinical phenotypes .","(('Six', 'O'), ('years', 'O'), ('on', 'O'), (',', 'O'), ('we', 'O'), ('review', 'O'), ('100', 'O'), ('reports', 'O'), ('of', 'O'), ('intragenic', 'O'), ('WT1', 'O'), ('mutations', 'O'), ('and', 'O'), ('examine', 'O'), ('the', 'O'), ('accompanying', 'O'), ('clinical', 'O'), ('phenotypes', 'O'), ('.', 'O'))"
"Here , we report that a mutation predicting the substitution of Gly 230 by glutamic acid ( G230E ) between segments D3 and D4 dramatically alters the pore properties of a recombinant human muscle Cl - channel ( hCIC - 1 ) expressed in a mammalian cell line ( tsA201 ) .","(('Here', 'O'), (',', 'O'), ('we', 'O'), ('report', 'O'), ('that', 'O'), ('a', 'O'), ('mutation', 'O'), ('predicting', 'O'), ('the', 'O'), ('substitution', 'O'), ('of', 'O'), ('Gly', 'O'), ('230', 'O'), ('by', 'O'), ('glutamic', 'O'), ('acid', 'O'), ('(', 'O'), ('G230E', 'O'), (')', 'O'), ('between', 'O'), ('segments', 'O'), ('D3', 'O'), ('and', 'O'), ('D4', 'O'), ('dramatically', 'O'), ('alters', 'O'), ('the', 'O'), ('pore', 'O'), ('properties', 'O'), ('of', 'O'), ('a', 'O'), ('recombinant', 'O'), ('human', 'O'), ('muscle', 'O'), ('Cl', 'O'), ('-', 'O'), ('channel', 'O'), ('(', 'O'), ('hCIC', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('expressed', 'O'), ('in', 'O'), ('a', 'O'), ('mammalian', 'O'), ('cell', 'O'), ('line', 'O'), ('(', 'O'), ('tsA201', 'O'), (')', 'O'), ('.', 'O'))"
The G230E mutation causes substantial changes in anion and cation selectivity as well as a fundamental change in rectification of the current - voltage relationship .,"(('The', 'O'), ('G230E', 'O'), ('mutation', 'O'), ('causes', 'O'), ('substantial', 'O'), ('changes', 'O'), ('in', 'O'), ('anion', 'O'), ('and', 'O'), ('cation', 'O'), ('selectivity', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('a', 'O'), ('fundamental', 'O'), ('change', 'O'), ('in', 'O'), ('rectification', 'O'), ('of', 'O'), ('the', 'O'), ('current', 'O'), ('-', 'O'), ('voltage', 'O'), ('relationship', 'O'), ('.', 'O'))"
"Whereas wild - type channels are characterized by pronounced inward rectification and a Cl > thiocyanate > Br > NO ( 3 ) > I > CH ( 3 ) SO ( 3 ) selectivity , G230E exhibits outward rectification at positive potentials and a thiocyanate > NO ( 3 ) > I > Br > Cl > CH ( 3 ) SO ( 3 ) selectivity .","(('Whereas', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('channels', 'O'), ('are', 'O'), ('characterized', 'O'), ('by', 'O'), ('pronounced', 'O'), ('inward', 'O'), ('rectification', 'O'), ('and', 'O'), ('a', 'O'), ('Cl', 'O'), ('>', 'O'), ('thiocyanate', 'O'), ('>', 'O'), ('Br', 'O'), ('>', 'O'), ('NO', 'O'), ('(', 'O'), ('3', 'O'), (')', 'O'), ('>', 'O'), ('I', 'O'), ('>', 'O'), ('CH', 'O'), ('(', 'O'), ('3', 'O'), (')', 'O'), ('SO', 'O'), ('(', 'O'), ('3', 'O'), (')', 'O'), ('selectivity', 'O'), (',', 'O'), ('G230E', 'O'), ('exhibits', 'O'), ('outward', 'O'), ('rectification', 'O'), ('at', 'O'), ('positive', 'O'), ('potentials', 'O'), ('and', 'O'), ('a', 'O'), ('thiocyanate', 'O'), ('>', 'O'), ('NO', 'O'), ('(', 'O'), ('3', 'O'), (')', 'O'), ('>', 'O'), ('I', 'O'), ('>', 'O'), ('Br', 'O'), ('>', 'O'), ('Cl', 'O'), ('>', 'O'), ('CH', 'O'), ('(', 'O'), ('3', 'O'), (')', 'O'), ('SO', 'O'), ('(', 'O'), ('3', 'O'), (')', 'O'), ('selectivity', 'O'), ('.', 'O'))"
"Furthermore , the cation - to - anion permeability ratio of the mutant is much greater than that of the wild - type channel .","(('Furthermore', 'O'), (',', 'O'), ('the', 'O'), ('cation', 'O'), ('-', 'O'), ('to', 'O'), ('-', 'O'), ('anion', 'O'), ('permeability', 'O'), ('ratio', 'O'), ('of', 'O'), ('the', 'O'), ('mutant', 'O'), ('is', 'O'), ('much', 'O'), ('greater', 'O'), ('than', 'O'), ('that', 'O'), ('of', 'O'), ('the', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('channel', 'O'), ('.', 'O'))"
Voltage - dependent blocks by intracellular and extracellular iodide help to distinguish two distinct ion binding sites within the hClC - 1 conduction pathway .,"(('Voltage', 'O'), ('-', 'O'), ('dependent', 'O'), ('blocks', 'O'), ('by', 'O'), ('intracellular', 'O'), ('and', 'O'), ('extracellular', 'O'), ('iodide', 'O'), ('help', 'O'), ('to', 'O'), ('distinguish', 'O'), ('two', 'O'), ('distinct', 'O'), ('ion', 'O'), ('binding', 'O'), ('sites', 'O'), ('within', 'O'), ('the', 'O'), ('hClC', 'O'), ('-', 'O'), ('1', 'O'), ('conduction', 'O'), ('pathway', 'O'), ('.', 'O'))"
Both binding sites are preserved in the mutant but have decreased affinities for iodide .,"(('Both', 'O'), ('binding', 'O'), ('sites', 'O'), ('are', 'O'), ('preserved', 'O'), ('in', 'O'), ('the', 'O'), ('mutant', 'O'), ('but', 'O'), ('have', 'O'), ('decreased', 'O'), ('affinities', 'O'), ('for', 'O'), ('iodide', 'O'), ('.', 'O'))"
These findings suggest that Gly 230 is critical for normal ion conductance in hClC - 1 and that this residue resides within the channel pore . .,"(('These', 'O'), ('findings', 'O'), ('suggest', 'O'), ('that', 'O'), ('Gly', 'O'), ('230', 'O'), ('is', 'O'), ('critical', 'O'), ('for', 'O'), ('normal', 'O'), ('ion', 'O'), ('conductance', 'O'), ('in', 'O'), ('hClC', 'O'), ('-', 'O'), ('1', 'O'), ('and', 'O'), ('that', 'O'), ('this', 'O'), ('residue', 'O'), ('resides', 'O'), ('within', 'O'), ('the', 'O'), ('channel', 'O'), ('pore', 'O'), ('.', 'O'), ('.', 'O'))"
Mutations were detected in 90 % of the cases .,"(('Mutations', 'O'), ('were', 'O'), ('detected', 'O'), ('in', 'O'), ('90', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('cases', 'O'), ('.', 'O'))"
Three mutation detection techniques were used to determine if one method was superior for this gene .,"(('Three', 'O'), ('mutation', 'O'), ('detection', 'O'), ('techniques', 'O'), ('were', 'O'), ('used', 'O'), ('to', 'O'), ('determine', 'O'), ('if', 'O'), ('one', 'O'), ('method', 'O'), ('was', 'O'), ('superior', 'O'), ('for', 'O'), ('this', 'O'), ('gene', 'O'), ('.', 'O'))"
"The protein truncation test ( PTT ) was used on RT - PCR products , SSCP on genomic PCR amplifications , and chemical cleavage of mismatch on both RT - PCR and genomic amplifications .","(('The', 'O'), ('protein', 'O'), ('truncation', 'O'), ('test', 'O'), ('(', 'O'), ('PTT', 'O'), (')', 'O'), ('was', 'O'), ('used', 'O'), ('on', 'O'), ('RT', 'O'), ('-', 'O'), ('PCR', 'O'), ('products', 'O'), (',', 'O'), ('SSCP', 'O'), ('on', 'O'), ('genomic', 'O'), ('PCR', 'O'), ('amplifications', 'O'), (',', 'O'), ('and', 'O'), ('chemical', 'O'), ('cleavage', 'O'), ('of', 'O'), ('mismatch', 'O'), ('on', 'O'), ('both', 'O'), ('RT', 'O'), ('-', 'O'), ('PCR', 'O'), ('and', 'O'), ('genomic', 'O'), ('amplifications', 'O'), ('.', 'O'))"
"For RT - PCR products , only the translated portion of the gene was screened .","(('For', 'O'), ('RT', 'O'), ('-', 'O'), ('PCR', 'O'), ('products', 'O'), (',', 'O'), ('only', 'O'), ('the', 'O'), ('translated', 'O'), ('portion', 'O'), ('of', 'O'), ('the', 'O'), ('gene', 'O'), ('was', 'O'), ('screened', 'O'), ('.', 'O'))"
"On genomic products exons 1 to 13 ( including 740 bp of the 3 untranslated sequence and all intron / exon boundaries ) were screened , as was a neuroretina specific enhancer in intron 4 .","(('On', 'O'), ('genomic', 'O'), ('products', 'O'), ('exons', 'O'), ('1', 'O'), ('to', 'O'), ('13', 'O'), ('(', 'O'), ('including', 'O'), ('740', 'O'), ('bp', 'O'), ('of', 'O'), ('the', 'O'), ('3', 'O'), ('untranslated', 'O'), ('sequence', 'O'), ('and', 'O'), ('all', 'O'), ('intron', 'O'), ('/', 'O'), ('exon', 'O'), ('boundaries', 'O'), (')', 'O'), ('were', 'O'), ('screened', 'O'), (',', 'O'), ('as', 'O'), ('was', 'O'), ('a', 'O'), ('neuroretina', 'O'), ('specific', 'O'), ('enhancer', 'O'), ('in', 'O'), ('intron', 'O'), ('4', 'O'), ('.', 'O'))"
"Ten of the possible 12 mutations in the five familial cases and five of the sporadic patients were found , all of which conformed to a functional outcome of haploinsufficiency .","(('Ten', 'O'), ('of', 'O'), ('the', 'O'), ('possible', 'O'), ('12', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('five', 'O'), ('familial', 'O'), ('cases', 'O'), ('and', 'O'), ('five', 'O'), ('of', 'O'), ('the', 'O'), ('sporadic', 'O'), ('patients', 'O'), ('were', 'O'), ('found', 'O'), (',', 'O'), ('all', 'O'), ('of', 'O'), ('which', 'O'), ('conformed', 'O'), ('to', 'O'), ('a', 'O'), ('functional', 'O'), ('outcome', 'O'), ('of', 'O'), ('haploinsufficiency', 'O'), ('.', 'O'))"
"Five were splice site mutations ( one in the donor site of intron 4 , two in the donor site of intron 6 , one in each of the acceptor sites of introns 8 and 9 ) and five were nonsense mutations in exons 8 , 9 , 10 , 11 , and 12 .","(('Five', 'O'), ('were', 'O'), ('splice', 'O'), ('site', 'O'), ('mutations', 'O'), ('(', 'O'), ('one', 'O'), ('in', 'O'), ('the', 'O'), ('donor', 'O'), ('site', 'O'), ('of', 'O'), ('intron', 'O'), ('4', 'O'), (',', 'O'), ('two', 'O'), ('in', 'O'), ('the', 'O'), ('donor', 'O'), ('site', 'O'), ('of', 'O'), ('intron', 'O'), ('6', 'O'), (',', 'O'), ('one', 'O'), ('in', 'O'), ('each', 'O'), ('of', 'O'), ('the', 'O'), ('acceptor', 'O'), ('sites', 'O'), ('of', 'O'), ('introns', 'O'), ('8', 'O'), ('and', 'O'), ('9', 'O'), (')', 'O'), ('and', 'O'), ('five', 'O'), ('were', 'O'), ('nonsense', 'O'), ('mutations', 'O'), ('in', 'O'), ('exons', 'O'), ('8', 'O'), (',', 'O'), ('9', 'O'), (',', 'O'), ('10', 'O'), (',', 'O'), ('11', 'O'), (',', 'O'), ('and', 'O'), ('12', 'O'), ('.', 'O'))"
"SSCP analysis of individually amplified exons , with which nine of the 10 mutations were seen , was the most useful detection method for PAX6 . .","(('SSCP', 'O'), ('analysis', 'O'), ('of', 'O'), ('individually', 'O'), ('amplified', 'O'), ('exons', 'O'), (',', 'O'), ('with', 'O'), ('which', 'O'), ('nine', 'O'), ('of', 'O'), ('the', 'O'), ('10', 'O'), ('mutations', 'O'), ('were', 'O'), ('seen', 'O'), (',', 'O'), ('was', 'O'), ('the', 'O'), ('most', 'O'), ('useful', 'O'), ('detection', 'O'), ('method', 'O'), ('for', 'O'), ('PAX6', 'O'), ('.', 'O'), ('.', 'O'))"
The human complement C9 gene : identification of two mutations causing deficiency and revision of the gene structure .,"(('The', 'O'), ('human', 'O'), ('complement', 'O'), ('C9', 'O'), ('gene', 'O'), (':', 'O'), ('identification', 'O'), ('of', 'O'), ('two', 'O'), ('mutations', 'O'), ('causing', 'O'), ('deficiency', 'O'), ('and', 'O'), ('revision', 'O'), ('of', 'O'), ('the', 'O'), ('gene', 'O'), ('structure', 'O'), ('.', 'O'))"
The ninth component of human complement ( C9 ) is the last of the terminal complement components creating the membrane attack complex .,"(('The', 'O'), ('ninth', 'O'), ('component', 'O'), ('of', 'O'), ('human', 'O'), ('complement', 'O'), ('(', 'O'), ('C9', 'O'), (')', 'O'), ('is', 'O'), ('the', 'O'), ('last', 'O'), ('of', 'O'), ('the', 'O'), ('terminal', 'O'), ('complement', 'O'), ('components', 'O'), ('creating', 'O'), ('the', 'O'), ('membrane', 'O'), ('attack', 'O'), ('complex', 'O'), ('.', 'O'))"
C9 is a single - chain serum protein that is encoded by a gene located on chromosome 5p .,"(('C9', 'O'), ('is', 'O'), ('a', 'O'), ('single', 'O'), ('-', 'O'), ('chain', 'O'), ('serum', 'O'), ('protein', 'O'), ('that', 'O'), ('is', 'O'), ('encoded', 'O'), ('by', 'O'), ('a', 'O'), ('gene', 'O'), ('located', 'O'), ('on', 'O'), ('chromosome', 'O'), ('5p', 'O'), ('.', 'O'))"
"One mutation , a C to A exchange , was detected in exon 2 at cDNA position 166 , the other , a C to T exchange , was located in exon 4 ( cDNA position 464 ) .","(('One', 'O'), ('mutation', 'O'), (',', 'O'), ('a', 'O'), ('C', 'O'), ('to', 'O'), ('A', 'O'), ('exchange', 'O'), (',', 'O'), ('was', 'O'), ('detected', 'O'), ('in', 'O'), ('exon', 'O'), ('2', 'O'), ('at', 'O'), ('cDNA', 'O'), ('position', 'O'), ('166', 'O'), (',', 'O'), ('the', 'O'), ('other', 'O'), (',', 'O'), ('a', 'O'), ('C', 'O'), ('to', 'O'), ('T', 'O'), ('exchange', 'O'), (',', 'O'), ('was', 'O'), ('located', 'O'), ('in', 'O'), ('exon', 'O'), ('4', 'O'), ('(', 'O'), ('cDNA', 'O'), ('position', 'O'), ('464', 'O'), (')', 'O'), ('.', 'O'))"
"Therefore , these mutations are sufficient to explain the complete deficiency of both the probands studied .","(('Therefore', 'O'), (',', 'O'), ('these', 'O'), ('mutations', 'O'), ('are', 'O'), ('sufficient', 'O'), ('to', 'O'), ('explain', 'O'), ('the', 'O'), ('complete', 'O'), ('deficiency', 'O'), ('of', 'O'), ('both', 'O'), ('the', 'O'), ('probands', 'O'), ('studied', 'O'), ('.', 'O'))"
"DNA sequencing of the exon - intron junctions revealed a number of revisions regarding the boundaries between exons 4 , 5 , and 6 as well as between exons 10 and 11 .","(('DNA', 'O'), ('sequencing', 'O'), ('of', 'O'), ('the', 'O'), ('exon', 'O'), ('-', 'O'), ('intron', 'O'), ('junctions', 'O'), ('revealed', 'O'), ('a', 'O'), ('number', 'O'), ('of', 'O'), ('revisions', 'O'), ('regarding', 'O'), ('the', 'O'), ('boundaries', 'O'), ('between', 'O'), ('exons', 'O'), ('4', 'O'), (',', 'O'), ('5', 'O'), (',', 'O'), ('and', 'O'), ('6', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('between', 'O'), ('exons', 'O'), ('10', 'O'), ('and', 'O'), ('11', 'O'), ('.', 'O'))"
No additional introns were detected in exons 6 and 10 .,"(('No', 'O'), ('additional', 'O'), ('introns', 'O'), ('were', 'O'), ('detected', 'O'), ('in', 'O'), ('exons', 'O'), ('6', 'O'), ('and', 'O'), ('10', 'O'), ('.', 'O'))"
"Furthermore , DNA marker studies were conducted using known polymorphisms of the C6 , C7 , and C9 genes , confirming the linkage of the observed C9 mutations with defined haplotypes . .","(('Furthermore', 'O'), (',', 'O'), ('DNA', 'O'), ('marker', 'O'), ('studies', 'O'), ('were', 'O'), ('conducted', 'O'), ('using', 'O'), ('known', 'O'), ('polymorphisms', 'O'), ('of', 'O'), ('the', 'O'), ('C6', 'O'), (',', 'O'), ('C7', 'O'), (',', 'O'), ('and', 'O'), ('C9', 'O'), ('genes', 'O'), (',', 'O'), ('confirming', 'O'), ('the', 'O'), ('linkage', 'O'), ('of', 'O'), ('the', 'O'), ('observed', 'O'), ('C9', 'O'), ('mutations', 'O'), ('with', 'O'), ('defined', 'O'), ('haplotypes', 'O'), ('.', 'O'), ('.', 'O'))"
BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer .,"(('BRCA1', 'O'), ('mutations', 'O'), ('in', 'O'), ('women', 'O'), ('attending', 'O'), ('clinics', 'O'), ('that', 'O'), ('evaluate', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('.', 'O'))"
"BACKGROUND To define the incidence of BRCA1 mutations among patients seen in clinics that evaluate the risk of breast cancer , we analyzed DNA samples from women seen in this setting and constructed probability tables to provide estimates of the likelihood of finding a BRCA1 mutation in individual families .","(('BACKGROUND', 'O'), ('To', 'O'), ('define', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('BRCA1', 'O'), ('mutations', 'O'), ('among', 'O'), ('patients', 'O'), ('seen', 'O'), ('in', 'O'), ('clinics', 'O'), ('that', 'O'), ('evaluate', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), (',', 'O'), ('we', 'O'), ('analyzed', 'O'), ('DNA', 'O'), ('samples', 'O'), ('from', 'O'), ('women', 'O'), ('seen', 'O'), ('in', 'O'), ('this', 'O'), ('setting', 'O'), ('and', 'O'), ('constructed', 'O'), ('probability', 'O'), ('tables', 'O'), ('to', 'O'), ('provide', 'O'), ('estimates', 'O'), ('of', 'O'), ('the', 'O'), ('likelihood', 'O'), ('of', 'O'), ('finding', 'O'), ('a', 'O'), ('BRCA1', 'O'), ('mutation', 'O'), ('in', 'O'), ('individual', 'O'), ('families', 'O'), ('.', 'O'))"
"METHODS Clinical information , family histories , and blood for DNA analysis were obtained from 263 women with breast cancer .","(('METHODS', 'O'), ('Clinical', 'O'), ('information', 'O'), (',', 'O'), ('family', 'O'), ('histories', 'O'), (',', 'O'), ('and', 'O'), ('blood', 'O'), ('for', 'O'), ('DNA', 'O'), ('analysis', 'O'), ('were', 'O'), ('obtained', 'O'), ('from', 'O'), ('263', 'O'), ('women', 'O'), ('with', 'O'), ('breast', 'B'), ('cancer', 'I'), ('.', 'O'))"
Conformation - sensitive gel electrophoresis and DNA sequencing were used to identify BRCA1 mutations .,"(('Conformation', 'O'), ('-', 'O'), ('sensitive', 'O'), ('gel', 'O'), ('electrophoresis', 'O'), ('and', 'O'), ('DNA', 'O'), ('sequencing', 'O'), ('were', 'O'), ('used', 'O'), ('to', 'O'), ('identify', 'O'), ('BRCA1', 'O'), ('mutations', 'O'), ('.', 'O'))"
RESULTS BRCA1 mutations were identified in 16 percent of women with a family history of breast cancer .,"(('RESULTS', 'O'), ('BRCA1', 'O'), ('mutations', 'O'), ('were', 'O'), ('identified', 'O'), ('in', 'O'), ('16', 'O'), ('percent', 'O'), ('of', 'O'), ('women', 'O'), ('with', 'O'), ('a', 'O'), ('family', 'O'), ('history', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('.', 'O'))"
Only 7 percent of women from families with a history of breast cancer but not ovarian cancer had BRCA1 mutations .,"(('Only', 'O'), ('7', 'O'), ('percent', 'O'), ('of', 'O'), ('women', 'O'), ('from', 'O'), ('families', 'O'), ('with', 'O'), ('a', 'O'), ('history', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('but', 'O'), ('not', 'O'), ('ovarian', 'B'), ('cancer', 'I'), ('had', 'O'), ('BRCA1', 'O'), ('mutations', 'O'), ('.', 'O'))"
The rates were higher among women from families with a history of both breast and ovarian cancer .,"(('The', 'O'), ('rates', 'O'), ('were', 'O'), ('higher', 'O'), ('among', 'O'), ('women', 'O'), ('from', 'O'), ('families', 'O'), ('with', 'O'), ('a', 'O'), ('history', 'O'), ('of', 'O'), ('both', 'O'), ('breast', 'B'), ('and', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('.', 'O'))"
"Among family members , an average age of less than 55 years at the diagnosis of breast cancer , the presence of ovarian cancer , the presence of breast and ovarian cancer in the same woman , and Ashkenazi Jewish ancestry were all associated with an increased risk of detecting a BRCA1 mutation .","(('Among', 'O'), ('family', 'O'), ('members', 'O'), (',', 'O'), ('an', 'O'), ('average', 'O'), ('age', 'O'), ('of', 'O'), ('less', 'O'), ('than', 'O'), ('55', 'O'), ('years', 'O'), ('at', 'O'), ('the', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), (',', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('ovarian', 'B'), ('cancer', 'I'), (',', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('breast', 'B'), ('and', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('in', 'O'), ('the', 'O'), ('same', 'O'), ('woman', 'O'), (',', 'O'), ('and', 'O'), ('Ashkenazi', 'O'), ('Jewish', 'O'), ('ancestry', 'O'), ('were', 'O'), ('all', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('increased', 'O'), ('risk', 'O'), ('of', 'O'), ('detecting', 'O'), ('a', 'O'), ('BRCA1', 'O'), ('mutation', 'O'), ('.', 'O'))"
"No association was found between the presence of bilateral breast cancer or the number of breast cancers in a family and the detection of a BRCA1 mutation , or between the position of the mutation in the BRCA1 gene and the presence of ovarian cancer in a family .","(('No', 'O'), ('association', 'O'), ('was', 'O'), ('found', 'O'), ('between', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('bilateral', 'O'), ('breast', 'B'), ('cancer', 'I'), ('or', 'O'), ('the', 'O'), ('number', 'O'), ('of', 'O'), ('breast', 'B'), ('cancers', 'I'), ('in', 'O'), ('a', 'O'), ('family', 'O'), ('and', 'O'), ('the', 'O'), ('detection', 'O'), ('of', 'O'), ('a', 'O'), ('BRCA1', 'O'), ('mutation', 'O'), (',', 'O'), ('or', 'O'), ('between', 'O'), ('the', 'O'), ('position', 'O'), ('of', 'O'), ('the', 'O'), ('mutation', 'O'), ('in', 'O'), ('the', 'O'), ('BRCA1', 'O'), ('gene', 'O'), ('and', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('ovarian', 'B'), ('cancer', 'I'), ('in', 'O'), ('a', 'O'), ('family', 'O'), ('.', 'O'))"
"CONCLUSIONS Among women with breast cancer and a family history of the disease , the percentage with BRCA1 coding - region mutations is less than the 45 percent predicted by genetic - linkage analysis .","(('CONCLUSIONS', 'O'), ('Among', 'O'), ('women', 'O'), ('with', 'O'), ('breast', 'B'), ('cancer', 'I'), ('and', 'O'), ('a', 'O'), ('family', 'O'), ('history', 'O'), ('of', 'O'), ('the', 'O'), ('disease', 'O'), (',', 'O'), ('the', 'O'), ('percentage', 'O'), ('with', 'O'), ('BRCA1', 'O'), ('coding', 'O'), ('-', 'O'), ('region', 'O'), ('mutations', 'O'), ('is', 'O'), ('less', 'O'), ('than', 'O'), ('the', 'O'), ('45', 'O'), ('percent', 'O'), ('predicted', 'O'), ('by', 'O'), ('genetic', 'O'), ('-', 'O'), ('linkage', 'O'), ('analysis', 'O'), ('.', 'O'))"
"These results suggest that even in a referral clinic specializing in screening women from high - risk families , the majority of tests for BRCA1 mutations will be negative and therefore uninformative . .","(('These', 'O'), ('results', 'O'), ('suggest', 'O'), ('that', 'O'), ('even', 'O'), ('in', 'O'), ('a', 'O'), ('referral', 'O'), ('clinic', 'O'), ('specializing', 'O'), ('in', 'O'), ('screening', 'O'), ('women', 'O'), ('from', 'O'), ('high', 'O'), ('-', 'O'), ('risk', 'O'), ('families', 'O'), (',', 'O'), ('the', 'O'), ('majority', 'O'), ('of', 'O'), ('tests', 'O'), ('for', 'O'), ('BRCA1', 'O'), ('mutations', 'O'), ('will', 'O'), ('be', 'O'), ('negative', 'O'), ('and', 'O'), ('therefore', 'O'), ('uninformative', 'O'), ('.', 'O'), ('.', 'O'))"
The ARP gene encodes a highly conserved arginine - rich protein from chromosomal band 3p21 .,"(('The', 'O'), ('ARP', 'O'), ('gene', 'O'), ('encodes', 'O'), ('a', 'O'), ('highly', 'O'), ('conserved', 'O'), ('arginine', 'O'), ('-', 'O'), ('rich', 'O'), ('protein', 'O'), ('from', 'O'), ('chromosomal', 'O'), ('band', 'O'), ('3p21', 'O'), ('.', 'O'))"
1 1 .,"(('1', 'O'), ('1', 'O'), ('.', 'O'))"
A group of patients with long - surviving mismatched kidney allografts were investigated for complement function using haemolytic assays in agarose gels .,"(('A', 'O'), ('group', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('long', 'O'), ('-', 'O'), ('surviving', 'O'), ('mismatched', 'O'), ('kidney', 'O'), ('allografts', 'O'), ('were', 'O'), ('investigated', 'O'), ('for', 'O'), ('complement', 'O'), ('function', 'O'), ('using', 'O'), ('haemolytic', 'O'), ('assays', 'O'), ('in', 'O'), ('agarose', 'O'), ('gels', 'O'), ('.', 'O'))"
One patient was found to have no alternative pathway activity but a low normal classical pathway .,"(('One', 'O'), ('patient', 'O'), ('was', 'O'), ('found', 'O'), ('to', 'O'), ('have', 'O'), ('no', 'O'), ('alternative', 'O'), ('pathway', 'O'), ('activity', 'O'), ('but', 'O'), ('a', 'O'), ('low', 'O'), ('normal', 'O'), ('classical', 'O'), ('pathway', 'O'), ('.', 'O'))"
"Surprisingly , investigation revealed that the patients complement was normal for all components except C9 , which was functionally absent .","(('Surprisingly', 'O'), (',', 'O'), ('investigation', 'O'), ('revealed', 'O'), ('that', 'O'), ('the', 'O'), ('patients', 'O'), ('complement', 'O'), ('was', 'O'), ('normal', 'O'), ('for', 'O'), ('all', 'O'), ('components', 'O'), ('except', 'O'), ('C9', 'O'), (',', 'O'), ('which', 'O'), ('was', 'O'), ('functionally', 'O'), ('absent', 'O'), ('.', 'O'))"
Serological analysis by ELISA revealed that he has trace concentrations of a non - functional C9 molecule .,"(('Serological', 'O'), ('analysis', 'O'), ('by', 'O'), ('ELISA', 'O'), ('revealed', 'O'), ('that', 'O'), ('he', 'O'), ('has', 'O'), ('trace', 'O'), ('concentrations', 'O'), ('of', 'O'), ('a', 'O'), ('non', 'O'), ('-', 'O'), ('functional', 'O'), ('C9', 'O'), ('molecule', 'O'), ('.', 'O'))"
Western blot analysis was not sufficiently sensitive to permit detection of this molecule .,"(('Western', 'O'), ('blot', 'O'), ('analysis', 'O'), ('was', 'O'), ('not', 'O'), ('sufficiently', 'O'), ('sensitive', 'O'), ('to', 'O'), ('permit', 'O'), ('detection', 'O'), ('of', 'O'), ('this', 'O'), ('molecule', 'O'), ('.', 'O'))"
Screening for ESR mutations in breast and ovarian cancer patients .,"(('Screening', 'O'), ('for', 'O'), ('ESR', 'O'), ('mutations', 'O'), ('in', 'O'), ('breast', 'B'), ('and', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('patients', 'O'), ('.', 'O'))"
"In the present study , leukocyte DNA from 143 patients with familial clustering of breast and / or ovarian cancer and tumour DNA from 96 breast carcinomas were screened for base mutations in the estrogen receptor gene ( ESR ) .","(('In', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), (',', 'O'), ('leukocyte', 'O'), ('DNA', 'O'), ('from', 'O'), ('143', 'O'), ('patients', 'O'), ('with', 'O'), ('familial', 'O'), ('clustering', 'O'), ('of', 'O'), ('breast', 'B'), ('and', 'I'), ('/', 'I'), ('or', 'I'), ('ovarian', 'I'), ('cancer', 'I'), ('and', 'O'), ('tumour', 'O'), ('DNA', 'O'), ('from', 'O'), ('96', 'O'), ('breast', 'B'), ('carcinomas', 'I'), ('were', 'O'), ('screened', 'O'), ('for', 'O'), ('base', 'O'), ('mutations', 'O'), ('in', 'O'), ('the', 'O'), ('estrogen', 'O'), ('receptor', 'O'), ('gene', 'O'), ('(', 'O'), ('ESR', 'O'), (')', 'O'), ('.', 'O'))"
Three patients with a family history of cancer were carrying a Gly160Cys germline substitution .,"(('Three', 'O'), ('patients', 'O'), ('with', 'O'), ('a', 'O'), ('family', 'O'), ('history', 'O'), ('of', 'O'), ('cancer', 'B'), ('were', 'O'), ('carrying', 'O'), ('a', 'O'), ('Gly160Cys', 'O'), ('germline', 'O'), ('substitution', 'O'), ('.', 'O'))"
"This alteration was also detected in eight ( four females and four males ) of 729 controls ( 366 female , 363 males ) , indicating that the substitution probably represents a polymorphism .","(('This', 'O'), ('alteration', 'O'), ('was', 'O'), ('also', 'O'), ('detected', 'O'), ('in', 'O'), ('eight', 'O'), ('(', 'O'), ('four', 'O'), ('females', 'O'), ('and', 'O'), ('four', 'O'), ('males', 'O'), (')', 'O'), ('of', 'O'), ('729', 'O'), ('controls', 'O'), ('(', 'O'), ('366', 'O'), ('female', 'O'), (',', 'O'), ('363', 'O'), ('males', 'O'), (')', 'O'), (',', 'O'), ('indicating', 'O'), ('that', 'O'), ('the', 'O'), ('substitution', 'O'), ('probably', 'O'), ('represents', 'O'), ('a', 'O'), ('polymorphism', 'O'), ('.', 'O'))"
"However , in the 229 female controls in whom family history of cancer was known , one of two who had a sister with breast cancer was carrying the variant allele .","(('However', 'O'), (',', 'O'), ('in', 'O'), ('the', 'O'), ('229', 'O'), ('female', 'O'), ('controls', 'O'), ('in', 'O'), ('whom', 'O'), ('family', 'O'), ('history', 'O'), ('of', 'O'), ('cancer', 'B'), ('was', 'O'), ('known', 'O'), (',', 'O'), ('one', 'O'), ('of', 'O'), ('two', 'O'), ('who', 'O'), ('had', 'O'), ('a', 'O'), ('sister', 'O'), ('with', 'O'), ('breast', 'B'), ('cancer', 'I'), ('was', 'O'), ('carrying', 'O'), ('the', 'O'), ('variant', 'O'), ('allele', 'O'), ('.', 'O'))"
"Hence , a possible clinical significance of the glycine into cysteine cannot be completely ruled out and should be further investigated .","(('Hence', 'O'), (',', 'O'), ('a', 'O'), ('possible', 'O'), ('clinical', 'O'), ('significance', 'O'), ('of', 'O'), ('the', 'O'), ('glycine', 'O'), ('into', 'O'), ('cysteine', 'O'), ('cannot', 'O'), ('be', 'O'), ('completely', 'O'), ('ruled', 'O'), ('out', 'O'), ('and', 'O'), ('should', 'O'), ('be', 'O'), ('further', 'O'), ('investigated', 'O'), ('.', 'O'))"
Exon PCR and sequencing revealed a heterozygous point mutation at the 3 splice acceptor site of intron 1 in one Irish family .,"(('Exon', 'O'), ('PCR', 'O'), ('and', 'O'), ('sequencing', 'O'), ('revealed', 'O'), ('a', 'O'), ('heterozygous', 'O'), ('point', 'O'), ('mutation', 'O'), ('at', 'O'), ('the', 'O'), ('3', 'O'), ('splice', 'O'), ('acceptor', 'O'), ('site', 'O'), ('of', 'O'), ('intron', 'O'), ('1', 'O'), ('in', 'O'), ('one', 'O'), ('Irish', 'B'), ('family', 'O'), ('.', 'O'))"
"In the other Irish family , exons 7 and 8 failed to amplify and they were shown to be deleted .","(('In', 'O'), ('the', 'O'), ('other', 'O'), ('Irish', 'B'), ('family', 'O'), (',', 'O'), ('exons', 'O'), ('7', 'O'), ('and', 'O'), ('8', 'O'), ('failed', 'O'), ('to', 'O'), ('amplify', 'O'), ('and', 'O'), ('they', 'O'), ('were', 'O'), ('shown', 'O'), ('to', 'O'), ('be', 'O'), ('deleted', 'O'), ('.', 'O'))"
"Marker haplotype studies of the C6 and C7 gene region and Southern blots show that the Irish family with the splice defect also segregate for the deletion , which is not easily detected in heterozygotes .","(('Marker', 'O'), ('haplotype', 'O'), ('studies', 'O'), ('of', 'O'), ('the', 'O'), ('C6', 'O'), ('and', 'O'), ('C7', 'O'), ('gene', 'O'), ('region', 'O'), ('and', 'O'), ('Southern', 'O'), ('blots', 'O'), ('show', 'O'), ('that', 'O'), ('the', 'O'), ('Irish', 'B'), ('family', 'O'), ('with', 'O'), ('the', 'O'), ('splice', 'O'), ('defect', 'O'), ('also', 'O'), ('segregate', 'O'), ('for', 'O'), ('the', 'O'), ('deletion', 'O'), (',', 'O'), ('which', 'O'), ('is', 'O'), ('not', 'O'), ('easily', 'O'), ('detected', 'O'), ('in', 'O'), ('heterozygotes', 'O'), ('.', 'O'))"
"However , one individual is heterozygous for markers at adjacent C6 loci , showing that there has been an intergenic recombination and suggesting that the deficiency mutation is of appreciable antiquity . .","(('However', 'O'), (',', 'O'), ('one', 'O'), ('individual', 'O'), ('is', 'O'), ('heterozygous', 'O'), ('for', 'O'), ('markers', 'O'), ('at', 'O'), ('adjacent', 'O'), ('C6', 'O'), ('loci', 'O'), (',', 'O'), ('showing', 'O'), ('that', 'O'), ('there', 'O'), ('has', 'O'), ('been', 'O'), ('an', 'O'), ('intergenic', 'O'), ('recombination', 'O'), ('and', 'O'), ('suggesting', 'O'), ('that', 'O'), ('the', 'O'), ('deficiency', 'O'), ('mutation', 'O'), ('is', 'O'), ('of', 'O'), ('appreciable', 'O'), ('antiquity', 'O'), ('.', 'O'), ('.', 'O'))"
"The most common variant of GALT , the Duarte variant , occurs as two types , Duarte - 1 ( D - 1 ) and Duarte - 2 ( D - 2 ) , both of which carry the sequence change N314D .","(('The', 'O'), ('most', 'O'), ('common', 'O'), ('variant', 'O'), ('of', 'O'), ('GALT', 'B'), (',', 'O'), ('the', 'O'), ('Duarte', 'O'), ('variant', 'O'), (',', 'O'), ('occurs', 'O'), ('as', 'O'), ('two', 'O'), ('types', 'O'), (',', 'O'), ('Duarte', 'O'), ('-', 'O'), ('1', 'O'), ('(', 'O'), ('D', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('and', 'O'), ('Duarte', 'O'), ('-', 'O'), ('2', 'O'), ('(', 'O'), ('D', 'O'), ('-', 'O'), ('2', 'O'), (')', 'O'), (',', 'O'), ('both', 'O'), ('of', 'O'), ('which', 'O'), ('carry', 'O'), ('the', 'O'), ('sequence', 'O'), ('change', 'O'), ('N314D', 'O'), ('.', 'O'))"
"D - 1 increases , whereas D - 2 decreases GALT activity .","(('D', 'O'), ('-', 'O'), ('1', 'O'), ('increases', 'O'), (',', 'O'), ('whereas', 'O'), ('D', 'O'), ('-', 'O'), ('2', 'O'), ('decreases', 'O'), ('GALT', 'O'), ('activity', 'O'), ('.', 'O'))"
"Q188R accounted for 60 % , K285N accounted for 28 % of these alleles .","(('Q188R', 'O'), ('accounted', 'O'), ('for', 'O'), ('60', 'O'), ('%', 'O'), (',', 'O'), ('K285N', 'O'), ('accounted', 'O'), ('for', 'O'), ('28', 'O'), ('%', 'O'), ('of', 'O'), ('these', 'O'), ('alleles', 'O'), ('.', 'O'))"
"On all D - 2 alleles N314D occurred in cis with two intronic sequence changes , on the D - 1 alleles in cis with a neutral mutation in exon 7 .","(('On', 'O'), ('all', 'O'), ('D', 'O'), ('-', 'O'), ('2', 'O'), ('alleles', 'O'), ('N314D', 'O'), ('occurred', 'O'), ('in', 'O'), ('cis', 'O'), ('with', 'O'), ('two', 'O'), ('intronic', 'O'), ('sequence', 'O'), ('changes', 'O'), (',', 'O'), ('on', 'O'), ('the', 'O'), ('D', 'O'), ('-', 'O'), ('1', 'O'), ('alleles', 'O'), ('in', 'O'), ('cis', 'O'), ('with', 'O'), ('a', 'O'), ('neutral', 'O'), ('mutation', 'O'), ('in', 'O'), ('exon', 'O'), ('7', 'O'), ('.', 'O'))"
"ATM is a member of the phosphatidylinositol - 3 - kinase superfamily , some of which are protein kinases and appear to have important roles in cell cycle control and radiation signal transduction .","(('ATM', 'O'), ('is', 'O'), ('a', 'O'), ('member', 'O'), ('of', 'O'), ('the', 'O'), ('phosphatidylinositol', 'O'), ('-', 'O'), ('3', 'O'), ('-', 'O'), ('kinase', 'O'), ('superfamily', 'O'), (',', 'O'), ('some', 'O'), ('of', 'O'), ('which', 'O'), ('are', 'O'), ('protein', 'O'), ('kinases', 'O'), ('and', 'O'), ('appear', 'O'), ('to', 'O'), ('have', 'O'), ('important', 'O'), ('roles', 'O'), ('in', 'O'), ('cell', 'O'), ('cycle', 'O'), ('control', 'O'), ('and', 'O'), ('radiation', 'O'), ('signal', 'O'), ('transduction', 'O'), ('.', 'O'))"
"In this report , we demonstrate that in addition to functional alterations these translocations are associated with fusion product overexpression .","(('In', 'O'), ('this', 'O'), ('report', 'O'), (',', 'O'), ('we', 'O'), ('demonstrate', 'O'), ('that', 'O'), ('in', 'O'), ('addition', 'O'), ('to', 'O'), ('functional', 'O'), ('alterations', 'O'), ('these', 'O'), ('translocations', 'O'), ('are', 'O'), ('associated', 'O'), ('with', 'O'), ('fusion', 'O'), ('product', 'O'), ('overexpression', 'O'), ('.', 'O'))"
"Furthermore , PAX3 - FKHR and PAX7 - FKHR overexpression occurs by distinct mechanisms .","(('Furthermore', 'O'), (',', 'O'), ('PAX3', 'O'), ('-', 'O'), ('FKHR', 'O'), ('and', 'O'), ('PAX7', 'O'), ('-', 'O'), ('FKHR', 'O'), ('overexpression', 'O'), ('occurs', 'O'), ('by', 'O'), ('distinct', 'O'), ('mechanisms', 'O'), ('.', 'O'))"
Transcription of PAX3 - FKHR is increased relative to wild - type PAX3 by a copy number - independent process .,"(('Transcription', 'O'), ('of', 'O'), ('PAX3', 'O'), ('-', 'O'), ('FKHR', 'O'), ('is', 'O'), ('increased', 'O'), ('relative', 'O'), ('to', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('PAX3', 'O'), ('by', 'O'), ('a', 'O'), ('copy', 'O'), ('number', 'O'), ('-', 'O'), ('independent', 'O'), ('process', 'O'), ('.', 'O'))"
"In contrast , PAX7 - FKHR overexpression results from fusion gene amplification .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('PAX7', 'O'), ('-', 'O'), ('FKHR', 'O'), ('overexpression', 'O'), ('results', 'O'), ('from', 'O'), ('fusion', 'O'), ('gene', 'O'), ('amplification', 'O'), ('.', 'O'))"
We postulate that these overexpression mechanisms ensure a critical level of gene product for the oncogenic effects of these fusions . .,"(('We', 'O'), ('postulate', 'O'), ('that', 'O'), ('these', 'O'), ('overexpression', 'O'), ('mechanisms', 'O'), ('ensure', 'O'), ('a', 'O'), ('critical', 'O'), ('level', 'O'), ('of', 'O'), ('gene', 'O'), ('product', 'O'), ('for', 'O'), ('the', 'O'), ('oncogenic', 'O'), ('effects', 'O'), ('of', 'O'), ('these', 'O'), ('fusions', 'O'), ('.', 'O'), ('.', 'O'))"
"The two genes are believed to interact in a number of pathways , including regulation of DNA damage - induced cell - cycle checkpoints , apoptosis and radiation sensitivity , and cellular proliferation .","(('The', 'O'), ('two', 'O'), ('genes', 'O'), ('are', 'O'), ('believed', 'O'), ('to', 'O'), ('interact', 'O'), ('in', 'O'), ('a', 'O'), ('number', 'O'), ('of', 'O'), ('pathways', 'O'), (',', 'O'), ('including', 'O'), ('regulation', 'O'), ('of', 'O'), ('DNA', 'O'), ('damage', 'O'), ('-', 'O'), ('induced', 'O'), ('cell', 'O'), ('-', 'O'), ('cycle', 'O'), ('checkpoints', 'O'), (',', 'O'), ('apoptosis', 'O'), ('and', 'O'), ('radiation', 'O'), ('sensitivity', 'O'), (',', 'O'), ('and', 'O'), ('cellular', 'O'), ('proliferation', 'O'), ('.', 'O'))"
"Atm - null mice , as well as those null for p53 , develop mainly T - cell lymphomas , supporting the view that these genes have similar roles in thymocyte development .","(('Atm', 'O'), ('-', 'O'), ('null', 'O'), ('mice', 'O'), (',', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('those', 'O'), ('null', 'O'), ('for', 'O'), ('p53', 'O'), (',', 'O'), ('develop', 'O'), ('mainly', 'O'), ('T', 'B'), ('-', 'I'), ('cell', 'I'), ('lymphomas', 'I'), (',', 'O'), ('supporting', 'O'), ('the', 'O'), ('view', 'O'), ('that', 'O'), ('these', 'O'), ('genes', 'O'), ('have', 'O'), ('similar', 'O'), ('roles', 'O'), ('in', 'O'), ('thymocyte', 'O'), ('development', 'O'), ('.', 'O'))"
"To study the interactions of these two genes on an organismal level , we bred mice heterozygous for null alleles of both atm and p53 to produce all genotypic combinations .","(('To', 'O'), ('study', 'O'), ('the', 'O'), ('interactions', 'O'), ('of', 'O'), ('these', 'O'), ('two', 'O'), ('genes', 'O'), ('on', 'O'), ('an', 'O'), ('organismal', 'O'), ('level', 'O'), (',', 'O'), ('we', 'O'), ('bred', 'O'), ('mice', 'O'), ('heterozygous', 'O'), ('for', 'O'), ('null', 'O'), ('alleles', 'O'), ('of', 'O'), ('both', 'O'), ('atm', 'O'), ('and', 'O'), ('p53', 'O'), ('to', 'O'), ('produce', 'O'), ('all', 'O'), ('genotypic', 'O'), ('combinations', 'O'), ('.', 'O'))"
"Mice doubly null for atm and p53 exhibited a dramatic acceleration of tumour formation relative to singly null mice , indicating that both genes collaborate in a significant manner to prevent tumorigenesis .","(('Mice', 'O'), ('doubly', 'O'), ('null', 'O'), ('for', 'O'), ('atm', 'O'), ('and', 'O'), ('p53', 'O'), ('exhibited', 'O'), ('a', 'O'), ('dramatic', 'O'), ('acceleration', 'O'), ('of', 'O'), ('tumour', 'B'), ('formation', 'O'), ('relative', 'O'), ('to', 'O'), ('singly', 'O'), ('null', 'O'), ('mice', 'O'), (',', 'O'), ('indicating', 'O'), ('that', 'O'), ('both', 'O'), ('genes', 'O'), ('collaborate', 'O'), ('in', 'O'), ('a', 'O'), ('significant', 'O'), ('manner', 'O'), ('to', 'O'), ('prevent', 'O'), ('tumorigenesis', 'B'), ('.', 'O'))"
"With respect to their roles in apoptosis , loss of atm rendered thymocytes only partly resistant to irradiation - induced apoptosis , whereas additional loss of p53 engendered complete resistance .","(('With', 'O'), ('respect', 'O'), ('to', 'O'), ('their', 'O'), ('roles', 'O'), ('in', 'O'), ('apoptosis', 'O'), (',', 'O'), ('loss', 'O'), ('of', 'O'), ('atm', 'O'), ('rendered', 'O'), ('thymocytes', 'O'), ('only', 'O'), ('partly', 'O'), ('resistant', 'O'), ('to', 'O'), ('irradiation', 'O'), ('-', 'O'), ('induced', 'O'), ('apoptosis', 'O'), (',', 'O'), ('whereas', 'O'), ('additional', 'O'), ('loss', 'O'), ('of', 'O'), ('p53', 'O'), ('engendered', 'O'), ('complete', 'O'), ('resistance', 'O'), ('.', 'O'))"
This implies that the irradiation - induced atm and p53 apoptotic pathways are not completely congruent .,"(('This', 'O'), ('implies', 'O'), ('that', 'O'), ('the', 'O'), ('irradiation', 'O'), ('-', 'O'), ('induced', 'O'), ('atm', 'O'), ('and', 'O'), ('p53', 'O'), ('apoptotic', 'O'), ('pathways', 'O'), ('are', 'O'), ('not', 'O'), ('completely', 'O'), ('congruent', 'O'), ('.', 'O'))"
3 ( refs 1 - 3 ) .,"(('3', 'O'), ('(', 'O'), ('refs', 'O'), ('1', 'O'), ('-', 'O'), ('3', 'O'), (')', 'O'), ('.', 'O'))"
"Previous work from our laboratory demonstrated that a DNase l - hypersensitive site located adjacent to the repeats on the wild - type allele is eliminated by repeat expansion , indicating that large CTG - repeat arrays may be associated with a local chromatin environment that represses gene expression .","(('Previous', 'O'), ('work', 'O'), ('from', 'O'), ('our', 'O'), ('laboratory', 'O'), ('demonstrated', 'O'), ('that', 'O'), ('a', 'O'), ('DNase', 'O'), ('l', 'O'), ('-', 'O'), ('hypersensitive', 'O'), ('site', 'O'), ('located', 'O'), ('adjacent', 'O'), ('to', 'O'), ('the', 'O'), ('repeats', 'O'), ('on', 'O'), ('the', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('allele', 'O'), ('is', 'O'), ('eliminated', 'O'), ('by', 'O'), ('repeat', 'O'), ('expansion', 'O'), (',', 'O'), ('indicating', 'O'), ('that', 'O'), ('large', 'O'), ('CTG', 'O'), ('-', 'O'), ('repeat', 'O'), ('arrays', 'O'), ('may', 'O'), ('be', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('local', 'O'), ('chromatin', 'O'), ('environment', 'O'), ('that', 'O'), ('represses', 'O'), ('gene', 'O'), ('expression', 'O'), ('.', 'O'))"
Here we report that the hypersensitive site contains an enhancer element that regulates transcription of the adjacent DMAHP homeobox gene .,"(('Here', 'O'), ('we', 'O'), ('report', 'O'), ('that', 'O'), ('the', 'O'), ('hypersensitive', 'O'), ('site', 'O'), ('contains', 'O'), ('an', 'O'), ('enhancer', 'O'), ('element', 'O'), ('that', 'O'), ('regulates', 'O'), ('transcription', 'O'), ('of', 'O'), ('the', 'O'), ('adjacent', 'O'), ('DMAHP', 'O'), ('homeobox', 'O'), ('gene', 'O'), ('.', 'O'))"
Allele - specific analysis of DMAHP expression showed that steady - state transcript levels from the expanded allele were greatly reduced in comparison to those from the wild - type allele .,"(('Allele', 'O'), ('-', 'O'), ('specific', 'O'), ('analysis', 'O'), ('of', 'O'), ('DMAHP', 'O'), ('expression', 'O'), ('showed', 'O'), ('that', 'O'), ('steady', 'O'), ('-', 'O'), ('state', 'O'), ('transcript', 'O'), ('levels', 'O'), ('from', 'O'), ('the', 'O'), ('expanded', 'O'), ('allele', 'O'), ('were', 'O'), ('greatly', 'O'), ('reduced', 'O'), ('in', 'O'), ('comparison', 'O'), ('to', 'O'), ('those', 'O'), ('from', 'O'), ('the', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('allele', 'O'), ('.', 'O'))"
"Mutations have been found throughout the gene ; however , these genetic alterations do not appear to be homogeneously distributed .","(('Mutations', 'O'), ('have', 'O'), ('been', 'O'), ('found', 'O'), ('throughout', 'O'), ('the', 'O'), ('gene', 'O'), (';', 'O'), ('however', 'O'), (',', 'O'), ('these', 'O'), ('genetic', 'O'), ('alterations', 'O'), ('do', 'O'), ('not', 'O'), ('appear', 'O'), ('to', 'O'), ('be', 'O'), ('homogeneously', 'O'), ('distributed', 'O'), ('.', 'O'))"
"In particular , a significant proportion of disease - causing mutations results in the premature termination of protein synthesis , and the majority of these mutations occur as C - - > T transitions at CpG dinucleotides ( CpGs ) .","(('In', 'O'), ('particular', 'O'), (',', 'O'), ('a', 'O'), ('significant', 'O'), ('proportion', 'O'), ('of', 'O'), ('disease', 'O'), ('-', 'O'), ('causing', 'O'), ('mutations', 'O'), ('results', 'O'), ('in', 'O'), ('the', 'O'), ('premature', 'O'), ('termination', 'O'), ('of', 'O'), ('protein', 'O'), ('synthesis', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('majority', 'O'), ('of', 'O'), ('these', 'O'), ('mutations', 'O'), ('occur', 'O'), ('as', 'O'), ('C', 'O'), ('-', 'O'), ('-', 'O'), ('>', 'O'), ('T', 'O'), ('transitions', 'O'), ('at', 'O'), ('CpG', 'O'), ('dinucleotides', 'O'), ('(', 'O'), ('CpGs', 'O'), (')', 'O'), ('.', 'O'))"
"Such recurrent CpG mutations , including those found in RB1 , are likely the result of the deamination of 5 - methylcytosine within these CpGs .","(('Such', 'O'), ('recurrent', 'O'), ('CpG', 'O'), ('mutations', 'O'), (',', 'O'), ('including', 'O'), ('those', 'O'), ('found', 'O'), ('in', 'O'), ('RB1', 'O'), (',', 'O'), ('are', 'O'), ('likely', 'O'), ('the', 'O'), ('result', 'O'), ('of', 'O'), ('the', 'O'), ('deamination', 'O'), ('of', 'O'), ('5', 'O'), ('-', 'O'), ('methylcytosine', 'O'), ('within', 'O'), ('these', 'O'), ('CpGs', 'O'), ('.', 'O'))"
"In the present study , we used the sodiumbisulfite conversion method to detect cytosine methylation in representative exons of RB1 .","(('In', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), (',', 'O'), ('we', 'O'), ('used', 'O'), ('the', 'O'), ('sodiumbisulfite', 'O'), ('conversion', 'O'), ('method', 'O'), ('to', 'O'), ('detect', 'O'), ('cytosine', 'O'), ('methylation', 'O'), ('in', 'O'), ('representative', 'O'), ('exons', 'O'), ('of', 'O'), ('RB1', 'O'), ('.', 'O'))"
"We analyzed DNA from a variety of tissues and specifically targeted CGA codons in RB1 , where recurrent premature termination mutations have been reported .","(('We', 'O'), ('analyzed', 'O'), ('DNA', 'O'), ('from', 'O'), ('a', 'O'), ('variety', 'O'), ('of', 'O'), ('tissues', 'O'), ('and', 'O'), ('specifically', 'O'), ('targeted', 'O'), ('CGA', 'O'), ('codons', 'O'), ('in', 'O'), ('RB1', 'O'), (',', 'O'), ('where', 'O'), ('recurrent', 'O'), ('premature', 'O'), ('termination', 'O'), ('mutations', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('.', 'O'))"
"We found that DNA methylation within RB1 exons 8 , 14 , 25 , and 27 appeared to be restricted to CpGs , including six CGA codons .","(('We', 'O'), ('found', 'O'), ('that', 'O'), ('DNA', 'O'), ('methylation', 'O'), ('within', 'O'), ('RB1', 'O'), ('exons', 'O'), ('8', 'O'), (',', 'O'), ('14', 'O'), (',', 'O'), ('25', 'O'), (',', 'O'), ('and', 'O'), ('27', 'O'), ('appeared', 'O'), ('to', 'O'), ('be', 'O'), ('restricted', 'O'), ('to', 'O'), ('CpGs', 'O'), (',', 'O'), ('including', 'O'), ('six', 'O'), ('CGA', 'O'), ('codons', 'O'), ('.', 'O'))"
Other codons containing methylated cytosines have not been reported to be mutated .,"(('Other', 'O'), ('codons', 'O'), ('containing', 'O'), ('methylated', 'O'), ('cytosines', 'O'), ('have', 'O'), ('not', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('be', 'O'), ('mutated', 'O'), ('.', 'O'))"
"Therefore , disease - causing mutations at CpGs in RB1 appear to be determined by several factors , including the constitutive presence of DNA methylation at cytosines within CpGs , the specific codon within which the methylated cytosine is located , and the particular region of the gene within which that codon resides . .","(('Therefore', 'O'), (',', 'O'), ('disease', 'O'), ('-', 'O'), ('causing', 'O'), ('mutations', 'O'), ('at', 'O'), ('CpGs', 'O'), ('in', 'O'), ('RB1', 'O'), ('appear', 'O'), ('to', 'O'), ('be', 'O'), ('determined', 'O'), ('by', 'O'), ('several', 'O'), ('factors', 'O'), (',', 'O'), ('including', 'O'), ('the', 'O'), ('constitutive', 'O'), ('presence', 'O'), ('of', 'O'), ('DNA', 'O'), ('methylation', 'O'), ('at', 'O'), ('cytosines', 'O'), ('within', 'O'), ('CpGs', 'O'), (',', 'O'), ('the', 'O'), ('specific', 'O'), ('codon', 'O'), ('within', 'O'), ('which', 'O'), ('the', 'O'), ('methylated', 'O'), ('cytosine', 'O'), ('is', 'O'), ('located', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('particular', 'O'), ('region', 'O'), ('of', 'O'), ('the', 'O'), ('gene', 'O'), ('within', 'O'), ('which', 'O'), ('that', 'O'), ('codon', 'O'), ('resides', 'O'), ('.', 'O'), ('.', 'O'))"
We have therefore assessed the effect of the VHL gene product on VEGF expression .,"(('We', 'O'), ('have', 'O'), ('therefore', 'O'), ('assessed', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('the', 'O'), ('VHL', 'O'), ('gene', 'O'), ('product', 'O'), ('on', 'O'), ('VEGF', 'O'), ('expression', 'O'), ('.', 'O'))"
wt - VHL protein inhibited VEGF promoter activity in a dose - dependent manner up to 5 - to 10 - fold .,"(('wt', 'O'), ('-', 'O'), ('VHL', 'O'), ('protein', 'O'), ('inhibited', 'O'), ('VEGF', 'O'), ('promoter', 'O'), ('activity', 'O'), ('in', 'O'), ('a', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('manner', 'O'), ('up', 'O'), ('to', 'O'), ('5', 'O'), ('-', 'O'), ('to', 'O'), ('10', 'O'), ('-', 'O'), ('fold', 'O'), ('.', 'O'))"
Deletion analysis defined a 144 - bp region of the VEGF promoter necessary for VHL repression .,"(('Deletion', 'O'), ('analysis', 'O'), ('defined', 'O'), ('a', 'O'), ('144', 'O'), ('-', 'O'), ('bp', 'O'), ('region', 'O'), ('of', 'O'), ('the', 'O'), ('VEGF', 'O'), ('promoter', 'O'), ('necessary', 'O'), ('for', 'O'), ('VHL', 'O'), ('repression', 'O'), ('.', 'O'))"
This VHL - responsive element is GC rich and specifically binds the transcription factor Sp1 in crude nuclear extracts .,"(('This', 'O'), ('VHL', 'O'), ('-', 'O'), ('responsive', 'O'), ('element', 'O'), ('is', 'O'), ('GC', 'O'), ('rich', 'O'), ('and', 'O'), ('specifically', 'O'), ('binds', 'O'), ('the', 'O'), ('transcription', 'O'), ('factor', 'O'), ('Sp1', 'O'), ('in', 'O'), ('crude', 'O'), ('nuclear', 'O'), ('extracts', 'O'), ('.', 'O'))"
"In Drosophila cells , cotransfected VHL represses Sp1 - mediated activation but not basal activity of the VEGF promoter .","(('In', 'O'), ('Drosophila', 'O'), ('cells', 'O'), (',', 'O'), ('cotransfected', 'O'), ('VHL', 'O'), ('represses', 'O'), ('Sp1', 'O'), ('-', 'O'), ('mediated', 'O'), ('activation', 'O'), ('but', 'O'), ('not', 'O'), ('basal', 'O'), ('activity', 'O'), ('of', 'O'), ('the', 'O'), ('VEGF', 'O'), ('promoter', 'O'), ('.', 'O'))"
"We next demonstrated in coimmunoprecipitates that VHL and Sp1 were part of the same complex and , by using a glutathione - S - transferase - VHL fusion protein and purified Sp1 , that VHL and Sp1 directly interact .","(('We', 'O'), ('next', 'O'), ('demonstrated', 'O'), ('in', 'O'), ('coimmunoprecipitates', 'O'), ('that', 'O'), ('VHL', 'O'), ('and', 'O'), ('Sp1', 'O'), ('were', 'O'), ('part', 'O'), ('of', 'O'), ('the', 'O'), ('same', 'O'), ('complex', 'O'), ('and', 'O'), (',', 'O'), ('by', 'O'), ('using', 'O'), ('a', 'O'), ('glutathione', 'O'), ('-', 'O'), ('S', 'O'), ('-', 'O'), ('transferase', 'O'), ('-', 'O'), ('VHL', 'O'), ('fusion', 'O'), ('protein', 'O'), ('and', 'O'), ('purified', 'O'), ('Sp1', 'O'), (',', 'O'), ('that', 'O'), ('VHL', 'O'), ('and', 'O'), ('Sp1', 'O'), ('directly', 'O'), ('interact', 'O'), ('.', 'O'))"
"We identified three missense mutations ( I66M , G270D , L618S ) and one exon - 6 skipping ( 535 - 573del ) .","(('We', 'O'), ('identified', 'O'), ('three', 'O'), ('missense', 'O'), ('mutations', 'O'), ('(', 'O'), ('I66M', 'O'), (',', 'O'), ('G270D', 'O'), (',', 'O'), ('L618S', 'O'), (')', 'O'), ('and', 'O'), ('one', 'O'), ('exon', 'O'), ('-', 'O'), ('6', 'O'), ('skipping', 'O'), ('(', 'O'), ('535', 'O'), ('-', 'O'), ('573del', 'O'), (')', 'O'), ('.', 'O'))"
"Two of the patients had only the I66M mutant mRNA , and one only the G27OD mutant mRNA .","(('Two', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('had', 'O'), ('only', 'O'), ('the', 'O'), ('I66M', 'O'), ('mutant', 'O'), ('mRNA', 'O'), (',', 'O'), ('and', 'O'), ('one', 'O'), ('only', 'O'), ('the', 'O'), ('G27OD', 'O'), ('mutant', 'O'), ('mRNA', 'O'), ('.', 'O'))"
The fourth patient carried a compound heterozygous mutation of 535 - 573del and L618S .,"(('The', 'O'), ('fourth', 'O'), ('patient', 'O'), ('carried', 'O'), ('a', 'O'), ('compound', 'O'), ('heterozygous', 'O'), ('mutation', 'O'), ('of', 'O'), ('535', 'O'), ('-', 'O'), ('573del', 'O'), ('and', 'O'), ('L618S', 'O'), ('.', 'O'))"
"To determine the enzymatic activities produced by these mutations , we constructed mutated GALC cDNAs and expressed them in COS - 1 cells .","(('To', 'O'), ('determine', 'O'), ('the', 'O'), ('enzymatic', 'O'), ('activities', 'O'), ('produced', 'O'), ('by', 'O'), ('these', 'O'), ('mutations', 'O'), (',', 'O'), ('we', 'O'), ('constructed', 'O'), ('mutated', 'O'), ('GALC', 'O'), ('cDNAs', 'O'), ('and', 'O'), ('expressed', 'O'), ('them', 'O'), ('in', 'O'), ('COS', 'O'), ('-', 'O'), ('1', 'O'), ('cells', 'O'), ('.', 'O'))"
"The I66M mutation in the wild - type GALC cDNA ( I289 ) had normal activity , but when this mutation and the V289 polymorphism were introduced into the same allele , it had decreased activity .","(('The', 'O'), ('I66M', 'O'), ('mutation', 'O'), ('in', 'O'), ('the', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('GALC', 'B'), ('cDNA', 'O'), ('(', 'O'), ('I289', 'O'), (')', 'O'), ('had', 'O'), ('normal', 'O'), ('activity', 'O'), (',', 'O'), ('but', 'O'), ('when', 'O'), ('this', 'O'), ('mutation', 'O'), ('and', 'O'), ('the', 'O'), ('V289', 'O'), ('polymorphism', 'O'), ('were', 'O'), ('introduced', 'O'), ('into', 'O'), ('the', 'O'), ('same', 'O'), ('allele', 'O'), (',', 'O'), ('it', 'O'), ('had', 'O'), ('decreased', 'O'), ('activity', 'O'), ('.', 'O'))"
"Thus , the combination of a unique mutation and polymorphism causes conformational change in the GALC enzyme , resulting in low enzymatic activity .","(('Thus', 'O'), (',', 'O'), ('the', 'O'), ('combination', 'O'), ('of', 'O'), ('a', 'O'), ('unique', 'O'), ('mutation', 'O'), ('and', 'O'), ('polymorphism', 'O'), ('causes', 'O'), ('conformational', 'O'), ('change', 'O'), ('in', 'O'), ('the', 'O'), ('GALC', 'O'), ('enzyme', 'O'), (',', 'O'), ('resulting', 'O'), ('in', 'O'), ('low', 'O'), ('enzymatic', 'O'), ('activity', 'O'), ('.', 'O'))"
